APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 12 DEC'99



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGMENT AND SERVICES

1999

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

Cumulative Supplement 12

DECEMBER 1999

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

19TH EDITION

CUMULATIVE SUPPLEMENT 12
DECEMBER 1999

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 19th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 19th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 20th Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ASTRA PHARMACEUTICALS LP (ASTRA PHARMS)	ASTRA ZENECA LP (ASTRA ZENECA)
PENEDERM INC (PENEDERM)	BERTEK PHARMACEUTICALS (BERTEK PHARMS)
SANOFI PHARMACEUTICALS INC (SANOFI)	SANOFI SYNTHELABO INC (SANOFI SYNTHELABO)

1.3 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.4 AVAILABILITY OF THE EDITION

The 19th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $90.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 19th annual edition of the 1998 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder/orange/19bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at
http://www.fda.gov/cder/orange/supplement/patents.pdf.

The current listing of the Orphan Product Designations and Approvals is available at
http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1998) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1998	JUN 1999	SEP 1999	DEC 1999
DRUG PRODUCTS LISTED	9923	10009	9939	10045
SINGLE SOURCE	2504 (25.2%)	2523 (25.2%)	2557 (25.7%)	2599 (25.9%)
MULTISOURCE	7308 (73.6%)	7375 (73.7%)	7271 (73.2%)	7335 (73.0%)
THERAPEUTICALLY EQUIVALENT	6934 (69.9%)	7012 (70.1%)	6923 (69.7%)	6986 (69.5%)
NOT THERAPEUTICALLY EQUIVALENT	374 (3.8%)	363 (3.6%)	348 (3.5%)	349 (3.5%)
EXCEPTIONS[1]	111 (1.1%)	111 (1.1%)	111 (1.1%)	111 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	10	5	13	0
NUMBER OF APPLICANTS	563	568	572	576

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HCL

> ADD >	**AB**	PAR PHARM	**EQ 200MG BASE**	**N75047 001**
> ADD >				DEC 30, 1999
> ADD >	**AB**		**EQ 400MG BASE**	**N75047 002**
> ADD >				DEC 30, 1999

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE

AB	GRAHAM DM		**325MG;50MG;40MG**	**N88758 001**
				MAR 27, 1985
	@ MALLINCKRODT		325MG;50MG;40MG	N88758 001
				MAR 27, 1985

FEMCET

AB	MALLINCKRODT		**325MG;50MG;40MG**	**N89102 001**
				JUN 19, 1985
	@		325MG;50MG;40MG	N89102 001
				JUN 19, 1985

TRIAD

AB	MALLINCKRODT		**325MG;50MG;40MG**	**N89023 001**
				JUN 19, 1985
	@		325MG;50MG;40MG	N89023 001
				JUN 19, 1985

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE

AB	WEST WARD		**500MG;50MG;40MG**	**N40336 001**
				AUG 18, 1999

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODONE BITARTRATE

	+ MIKART		712.8MG;60MG;32MG	N40316 001
				APR 28, 1999

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ALLAY

AA	ZENITH GOLDLINE		**500MG;5MG**	**N89907 001**
				JAN 13, 1989

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MALLINCKRODT		**500MG;5MG**	**N88956 001**
				JUL 19, 1985

ZYDONE

AA	MALLINCKRODT		**500MG;5MG**	**N88956 001**
				JUL 19, 1985

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	DURAMED		**500MG;5MG**	**N40289 001**
				MAR 16, 1999
> ADD > **AA**	ENDO PHARMS		**500MG;5MG**	**N40303 001**
> ADD >				DEC 30, 1999

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	AMIDE PHARM		**325MG;5MG**	**N40203 001**
				MAR 15, 1999

PERCOCET

	ENDO PARMS		325MG;2.5MG	N40330 001
				JUN 25, 1999
AA	ENDO PHARMS		**325MG;5MG**	**N40330 002**
				JUN 25, 1999
	+		325MG;2.5MG	N40330 001
				JUN 25, 1999
	+		500MG;7.5MG	N40341 001
				JUL 26, 1999
	+		650MG;10MG	N40341 002
				JUL 26, 1999

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPACET 100

AB	TEVA		**650MG;100MG**	**N70107 001**
				JUN 12, 1985
	@		650MG;100MG	N70107 001
				JUN 12, 1985

ACITRETIN

CAPSULE; ORAL

	SORIATANE			
	HLR		10MG	N19821 001 OCT 28, 1996
	+		25MG	N19821 002 OCT 28, 1996
	ROCHE		10MG	N19821 001 OCT 28, 1996
	*		25MG	N19821 002 OCT 28, 1996

ACYCLOVIR

CAPSULE; ORAL

	ACYCLOVIR			
AB	STASON		**200MG**	**N75090 001 JAN 26, 1999**

TABLET; ORAL

	ACYCLOVIR			
AB	CARLSBAD		**400MG**	**N75382 001 APR 30, 1999**
AB			**800MG**	**N75382 002 APR 30, 1999**

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

	ACYCLOVIR			
AP	ABBOTT		**EQ 50MG BASE/ML**	**N75114 001 JUL 26, 1999**
	ACYCLOVIR SODIUM			
AP	+ AM PHARM PARTNERS		**EQ 50MG BASE/ML**	**N74930 001 MAY 13, 1998**
	*		EQ 50MG BASE/ML	N74930 001 MAY 13, 1998
AP	MERIDIAN MEDCL TECHN		**EQ 50MG BASE/ML**	**N75065 001 FEB 25, 1999**

ALBUTEROL

AEROSOL, METERED; INHALATION

	ALBUTEROL			
AB	MEDEVA		**0.09MG/INH**	**N72273 001 AUG 14, 1996**

ALBUTEROL

AEROSOL, METERED; INHALATION

	ALBUTEROL			
AB	MEDEVA PHARMS MA		**0.09MG/INH**	**N72273 001 AUG 14, 1996**

ALBUTEROL SULFATE

SOLUTION; INHALATION

	ALBUTEROL SULFATE			
AN	HI TECH PHARMA		**EQ 0.083% BASE**	**N75063 001 FEB 09, 1999**
AN	MORTON GROVE		**EQ 0.083% BASE**	**N75394 001 NOV 22, 1999**
AN	STERIPAK		**EQ 0.083% BASE**	**N75343 001 NOV 09, 1999**

SYRUP; ORAL

	ALBUTEROL SULFATE			
AA	UDL		**EQ 2MG BASE/5ML**	**N75262 001 MAR 30, 1999**
	VENTOLIN			
AA	* GLAXO WELLCOME		**EQ 2MG BASE/5ML**	**N19621 001 JUN 10, 1987**
	@		EQ 2MG BASE/5ML	N19621 001 JUN 10, 1987

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

	ALCOHOL 5% IN DEXTROSE 5% IN WATER			
AP	BAXTER HLTHCARE		**5ML/100ML;5GM/100ML**	**N83256 001**
	@		5ML/100ML;5GM/100ML	N83256 001

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

	ALFENTA			
AP	+ AKORN		**EQ 0.5MG BASE/ML**	**N19353 001 DEC 29, 1986**
	*		EQ 0.5MG BASE/ML	N19353 001 DEC 29, 1986
	ALFENTANIL			
AP	ABBOTT		**EQ 0.5MG BASE/ML**	**N75221 001 OCT 28, 1999**

ALITRETINOIN

GEL; TOPICAL
PANRETIN
+ LIGAND — EQ 0.1% BASE — N20886 001 FEB 02, 1999

ALLOPURINOL

TABLET; ORAL
ZYLOPRIM
AB FARO PHARMS — 100MG — N16084 001
AB + — 300MG — N16084 002
AB GLAXO WELLCOME — 100MG — N16084 001
AB + — 300MG — N16084 002

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ALOPRIM
+ CATALYTICA PHARMS — EQ 500MG BASE/VIAL — N20298 001 MAY 17, 1996
ZYLOPRIM
+ CATALYTICA PHARMS — EQ 500MG BASE/VIAL — N20298 001 MAY 17, 1996

ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN, D-; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A

INJECTABLE; INJECTION
CERNEVIT-12
+ BAXTER HLTHCARE — 11.2 IU/VIAL;125MG/VIAL;60 UGM/VIAL; 200 IU/VIAL;5.5MG/VIAL;414 UGM/VIAL; 46MG/VIAL;17.25MG/VIAL;4.53MG/VIAL; 4.14MG/VIAL;3.51MG/VIAL; 3,500 IU/VIAL — N20924 001 APR 06, 1999

ALPRAZOLAM

CONCENTRATE; ORAL
ALPRAZOLAM
ROXANE — 1MG/ML — N74312 001 OCT 31, 1993

ALPRAZOLAM

CONCENTRATE; ORAL
ALPRAZOLAM
+ ROXANE — 1MG/ML — N74312 001 OCT 31, 1993

SOLUTION; ORAL
ALPRAZOLAM
ROXANE — 0.5MG/5ML — N74314 001 OCT 31, 1993
+ — 0.5MG/5ML — N74314 001 OCT 31, 1993

TABLET; ORAL
ALPRAZOLAM
AB ALPHAPHARM — 2MG — N74046 004 MAY 07, 1997

ALPROSTADIL

INJECTABLE; INJECTION
ALPROSTADIL
AP GENSIA SICOR PHARMS — 0.5MG/ML — N75196 001 APR 30, 1999

AMCINONIDE

CREAM; TOPICAL
CYCLOCORT
@ FUJISAWA HLTHCARE — 0.025% — N18116 001
+ — 0.1% — N18116 002
LEDERLE — 0.025% — N18116 001
+ — 0.1% — N18116 002

LOTION; TOPICAL
CYCLOCORT
+ FUJISAWA HLTHCARE — 0.1% — N19729 001 JUN 13, 1988
+ LEDERLE — 0.1% — N19729 001 JUN 13, 1988

OINTMENT; TOPICAL
CYCLOCORT
+ FUJISAWA HLTHCARE — 0.1% — N18498 001
+ WYETH AYERST — 0.1% — N18498 001

AMIFOSTINE

> ADD >

INJECTABLE; INJECTION
> ADD >
ETHYOL
> ADD >
US BIOSCIENCE 375MG/VIAL N20221 002
SEP 10, 1999
> ADD >

AMINO ACIDS

INJECTABLE; INJECTION
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
FRESENIUS KABI 5.2% N18901 001
APR 06, 1984
PHARMACIA AND UPJOHN 5.2% N18901 001
APR 06, 1984
NEOPHAM 6.4%
@ FRESENIUS KABI 6.4% N18792 001
JAN 17, 1984
@ PHARMACIA AND UPJOHN 6.4% N18792 001
JAN 17, 1984
NOVAMINE 11.4%
FRESENIUS KABI 11.4% N17957 003
AUG 09, 1982
PHARMACIA AND UPJOHN 11.4% N17957 003
AUG 09, 1982
NOVAMINE 15%
FRESENIUS KABI 15% N17957 004
NOV 28, 1986
PHARMACIA AND UPJOHN 15% N17957 004
NOV 28, 1986
NOVAMINE 8.5%
@ FRESENIUS KABI 8.5% N17957 002
AUG 09, 1982
@ PHARMACIA AND UPJOHN 8.5% N17957 002
AUG 09, 1982

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION
VEINAMINE 8%
@ FRESENIUS KABI 8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML N17957 001
@ PHARMACIA AND UPJOHN 8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML N17957 001

AMINOLEVULINIC ACID HYDROCHLORIDE

SOLUTION; TOPICAL
LEVULAN
+ DUSA 20% N20965 001
DEC 03, 1999

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE
AP SMITH AND NEPHEW **25MG/ML** **N88749 001**
MAY 30, 1985
@ 25MG/ML N88749 001
MAY 30, 1985

AMIODARONE HYDROCHLORIDE

TABLET; ORAL
AMIODARONE HCL
AB ALPHAPHARM **200MG** **N75188 001**
FEB 24, 1999
AB NOVOPHARM **200MG** **N74895 001**
APR 16, 1999

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION
AMITRIPTYLINE HCL
AP STERIS **10MG/ML** N85594 001
@ 10MG/ML N85594 001
ELAVIL
AP + ZENECA **10MG/ML** N12704 001
+ 10MG/ML N12704 001

TABLET; ORAL
AMITRIPTYLINE HCL
BP COPLEY PHARM 10MG N88421 001
APR 30, 1984
BP 25MG N88422 001
APR 30, 1984
BP 50MG N88423 001
APR 30, 1984
BP 75MG N88424 001
APR 30, 1984

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
AMITRIPTYLINE HCL

BP	COPLEY PHARM	100MG	N88425 001	
			APR 30, 1984	
BP		150MG	N88426 001	
			APR 30, 1984	
	@	10MG	N88421 001	
			APR 30, 1984	
	@	25MG	N88422 001	
			APR 30, 1984	
	@	50MG	N88423 001	
			APR 30, 1984	
	@	75MG	N88424 001	
			APR 30, 1984	
	@	100MG	N88425 001	
			APR 30, 1984	
	@	150MG	N88426 001	
			APR 30, 1984	
	ENDEP			
AB	ROCHE	10MG	N83639 001	
AB		25MG	N83639 002	
AB		50MG	N83639 003	
AB		75MG	N83639 004	
AB		100MG	N83639 005	
	@	10MG	N83639 001	
	@	25MG	N83639 002	
	@	50MG	N83639 003	
	@	75MG	N83639 004	
	@	100MG	N83639 005	

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

AB	RANBAXY	**250MG**	**N65016 001**	
			APR 08, 1999	
AB		**500MG**	**N65016 002**	
			APR 08, 1999	
	AMOXIL			
> DLT > AB	+ SMITHKLINE BEECHAM	250MG	N62216 001	
> ADD > **AB**		**250MG**	**N62216 001**	

POWDER FOR RECONSTITUTION; ORAL
AMOXIL

SMITHKLINE BEECHAM	200MG/5ML	N50760 001	
		APR 15, 1999	

AMOXICILLIN

POWDER FOR RECONSTITUTION; ORAL
AMOXIL

+ SMITHKLINE BEECHAM	400MG/5ML	N50760 002	
		APR 15, 1999	

TABLET; ORAL
AMOXIL

+ SMITHKLINE BEECHAM	500MG	N50754 002	
		JUL 10, 1998	
	500MG	N50754 002	
		JUL 10, 1998	

TABLET, CHEWABLE; ORAL
AMOXICILLIN

> ADD > **AB**	RANBAXY	**125MG**	**N65021 001**	
> ADD >			DEC 23, 1999	
> ADD > **AB**		**250MG**	**N65021 002**	
> ADD >			DEC 23, 1999	
	AMOXIL			
	SMITHKLINE BEECHAM	200MG	N50761 001	
			APR 15, 1999	
	+	400MG	N50761 002	
			APR 15, 1999	

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION
AMPHOTEC

+ ALZA	50MG/VIAL	N50729 001	
		NOV 22, 1996	
+	100MG/VIAL	N50729 002	
		NOV 22, 1996	
+ SEQUUS	50MG/VIAL	N50729 001	
		NOV 22, 1996	
+	100MG/VIAL	N50729 002	
		NOV 22, 1996	

AMPRENAVIR

CAPSULE; ORAL
AGENERASE

GLAXO WELLCOME	50MG	N21007 001	
		APR 15, 1999	
+	150MG	N21007 002	
		APR 15, 1999	

AMPRENAVIR

SOLUTION; ORAL
AGENERASE
+ GLAXO WELLCOME 15MG/ML N21039 001
APR 15, 1999

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
KABIVITE PED F + W KIT
+ FRESENIUS KABI N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A N20176 001
DEC 29, 1993
+ PHARMACIA AND UPJOHN N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A N20176 001
DEC 29, 1993

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
AB ENDO PHARMS **325MG;50MG;40MG;30MG** **N75351 001**
MAR 05, 1999

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE
AB STEVENS J **385MG;30MG;25MG** **N74988 001**
APR 30, 1999
AB **770MG;60MG;50MG** **N74988 002**
APR 30, 1999

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL
AGGRENOX
+ BOEHRINGER INGELHEIM 25MG;200MG N20884 001
NOV 22, 1999

ASTEMIZOLE

TABLET; ORAL
HISMANAL
+ JANSSEN 10MG N19402 001
DEC 29, 1988

ATENOLOL

TABLET; ORAL
ATENOLOL
AB APOTHECON 50MG **N73317 001**
MAR 20, 1992
AB **100MG** **N73318 001**
MAR 20, 1992
@ 50MG N73317 001
MAR 20, 1992
@ 100MG N73318 001
MAR 20, 1992
MYLAN 25MG N73457 002
APR 26, 1999

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
TRACRIUM
AP + ABBOTT **10MG/ML** **N18831 002**
JUN 20, 1985
AP + GLAXO WELLCOME 10MG/ML N18831 002
JUN 20, 1985

TRACRIUM PRESERVATIVE FREE
AP + ABBOTT **10MG/ML** **N18831 001**
NOV 23, 1983
AP + GLAXO WELLCOME 10MG/ML N18831 001
NOV 23, 1983

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

		DIPHENOXYLATE HCL AND ATROPINE SULFATE		
AA		PHARMERAL	0.025MG;2.5MG	N85035 001
AA		R AND S PHARMA	0.025MG;2.5MG	N85035 001
		DIPHENOXYLATE HCL W/ ATROPINE SULFATE		
AA		ZENITH GOLDLINE	0.025MG;2.5MG	N86727 001
	@		0.025MG;2.5MG	N86727 001

AZATHIOPRINE

TABLET; ORAL

		AZATHIOPRINE		
AB		APPLIED ANAL	50MG	N75252 001 JUN 07, 1999
> ADD > AB		GENPHARM	50MG	N75568 001 DEC 13, 1999
		IMURAN		
AB	+	FARO PHARMS	50MG	N16324 001
	@		25MG	N16324 002
AB	+	GLAXO WELLCOME	50MG	N16324 001
	@		25MG	N16324 002

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

		IMURAN		
AP	+	FARO PHARMS	EQ 100MG BASE/VIAL	N17391 001
AP	+	GLAXO WELLCOME	EQ 100MG BASE/VIAL	N17391 001

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

POWDER FOR RECONSTITUTION, TABLET; ORAL

		TROVAN/ZITHROMAX COMPLIANCE PAK		
	+	PFIZER	EQ 1GM BASE,N/A;N/A, EQ 100MG BASE	N50762 001 DEC 18, 1998
	@		EQ 1GM BASE,N/A;N/A, EQ 100MG BASE	N50762 001 DEC 18, 1998

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

		BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE		
AT	+	ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N60731 002
	@		400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N60731 002
AT		PHARMADERM	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62166 002
	+		400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62166 002

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

		CORZIDE		
		APOTHECON	5MG;40MG	N18647 001 MAY 25, 1983
	+		5MG;80MG	N18647 002 MAY 25, 1983
		BRISTOL MYERS SQUIBB	5MG;40MG	N18647 001 MAY 25, 1983
	+		5MG;80MG	N18647 002 MAY 25, 1983

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION

		PRE-PEN		
	+	BAYER	60 UMOLAR	N50114 001
	+	HOLLISTER STIER LABS	60 UMOLAR	N50114 001

BETAMETHASONE DIPROPIONATE

OINTMENT, AUGMENTED; TOPICAL

		BETAMETHASONE DIPROPIONATE		
AB		ALTANA	EQ 0.05% BASE	N75373 001 JUN 22, 1999

BETAMETHASONE VALERATE

AEROSOL; TOPICAL

	LUXIQ			
	+ CONNETICS	EQ 0.12% BASE	N20934 001	FEB 28, 1999

BETAXOLOL HYDROCHLORIDE

TABLET; ORAL

	BETAXOLOL HCL			
AB	AMIDE PHARM	**10MG**	**N75541 001**	OCT 22, 1999
AB		**20MG**	**N75541 002**	OCT 22, 1999
	KERLONE			
AB	LOREX	**10MG**	**N19507 001**	OCT 27, 1989
AB	+	**20MG**	**N19507 002**	OCT 27, 1989
		10MG	N19507 001	OCT 27, 1989
	+	20MG	N19507 002	OCT 27, 1989

> ADD > BEXAROTENE

> ADD > CAPSULE; ORAL

> ADD >	TARGRETIN			
> ADD >	+ LIGAND	75MG	N21055 001	DEC 29, 1999

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

	BRETYLIUM TOSYLATE			
AP	ASTRA PHARMS	50MG/ML	N71153 001	AUG 10, 1987
	@ ASTRAZENECA	50MG/ML	N71153 001	AUG 10, 1987

BUDESONIDE

SPRAY, METERED; NASAL

	RHINOCORT			
	ASTRAZENECA	0.032MG/INH	N20746 001	OCT 01, 1999
	+	0.064MG/INH	N20746 002	OCT 01, 1999

BUPROPION HYDROCHLORIDE

TABLET; ORAL

	BUPROPION HCL			
AB	TEVA	**75MG**	**N75310 001**	NOV 29, 1999
AB		**100MG**	**N75310 002**	NOV 29, 1999
	WELLBUTRIN			
AB	GLAXO WELLCOME	**75MG**	**N18644 002**	DEC 30, 1985
AB	+	**100MG**	**N18644 003**	DEC 30, 1985
		75MG	N18644 002	DEC 30, 1985
	+	100MG	N18644 003	DEC 30, 1985

TABLET, EXTENDED RELEASE; ORAL

	WELLBUTRIN			
+	GLAXO WELLCOME	50MG	N20358 001	OCT 04, 1996
+		100MG	N20358 002	OCT 04, 1996
+		150MG	N20358 003	OCT 04, 1996
	WELLBUTRIN SR			
+	GLAXO WELLCOME	50MG	N20358 001	OCT 04, 1996
+		100MG	N20358 002	OCT 04, 1996
+		150MG	N20358 003	OCT 04, 1996

BUSULFAN

INJECTABLE; INJECTION
BUSULFEX
+ ORPHAN MEDCL 6MG/ML N20954 001 FEB 04, 1999

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT
+ SYNTEX 2% N19215 001 NOV 25, 1985
@ 2% N19215 001 NOV 25, 1985

FEMSTAT ONE
+ KV PHARM 2% N19881 001 FEB 07, 1997
+ SYNTEX 2% N19881 001 FEB 07, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE
AP MERIDIAN MEDCL TECHN **1MG/ML** **N75342 001** NOV 04, 1999
AP **2MG/ML** **N75342 002** NOV 04, 1999

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL
CAFCIT
+ OPR DEVELOP LP EQ 10MG BASE/ML N20793 001 SEP 21, 1999

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
ENDOSOL EXTRA
AT AKORN **0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML** **N20079 001** NOV 27, 1991
AT ALLERGAN **0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML** **N20079 001** NOV 27, 1991

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N18271 001
@ 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N18271 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML N18269 002 JAN 17, 1983
@ 35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML N18269 002 JAN 17, 1983

CALFACTANT

INJECTABLE; INJECTION
INFASURF PRESERVATIVE FREE
+ ONY 35MG/ML N20521 001 JUL 01, 1998

CALFACTANT

SUSPENSION; INTRATRACHEAL
INFASURF PRESERVATIVE FREE

+	ONY	35MG/ML	N20521 001	JUL 01, 1998

CAPECITABINE

TABLET; ORAL
XELODA

	HLR	150MG	N20896 001	APR 30, 1998
	ROCHE	150MG	N20896 001	APR 30, 1998

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	BAKER NORTON	12.5MG	**N74590 004**	AUG 30, 1996
AB		25MG	**N74590 002**	AUG 30, 1996
AB		50MG	**N74590 001**	AUG 30, 1996
AB		100MG	**N74590 003**	AUG 30, 1996
AB	ZENITH GOLDLINE	12.5MG	**N74590 004**	AUG 30, 1996
AB		25MG	**N74590 002**	AUG 30, 1996
AB		50MG	**N74590 001**	AUG 30, 1996
AB		100MG	**N74590 003**	AUG 30, 1996

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL
CARBATROL

> ADD >	+ SHIRE LABS	100MG	N20712 003	DEC 22, 1999

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION
GEOPEN

+	ROERIG	EQ 1GM BASE/VIAL	N50306 001	
+		EQ 2GM BASE/VIAL	N50306 004	
+		EQ 5GM BASE/VIAL	N50306 002	
+		EQ 10GM BASE/VIAL	N50306 006	
+		EQ 10GM BASE/VIAL	N50306 007	
@		EQ 1GM BASE/VIAL	N50306 001	
@		EQ 2GM BASE/VIAL	N50306 004	
@		EQ 5GM BASE/VIAL	N50306 002	
@		EQ 10GM BASE/VIAL	N50306 006	
@		EQ 30GM BASE/VIAL	N50306 007	

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL
CARBIDOPA AND LEVODOPA

AB	MYLAN	**50MG;200MG**	**N75091 001**	SEP 30, 1999
	SINEMET CR			
AB	+ DUPONT PHARMS	**50MG;200MG**	**N19856 001**	MAY 30, 1991
	+	50MG;200MG	N19856 001	MAY 30, 1991

CARBINOXAMINE MALEATE

ELIXIR; ORAL
CLISTIN

> ADD >	@ MCNEIL	4MG/5ML	N08955 001	

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OCUPRESS

+	CIBA	1%	N19972 001	MAY 23, 1990
+	OTSUKA	1%	N19972 001	MAY 23, 1990

CEFACLOR

CAPSULE; ORAL

	CEFACLOR			
AB	LEDERLE	EQ 250MG BASE	N64107 001	APR 27, 1995
AB		EQ 500MG BASE	N64107 002	APR 27, 1995
@		EQ 250MG BASE	N64107 001	APR 27, 1995
@		EQ 500MG BASE	N64107 002	APR 27, 1995
AB	TEVA	EQ 250MG BASE	N64081 001	SEP 16, 1996
AB		EQ 500MG BASE	N64081 002	SEP 16, 1996
@		EQ 250MG BASE	N64081 001	SEP 16, 1996
@		EQ 500MG BASE	N64081 002	SEP 16, 1996

POWDER FOR RECONSTITUTION; ORAL

	CEFACLOR			
AB	LEDERLE	EQ 125MG BASE/5ML	N64114 001	APR 28, 1995
AB		EQ 187MG BASE/5ML	N64115 001	APR 28, 1995
AB		EQ 250MG BASE/5ML	N64116 001	APR 28, 1995
AB		EQ 375MG BASE/5ML	N64110 001	APR 28, 1995
@		EQ 125MG BASE/5ML	N64114 001	APR 28, 1995
@		EQ 187MG BASE/5ML	N64115 001	APR 28, 1995
@		EQ 250MG BASE/5ML	N64116 001	APR 28, 1995
@		EQ 375MG BASE/5ML	N64110 001	APR 28, 1995

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

	CEFADROXIL			
AB	BARR	EQ 500MG BASE	N65015 001	JUN 22, 1999

POWDER FOR RECONSTITUTION; ORAL

	CEFADROXIL			
AB	APOTHECON	EQ 125MG BASE/5ML	N62334 001	

CEFADROXIL/CEFADROXIL HEMIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

	CEFADROXIL			
AB	APOTHECON	EQ 250MG BASE/5ML	N62334 002	
AB		EQ 500MG BASE/5ML	N62334 003	
@		EQ 125MG BASE/5ML	N62334 001	
@		EQ 250MG BASE/5ML	N62334 002	
@		EQ 500MG BASE/5ML	N62334 003	
	DURICEF			
AB	+ BRISTOL MYERS SQUIBB	EQ 125MG BASE/5ML	N50527 002	
AB	+	EQ 250MG BASE/5ML	N50527 003	
AB	+	EQ 500MG BASE/5ML	N50527 001	
+		EQ 125MG BASE/5ML	N50527 002	
+		EQ 250MG BASE/5ML	N50527 003	
+		EQ 500MG BASE/5ML	N50527 001	

TABLET; ORAL

	CEFADROXIL			
AB	RANBAXY	EQ 1GM BASE	N65018 001	APR 23, 1999
	ULTRACEF			
AB	APOTHECON	EQ 1GM BASE	N62390 001	JUN 10, 1982
@		EQ 1GM BASE	N62390 001	JUN 10, 1982

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

	CEPTAZ			
AP	+ GLAXO WELLCOME	1GM/VIAL	N50646 002	SEP 27, 1990
AP	+	2GM/VIAL	N50646 003	SEP 27, 1990
AP	+	10GM/VIAL	N50646 004	SEP 27, 1990
+		1GM/VIAL	N50646 002	SEP 27, 1990
+		2GM/VIAL	N50646 003	SEP 27, 1990
+		10GM/VIAL	N50646 004	SEP 27, 1990
	PENTACEF			
AP	SMITHKLINE BEECHAM	1GM/VIAL	N63322 001	NOV 07, 1995
AP		1GM/VIAL	N64006 001	MAR 31, 1992

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION
PENTACEF

AP	SMITHKLINE BEECHAM	2GM/VIAL	N63322 002	NOV 07, 1995
AP		2GM/VIAL	N64006 002	MAR 31, 1992
AP		10GM/VIAL	N64008 002	MAR 31, 1992
		6GM/VIAL	N64008 001	MAR 31, 1992
	@	1GM/VIAL	N63322 001	NOV 07, 1995
	@	1GM/VIAL	N64006 001	MAR 31, 1992
	@	2GM/VIAL	N63322 002	NOV 07, 1995
	@	2GM/VIAL	N64006 002	MAR 31, 1992
	@	6GM/VIAL	N64008 001	MAR 31, 1992
	@	10GM/VIAL	N64008 002	MAR 31, 1992

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME

AB	ASTRA PHARMS	EQ 750MG BASE/VIAL	N64192 002	APR 16, 1998
AP		EQ 1.5GM BASE/VIAL	N64192 001	APR 16, 1998
AP		EQ 7.5GM BASE/VIAL	N64191 001	APR 16, 1998
AB	TEVA	EQ 750MG BASE/VIAL	N64192 002	APR 16, 1998
AP		EQ 1.5GM BASE/VIAL	N64192 001	APR 16, 1998
AP		EQ 7.5GM BASE/VIAL	N64191 001	APR 16, 1998

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	RANBAXY	EQ 250MG BASE	N65007 001	SEP 16, 1999

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	RANBAXY	EQ 500MG BASE	N65007 002	SEP 16, 1999

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM

AP	ABBOTT	EQ 1GM BASE/VIAL	N62547 001	SEP 11, 1985
AP		EQ 2GM BASE/VIAL	N62547 002	SEP 11, 1985
	@	EQ 1GM BASE/VIAL	N62547 001	SEP 11, 1985
	@	EQ 2GM BASE/VIAL	N62547 002	SEP 11, 1985

CERIVASTATIN SODIUM

TABLET; ORAL
BAYCOL

*	BAYER	0.3MG	N20740 004	JUN 26, 1997
		0.3MG	N20740 004	JUN 26, 1997
+		0.4MG	N20740 005	MAY 24, 1999

CHLORAMPHENICOL

SOLUTION/DROPS; OPHTHALMIC
CHLORAMPHENICOL

AT	ALCON	0.5%	N62628 001	SEP 25, 1985
AT	STERIS	0.5%	N62628 001	SEP 25, 1985

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
A-POXIDE

@	ABBOTT	5MG	N85517 001	

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

	A-POXIDE			
	@ ABBOTT	5MG		N85517 001
	CHLORDIAZEPOXIDE HCL			
AB	MAST MM	10MG		N86217 001
	@	10MG		N86217 001

CHLOROQUINE PHOSPHATE

TABLET; ORAL

	CHLOROQUINE PHOSPHATE			
AA	MD PHARM	EQ 150MG BASE		N87228 001
	@	EQ 150MG BASE		N87228 001
AA	WEST WARD	EQ 300MG BASE		N83082 002 SEP 17, 1999

CHLOROTRIANISENE

CAPSULE; ORAL

	CHLOROTRIANISENE			
AA	BANNER PHARMACAPS	12MG		N84652 001
	@	12MG		N84652 001
	TACE			
AA	+ HOECHST MARION RSSL	12MG		N08102 004
	+	12MG		N08102 004

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

		CHLORPROMAZINE HCL			
> ADD >	AA	PHARM ASSOC	30MG/ML		N40231 001 DEC 30, 1999
> ADD >	AA		100MG/ML		N40224 001 JAN 26, 1999

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE			
AB	ABBOTT	25MG		N87364 001
	@	25MG		N87364 001
AB	DANBURY PHARMA	25MG		N87296 001
AB		25MG		N87706 001

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE			
AB	DANBURY PHARMA	50MG		N87521 001
AB		50MG		N87689 001
	@	25MG		N87296 001
	@	25MG		N87706 001
	@	50MG		N87521 001
	@	50MG		N87689 001
AB	EON	50MG		N87118 001
	@	50MG		N87118 001
AB	KV PHARM	25MG		N87311 001
AB		50MG		N87312 001
	@	25MG		N87311 001
	@	50MG		N87312 001
AB	LEDERLE	25MG		N87451 001
AB		50MG		N87450 001
	@	25MG		N87451 001
	@	50MG		N87450 001

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	BAKER NORTON	EQ 4GM RESIN/PACKET		N74771 001 JUL 09, 1997
AB		EQ 4GM RESIN/SCOOPFUL		N74771 002 JUL 09, 1997
AB	ZENITH GOLDLINE	EQ 4GM RESIN/PACKET		N74771 001 JUL 09, 1997
AB		EQ 4GM RESIN/SCOOPFUL		N74771 002 JUL 09, 1997
	CHOLESTYRAMINE LIGHT			
AB	COPLEY PHARM	EQ 4GM RESIN/SCOOPFUL		N74555 002 SEP 30, 1998

> ADD > TABLET; ORAL
> ADD > QUESTRAN
> ADD > + APOTHECON EQ 800MG RESIN N73403 002 DEC 27, 1999
> ADD >

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

	CATARASE			
	+ CIBA	300 UNITS/VIAL		N16938 001

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

	CATARASE			
	@ CIBA	300 UNITS/VIAL	N16938 001	
	ZOLYSE			
	ALCON	750 UNITS/VIAL	N11903 001	
+		750 UNITS/VIAL	N11903 001	

CICLOPIROX

> ADD >
> ADD >
> ADD >
> ADD >

SOLUTION; TOPICAL

	PENLAC			
+	AVENTIS PHARM	8%	N21022 001	
			DEC 17, 1999	

CILOSTAZOL

TABLET; ORAL

	PLETAL			
	OTSUKA	50MG	N20863 001	
			JAN 15, 1999	
+		100MG	N20863 002	
			JAN 15, 1999	

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

	NIMBEX			
+	ABBOTT	EQ 2MG BASE/ML	N20551 001	
			DEC 15, 1995	
*	GLAXO WELLCOME	EQ 2MG BASE/ML	N20551 001	
			DEC 15, 1995	
	NIMBEX PRESERVATIVE FREE			
+	ABBOTT	EQ 2MG BASE/ML	N20551 003	
			DEC 15, 1995	
+		EQ 10MG BASE/ML	N20551 002	
			DEC 15, 1995	
*	GLAXO WELLCOME	EQ 2MG BASE/ML	N20551 003	
			DEC 15, 1995	
*		EQ 10MG BASE/ML	N20551 002	
			DEC 15, 1995	

CISPLATIN

INJECTABLE; INJECTION

		CISPLATIN			
AP		AM PHARM PARTNERS	1MG/ML	N74735 001	
				JUL 16, 1999	
		PLATINOL-AQ			
AP	+	BRISTOL MYERS	1MG/ML	N18057 004	
				NOV 08, 1988	
	*		1MG/ML	N18057 004	
				NOV 08, 1988	

CITALOPRAM HYDROBROMIDE

> ADD >
> ADD >
> ADD >
> ADD >

SOLUTION; ORAL

	CELEXA			
+	FOREST LABS	EQ 10MG BASE/5ML	N21046 001	
			DEC 22, 1999	

CLARITHROMYCIN

GRANULE, FOR RECONSTITUTION; ORAL

	BIAXIN			
	ABBOTT	187MG/5ML	N50698 003	
			SEP 30, 1998	

TABLET; ORAL

	BIAXIN			
*	ABBOTT	250MG	N50662 001	
			OCT 31, 1991	
		250MG	N50662 001	
			OCT 31, 1991	

> DLT >
> DLT >
> ADD >
> ADD >

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

		CLEOCIN HCL			
AB	*	PHARMACIA AND UPJOHN	EQ 75MG BASE	N50162 001	
AB			EQ 75MG BASE	N50162 001	
AB	*		EQ 150MG BASE	N50162 002	
AB			EQ 150MG BASE	N50162 002	
			EQ 300MG BASE	N50162 003	
				APR 14, 1988	
	+		EQ 300MG BASE	N50162 003	
				APR 14, 1988	

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

	CLINDAMYCIN PHOSPHATE		
AP	SOLOPAK	EQ 150MG BASE/ML	N62819 001 MAR 15, 1988
AP		EQ 150MG BASE/ML	N62852 001 MAR 17, 1988
@		EQ 150MG BASE/ML	N62819 001 MAR 15, 1988
@		EQ 150MG BASE/ML	N62852 001 MAR 17, 1988
AP	STERIS	EQ 150MG BASE/ML	N62900 001 JUN 08, 1988
AP		EQ 150MG BASE/ML	N63079 001 MAR 05, 1990
@		EQ 150MG BASE/ML	N62900 001 JUN 08, 1988
@		EQ 150MG BASE/ML	N63079 001 MAR 05, 1990

SUPPOSITORY; VAGINAL

	CLEOCIN		
+	PHARMACIA AND UPJOHN	100MG	N50767 001 AUG 13, 1999

CLOBETASOL PROPIONATE

CREAM; TOPICAL

	CLOBETASOL PROPIONATE		
AB	ALPHARMA US PHARM	0.05%	N74139 001 AUG 03, 1994
AB	NNC	0.05%	N74139 001 AUG 03, 1994
	CLOBETASOL PROPIONATE (EMOLLIENT)		
AB2	ALTANA	0.05%	N75430 001 MAY 26, 1999
@		0.05%	N75430 001 MAY 26, 1999

GEL; TOPICAL

	CLOBETASOL PROPIONATE		
AB	TARO	0.05%	N75279 001 MAY 28, 1999

SOLUTION; TOPICAL

	CLOBETASOL PROPIONATE		
AT	ALTANA	0.05%	N75391 001 FEB 08, 1999

CLOMIPHENE CITRATE

TABLET; ORAL

	CLOMIPHENE CITRATE		
AB	PAR PHARM	50MG	N75528 001 AUG 30, 1999

CLOXACILLIN SODIUM

CAPSULE; ORAL

	CLOXAPEN		
AB	SMITHKLINE BEECHAM	EQ 250MG BASE	N62233 001
AB		EQ 500MG BASE	N62233 002
@		EQ 250MG BASE	N62233 001
@		EQ 500MG BASE	N62233 002

POWDER FOR RECONSTITUTION; ORAL

	CLOXACILLIN SODIUM		
AA	TEVA	EQ 125MG BASE/5ML	N62268 001
+		EQ 125MG BASE/5ML	N62268 001
	TEGOPEN		
AA	+ APOTHECON	EQ 125MG BASE/5ML	N61453 001
@		EQ 125MG BASE/5ML	N61453 001

CLOZAPINE

TABLET; ORAL

	CLOZAPINE		
AB	CREIGHTON	25MG	N74546 001 AUG 30, 1996
AB		100MG	N74546 002 AUG 30, 1996
AB	GENEVA PHARMS	25MG	N74546 001 AUG 30, 1996
AB		100MG	N74546 002 AUG 30, 1996
AB	MYLAN	25MG	N75417 001 MAY 27, 1999
AB		100MG	N75417 002 MAY 27, 1999

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

	COLISTIMETHATE		
AP	PHARMA TEK	EQ 150MG BASE/VIAL	N64216 001 FEB 26, 1999

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLY-MYCIN M

AP	+	PARKEDALE	EQ 150MG BASE/VIAL	N50108 002
	*		EQ 150MG BASE/VIAL	N50108 002

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE
COPPER T MODEL TCU 380A

> ADD >		+ JOHNSON RW	309MG/COPPER	N18680 001 NOV 15, 1984
> DLT >		* POPULATION COUNCIL	309MG/COPPER	N18680 001 NOV 15, 1984

CORTICOTROPIN

INJECTABLE; INJECTION
CORTICOTROPIN

AP	*	STERIS	40 UNITS/VIAL	N88772 001 NOV 21, 1984
	@		40 UNITS/VIAL	N88772 001 NOV 21, 1984

CROMOLYN SODIUM

CAPSULE; ORAL
GASTROCROM

	+	MEDEVA	100MG	N19188 001 DEC 22, 1989
	@		100MG	N19188 001 DEC 22, 1989

SOLUTION; INHALATION
CROMOLYN SODIUM

AN		ALPHARMA	10MG/ML	N75067 001 JUL 19, 1999
AN		MORTON GROVE	10MG/ML	N75346 001 OCT 25, 1999
AN		ROXANE	10MG/ML	N75175 001 SEP 30, 1999

SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

AT		ALCON	4%	N75282 001 JUN 16, 1999

CROMOLYN SODIUM

SOLUTION/DROPS; OPHTHALMIC
CROMOPTIC

AT		KING PHARMS	4%	N75088 001 APR 27, 1999

CROTAMITON

LOTION; TOPICAL
CROTAN

AT		GALDERMA	10%	N87204 001
AT		SUMMERS	10%	N87204 001

CYANOCOBALAMIN

INJECTABLE; INJECTION
RUVITE

AP		SAVAGE LABS	1MG/ML	N80570 002
	@		1MG/ML	N80570 002

CYCLOPHOSPHAMIDE

TABLET; ORAL
CYCLOPHOSPHAMIDE

AB		ROXANE	25MG	N40032 001 AUG 17, 1999
AB			50MG	N40032 002 AUG 17, 1999

CYTOXAN

AB		BRISTOL MYERS SQUIBB	25MG	N12141 002
AB	+		50MG	N12141 001
	*		25MG	N12141 002
	*		50MG	N12141 001

CYCLOSPORINE

INJECTABLE; INJECTION
CYCLOSPORINE

AP		BEDFORD	50MG/ML	N65004 001 OCT 29, 1999

SANDIMMUNE

AP	+	NOVARTIS	50MG/ML	N50573 001 NOV 14, 1983

CYCLOSPORINE

INJECTABLE; INJECTION

	SANDIMMUNE			
	* NOVARTIS	50MG/ML	N50573 001	
			NOV 14, 1983	

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

	CYPROHEPTADINE HCL			
AA	MD PHARM	4MG	N87566 001	
			NOV 10, 1982	
	@	4MG	N87566 001	
			NOV 10, 1982	

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CYSTEINE HCL			
	@ FRESENIUS KABI	7.25%	N19523 001	
			OCT 22, 1986	
	@ PHARMACIA AND UPJOHN	7.25%	N19523 001	
			OCT 22, 1986	

CYTARABINE

INJECTABLE; INJECTION

	CYTARABINE			
AP	FAULDING	2GM/VIAL	N75383 001	
			NOV 22, 1999	

INJECTABLE, LIPOSOMAL; INJECTION

	DEPOCYT			
	* DEPOTECH	10MG/ML	N21041 001	
			APR 01, 1999	
	+ SKYEPHARMA	10MG/ML	N21041 001	
			APR 01, 1999	

DACARBAZINE

INJECTABLE; INJECTION

	DACARBAZINE			
AP	AM PHARM PARTNERS	100MG/VIAL	N75371 001	
			AUG 27, 1999	

DACARBAZINE

INJECTABLE; INJECTION

	DACARBAZINE			
AP	AM PHARM PARTNERS	200MG/VIAL	N75371 002	
			AUG 27, 1999	
	DTIC-DOME			
AP	+ BAYER	100MG/VIAL	N17575 001	
	*	100MG/VIAL	N17575 001	

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; INJECTION

	SYNERCID			
	RHONE POULENC RORER	350MG/VIAL; EQ 150MG BASE/VIAL	N50747 001	
			SEP 21, 1999	
		350MG/VIAL; EQ 150MG BASE/VIAL	N50748 001	
			SEP 21, 1999	

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	CERUBIDINE			
AP	+ BEDFORD	EQ 20MG BASE/VIAL	N64103 001	
			FEB 03, 1995	
	*	EQ 20MG BASE/VIAL	N64103 001	
			FEB 03, 1995	
	DAUNORUBICIN HCL			
	+ BEDFORD	EQ 5MG BASE/ML	N50731 001	
			JAN 30, 1998	
AP	BIGMAR	EQ 20MG BASE/VIAL	N65000 001	
			MAY 25, 1999	
AP	GENSIA SICOR PHARMS	EQ 20MG BASE/VIAL	N64212 001	
			JUN 23, 1998	
	DAUNORUBICIN HCL PRESERVATIVE FREE			
AP	* BEDFORD	EQ 20MG BASE/VIAL	N50731 001	
			JAN 30, 1998	
AP	GENSIA SICOR PHARMS	EQ 20MG BASE/VIAL	N64212 001	
			JUN 23, 1998	

DELAVIRDINE MESYLATE

TABLET; ORAL
RESCRIPTOR

> ADD >		+	AGOURON	100MG	N20705 001
> ADD >					APR 04, 1997
> DLT >		+	PHARMACIA AND UPJOHN	100MG	N20705 001
> DLT >					APR 04, 1997

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DDAVP

AB	+	RHONE POULENC RORER	0.01MG/SPRAY	N17922 002
				FEB 06, 1989
AB	+		0.01MG/SPRAY	N17922 003
				AUG 07, 1996
	@		0.01MG/SPRAY	N17922 002
				FEB 06, 1989

DDAVP (NEEDS NO REFRIGERATION)

AB	+	RHONE POULENC RORER	0.01MG/SPRAY	N17922 003
				AUG 07, 1996

DESMOPRESSIN ACETATE

AB		BAUSCH AND LOMB	0.01MG/SPRAY	N74830 001
				JAN 25, 1999

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21
DESOGESTREL AND ETHINYL ESTRADIOL

AB		DURAMED	0.15MG;0.03MG	N75256 001
				AUG 12, 1999

ORTHO-CEPT

AB	+	JOHNSON RW	0.15MG;0.03MG	N20301 001
				DEC 14, 1992
	+		0.15MG;0.03MG	N20301 001
				DEC 14, 1992

TABLET; ORAL-28
DESOGESTREL AND ETHINYL ESTRADIOL

AB		DURAMED	0.15MG;0.03MG	N75256 002
				AUG 12, 1999

DESONIDE

CREAM; TOPICAL
TRIDESILON

AB	+	BAYER	0.05%	N17010 001
AB	+	CLAY PARK	0.05%	N17010 001

OINTMENT; TOPICAL
TRIDESILON

AB	+	BAYER	0.05%	N17426 001
AB	+	CLAY PARK	0.05%	N17426 001

DEXAMETHASONE

SUSPENSION/DROPS; OPHTHALMIC
DEXAMETHASONE

AT		STERIS	0.1%	N89170 001
				MAY 09, 1989
	@		0.1%	N89170 001
				MAY 09, 1989

MAXIDEX

AT	+	ALCON	0.1%	N13422 001
	+		0.1%	N13422 001

TABLET; ORAL
DEXONE 0.5

BP		SOLVAY	0.5MG	N84991 001
	@		0.5MG	N84991 001

DEXONE 0.75

BP		SOLVAY	0.75MG	N84993 001
	@		0.75MG	N84993 001

DEXONE 4

BP		SOLVAY	4MG	N84992 001
	@		4MG	N84992 001

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
MAXITROL

AT	+	ALCON	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50065 002
AT	+	FALCON PHARMS	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50065 002

SUSPENSION/DROPS; OPHTHALMIC
MAXITROL

AT	+	ALCON	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50023 002

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

		MAXITROL		
AT	+	FALCON PHARMS	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N50023 002**

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION; OPHTHALMIC

		TOBRADEX		
	+	ALCON	0.1%;0.3%	N50592 001 AUG 18, 1988

SUSPENSION/DROPS; OPHTHALMIC

		TOBRADEX		
AB	+	ALCON	**0.1%;0.3%**	**N50592 001** AUG 18, 1988
		TOBRAMYCIN AND DEXAMETHASONE		
AB		BAUSCH AND LOMB	**0.1%;0.3%**	**N64134 001** OCT 27, 1999

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

		DECADRON		
AP	+	MERCK	**EQ 24MG PHOSPHATE/ML**	**N12071 004**
	+		EQ 24MG PHOSPHATE/ML	N12071 004
		DEXAMETHASONE SODIUM PHOSPHATE		
AP		STERIS	**EQ 4MG PHOSPHATE/ML**	**N83702 001**
AP			**EQ 24MG PHOSPHATE/ML**	**N85606 001**
	@		EQ 4MG PHOSPHATE/ML	N83702 001
	@		EQ 24MG PHOSPHATE/ML	N85606 001

> ADD > DEXMEDETOMIDINE

> ADD > INJECTABLE; INJECTION

> ADD >		PRECEDEX		
> ADD >	+	ABBOTT	EQ 100 UGM BASE/ML	N21038 001 DEC 17, 1999

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

		DEXTROAMPHETAMINE SULFATE		
AA		ENDO PHARMS	**5MG**	**N40299 001** MAY 13, 1999

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 25%		
	ABBOTT	250MG/ML	N19445 002 NOV 23, 1998

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
AP	B BRAUN	**2.5GM/100ML;450MG/100ML**	**N18030 001**
@		2.5GM/100ML;450MG/100ML	N18030 001
	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER		
	B BRAUN	5GM/100ML;110MG/100ML	N18030 005
@		5GM/100ML;110MG/100ML	N18030 005
	DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER		
AP	B BRAUN	**5GM/100ML;200MG/100ML**	**N18030 004**
@		5GM/100ML;200MG/100ML	N18030 004
	DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER		
AP	B BRAUN	**5GM/100ML;330MG/100ML**	**N18030 003**
@		5GM/100ML;330MG/100ML	N18030 003
	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER		
AP	B BRAUN	**5GM/100ML;450MG/100ML**	**N18030 002**
@		5GM/100ML;450MG/100ML	N18030 002

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

	MD-76		
AP	MALLINCKRODT	**66%;10%**	**N87073 001**
@		66%;10%	N87073 001

DIAZEPAM

GEL; RECTAL

DIASTAT

+	ATHENA	2.5MG/0.5ML	N20648 001	JUL 29, 1997
		5MG/ML	N20648 002	JUL 29, 1997
		10MG/2ML	N20648 003	JUL 29, 1997
		15MG/3ML	N20648 004	JUL 29, 1997
+		20MG/4ML	N20648 005	JUL 29, 1997
+	ELAN PHARMS	2.5MG/0.5ML	N20648 001	JUL 29, 1997
		5MG/ML	N20648 002	JUL 29, 1997
		10MG/2ML	N20648 003	JUL 29, 1997
		15MG/3ML	N20648 004	JUL 29, 1997
+		20MG/4ML	N20648 005	JUL 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

AP	STERIS	5MG/ML	N70911 001	AUG 28, 1986
AP		5MG/ML	N70930 001	DEC 01, 1986
@		5MG/ML	N70911 001	AUG 28, 1986
@		5MG/ML	N70930 001	DEC 01, 1986

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

AB	MYLAN	50MG	N75463 001	JUL 26, 1999

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

AB	ALCON	0.1%	N20809 001	MAY 04, 1998
AB	FALCON PHARMS	0.1% †	N20809 001	MAY 04, 1998

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB	MARTEC	50MG	N74986 001	FEB 26, 1999
AB		75MG	N74986 002	FEB 26, 1999
AB	NOVOPHARM	50MG	N74723 001	MAR 30, 1999
AB	SIDMAK LABS NJ	50MG	N74432 002	JUL 29, 1999
AB		75MG	N74432 003	JUL 29, 1999

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HCL

AB	MYLAN	10MG	N40319 001	SEP 07, 1999

TABLET; ORAL

DICYCLOMINE HCL

AB	LANNETT	20MG	N40230 001	FEB 26, 1999
AB	MYLAN	20MG	N40317 001	SEP 07, 1999

DIDANOSINE

TABLET, CHEWABLE; ORAL

VIDEX

	BRISTOL MYERS SQUIBB	25MG	N20154 002	OCT 09, 1991
+		150MG	N20154 005	OCT 09, 1991
+		25MG	N20154 002	OCT 09, 1991

† SEE SECTION 1.3 OF INTRODUCTION

DIDANOSINE

TABLET, CHEWABLE; ORAL

	VIDEX			
	BRISTOL MYERS SQUIBB	150MG	N20154 005	
			OCT 09, 1991	
		200MG	N20154 006	
			OCT 28, 1999	

DIFLORASONE DIACETATE

CREAM; TOPICAL

	DIFLORASONE DIACETATE			
AB	TARO	0.05%	N75331 001	
			MAY 14, 1999	

OINTMENT; TOPICAL

	DIFLORASONE DIACETATE			
AB	ALTANA	0.05%	N75374 001	
			APR 27, 1999	
AB	TARO	0.05%	N75331 001	
			MAY 14, 1999	
	PSORCON			
AB +	PHARMACIA AND UPJOHN	0.05%	N19260 001	
			AUG 28, 1985	
+		0.05%	N19260 001	
			AUG 28, 1985	

DIFLUNISAL

TABLET; ORAL

	DIFLUNISAL			
AB	PUREPAC PHARM	250MG	N74285 001	
			MAY 07, 1996	
AB		500MG	N74285 002	
			MAY 07, 1996	
	@	250MG	N74285 001	
			MAY 07, 1996	
	@	500MG	N74285 002	
			MAY 07, 1996	

DIGOXIN

TABLET; ORAL

	DIGOXIN			
> ADD > AB	AMIDE PHARM	0.125MG	N40282 001	
> ADD >			DEC 23, 1999	
> ADD >				

DIGOXIN

TABLET; ORAL

	DIGOXIN			
> ADD > AB	AMIDE PHARM	0.25MG	N40282 002	
> ADD >			DEC 23, 1999	
	LANOXIN			
> ADD > AB	GLAXO WELLCOME	0.125MG	N20405 002	
> ADD >			SEP 30, 1997	
> ADD > AB +		0.25MG	N20405 004	
> ADD >			SEP 30, 1997	
> DLT >		0.125MG	N20405 002	
> DLT >			SEP 30, 1997	
> DLT > +		0.25MG	N20405 004	
> DLT >			SEP 30, 1997	

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CARDIZEM CD			
AB3 +	CARDERM	120MG	N20062 001	
			AUG 10, 1992	
AB3 +		180MG	N20062 002	
			DEC 27, 1991	
AB3 +		240MG	N20062 003	
			DEC 27, 1991	
AB3 +		300MG	N20062 004	
			DEC 27, 1991	
BC +		120MG	N20062 001	
			AUG 10, 1992	
BC +		180MG	N20062 002	
			DEC 27, 1991	
BC +		240MG	N20062 003	
			DEC 27, 1991	
BC +		300MG	N20062 004	
			DEC 27, 1991	
	CARTIA XT			
AB3	ANDRX PHARMS	120MG	N74752 002	
			JUL 09, 1998	
AB3		180MG	N74752 001	
			JUL 09, 1998	
AB3		240MG	N74752 003	
			JUL 09, 1998	
AB3		300MG	N74752 004	
			JUL 09, 1998	
@		120MG	N74752 002	
			JUL 09, 1998	

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CARTIA XT			
	@ ANDRX PHARMS	180MG	N74752 001	
			JUL 09, 1998	
	@	240MG	N74752 003	
			JUL 09, 1998	
	@	300MG	N74752 004	
			JUL 09, 1998	
	DILTIAZEM HCL			
AB1	BIOVAIL	60MG	**N74845 001**	
			SEP 15, 1999	
AB1		90MG	**N74845 002**	
			SEP 15, 1999	
AB1		120MG	**N74845 003**	
			SEP 15, 1999	
> ADD > AB3		120MG	**N75116 001**	
> ADD >			DEC 23, 1999	
> ADD > AB3		180MG	**N75116 002**	
> ADD >			DEC 23, 1999	
> ADD > AB3		240MG	**N75116 003**	
> ADD >			DEC 23, 1999	
> ADD > AB3		300MG	**N75116 004**	
> ADD >			DEC 23, 1999	
> ADD > AB3	PUREPAC PHARM	120MG	**N74984 001**	
> ADD >			DEC 20, 1999	
> ADD > AB3		180MG	**N74984 002**	
> ADD >			DEC 20, 1999	
> ADD > AB3		240MG	**N74984 003**	
> ADD >			DEC 20, 1999	
> ADD > AB3		300MG	**N74984 004**	
> ADD >			DEC 20, 1999	

INJECTABLE; INJECTION

	DILTIAZEM HCL		
AP	APOTEX	5MG/ML	**N75375 001**
			SEP 30, 1999
AP	MERIDIAN MEDCL TECHN	5MG/ML	**N75106 001**
			APR 29, 1999

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	DIPHENHYDRAMINE HCL		
AA	PUREPAC PHARM	25MG	N85156 001
AA		50MG	N85150 001
	@	25MG	N85156 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	DIPHENHYDRAMINE HCL		
	@ PUREPAC PHARM	50MG	N85150 001

ELIXIR; ORAL

	HYDRAMINE		
AA	ALPHARMA	12.5MG/5ML	N80763 002
	@	12.5MG/5ML	N80763 002

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	DIPIVEFRIN HCL		
AT	ALCON	0.1%	N73636 001
			JUN 30, 1994
AT	FALCON PHARMS	0.1%	**N73636 001**
			JUN 30, 1994

DIPYRIDAMOLE

TABLET; ORAL

	DIPYRIDAMOLE		
AB	PUREPAC PHARM	25MG	**N89425 001**
			JUL 12, 1990
AB		50MG	N89426 001
			JUL 12, 1990
	@	25MG	N89425 001
			JUL 12, 1990
	@	50MG	N89426 001
			JUL 12, 1990

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

	DYNABAC		
	+ LILLY	250MG	N50678 001
			JUN 19, 1995
	+ LILLY RES LABS	250MG	N50678 001
			JUN 19, 1995

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL
DEPAKOTE

> DLT >	ABBOTT	EQ 125MG VALPROIC ACID	N18723 003	
> DLT >			OCT 26, 1984	
> DLT >		EQ 250MG VALPROIC ACID	N18723 001	
> DLT >			MAR 10, 1983	
> ADD >	+	EQ 125MG VALPROIC ACID	N18723 003	
> ADD >			OCT 26, 1984	
> ADD >	+	EQ 250MG VALPROIC ACID	N18723 001	
> ADD >			MAR 10, 1983	

DOFETILIDE

CAPSULE; ORAL
TIKOSYN

	PFIZER	0.125MG	N20931 001
			OCT 01, 1999
		0.25MG	N20931 002
			OCT 01, 1999
	+	0.5MG	N20931 003
			OCT 01, 1999

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

AP	SMITH AND NEPHEW	40MG/ML	N70046 001
			AUG 29, 1985
AP		80MG/ML	N70047 001
			AUG 29, 1985
	@	40MG/ML	N70046 001
			AUG 29, 1985
	@	80MG/ML	N70047 001
			AUG 29, 1985

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION
NUROMAX

	+ ABBOTT	EQ 1MG BASE/ML	N19946 001
			MAR 07, 1991
	# GLAXO WELLCOME	EQ 1MG BASE/ML	N19946 001
			MAR 07, 1991

DOXERCALCIFEROL

CAPSULE; ORAL
HECTOROL

	+ BONE CARE	2.5 UGM	N20862 001
			JUN 09, 1999

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL; INJECTION
DOXIL

	+ ALZA	2MG/ML	N50718 001
			NOV 17, 1995
	# SEQUUS	2MG/ML	N50718 001
			NOV 17, 1995

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

		DOXYCHEL HYCLATE		
> DLT >	AB	RACHELLE	EQ 50MG BASE	N61717 001
> DLT >	AB		EQ 100MG BASE	N61717 002
> ADD >		**DOXYCYCLINE HYCLATE**		
> ADD >	AB	HOUBA	EQ 50MG BASE	N61717 001
> ADD >	AB		EQ 100MG BASE	N61717 002
		@ PUREPAC PHARM	EQ 50MG BASE	N62479 001
				DEC 23, 1983
		@	EQ 100MG BASE	N62479 002
				DEC 23, 1983
		@ RANBAXY	EQ 50MG BASE	N62479 001
				DEC 23, 1983
		@	EQ 100MG BASE	N62479 002
				DEC 23, 1983

TABLET; ORAL

> DLT >		**DOXY-TABS**		
> DLT >	AB	RACHELLE	EQ 100MG BASE	N62269 001
> DLT >	AB		EQ 100MG BASE	N62269 002
> DLT >				NOV 08, 1982
> DLT >		@	EQ 50MG BASE	N62269 003
> ADD >		**DOXYCYCLINE HYCLATE**		
> ADD >	AB	HOUBA	EQ 100MG BASE	N62269 001
> ADD >	AB		EQ 100MG BASE	N62269 002
> ADD >				NOV 08, 1982
> ADD >		DOXYCYCLINE HYLATE		
> ADD >		@ HOUBA	EQ 50MG BASE	N62269 003

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
BENDECTIN
@ HOECHST MARION RSSL 10MG;10MG N10598 002

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL
AP SOLOPAK 2.5MG/ML N71754 001 SEP 06, 1988
AP 2.5MG/ML N71755 001 SEP 06, 1988
@ 2.5MG/ML N71754 001 SEP 06, 1988
@ 2.5MG/ML N71755 001 SEP 06, 1988
AP STERIS 2.5MG/ML N73520 001 NOV 27, 1991
AP 2.5MG/ML N73521 001 NOV 27, 1991
AP 2.5MG/ML N73523 001 NOV 27, 1991
@ 2.5MG/ML N73520 001 NOV 27, 1991
@ 2.5MG/ML N73521 001 NOV 27, 1991
@ 2.5MG/ML N73523 001 NOV 27, 1991
INAPSINE
> ADD > AP + AKORN 2.5MG/ML N16796 001
> DLT > AP + AKORN MFG 2.5MG/ML N16796 001

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION
INNOVAR
> ADD > @ AKORN MFG 2.5MG/ML; EQ 0.05MG BASE/ML N16049 001
> DLT > @ JANSSEN 2.5MG/ML; EQ 0.05MG BASE/ML N16049 001

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
LEXXEL
+ ASTRAZENECA 5MG;2.5MG N20668 002 OCT 28, 1998

ENTACAPONE

TABLET; ORAL
COMTAN
+ ORION 200MG N20796 001 OCT 19, 1999

EPINEPHRINE

INJECTABLE; INJECTION
SUS-PHRINE
+ FOREST LABS 5MG/ML N07942 001
SUS-PHRINE SULFITE-FREE
FOREST LABS 1.5MG/AMP N07942 003 FEB 05, 1999
+ 5MG/ML N07942 001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
ELLENCE
+ PHARMACIA AND UPJOHN 2MG/ML N50778 001 SEP 15, 1999

EPROSARTAN MESYLATE

TABLET; ORAL
TEVETEN
SMITHKLINE BEECHAM EQ 300MG BASE N20738 004 DEC 22, 1997
EQ 400MG BASE N20738 005 DEC 22, 1997
+ EQ 600MG BASE N20738 006 MAY 27, 1999
UNIMED PHARMS EQ 300MG BASE N20738 004 DEC 22, 1997
EQ 400MG BASE N20738 005 DEC 22, 1997

EPROSARTAN MESYLATE

TABLET; ORAL

	TEVETEN			
+	UNIMED PHARMS	EQ 600MG BASE	N20738 006 MAY 27, 1999	

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION

	MEDIHALER ERGOTAMINE			
+	3M	0.36MG/INH	N12102 001	
@		0.36MG/INH	N12102 001	

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

	ERYC			
@	PARKE DAVIS	250MG	N62338 001	
@	WARNER CHILCOTT	250MG	N62338 001	

SOLUTION; TOPICAL

	C-SOLVE-2			
AT	BIOGLAN PHAR	**2%**	**N62468 001** JUL 03, 1985	
AT	ZENITH GOLDLINE	**2%**	**N62468 001** JUL 03, 1985	

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	ALORA			
BX	PROCTER AND GAMBLE	0.05MG/24HR	N20655 001 DEC 20, 1996	
BX		0.075MG/24HR	N20655 002 DEC 20, 1996	
BX		0.1MG/24HR	N20655 003 DEC 20, 1996	
BX	WATSON LABS	0.05MG/24HR	N20655 001 DEC 20, 1996	
BX		0.075MG/24HR	N20655 002 DEC 20, 1996	
BX		0.1MG/24HR	N20655 003 DEC 20, 1996	
	CLIMARA			
BX +	BERLEX LABS	0.025MG/24HR	N20375 004 MAR 05, 1999	

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	ESCLIM			
BX	FOURNIER	0.025MG/24HR	N20847 001 AUG 04, 1998	
BX		0.0375MG/24HR	N20847 002 AUG 04, 1998	
BX		0.05MG/24HR	N20847 003 AUG 04, 1998	
BX		0.075MG/24HR	N20847 004 AUG 04, 1998	
BX		0.1MG/24HR	N20847 005 AUG 04, 1998	
BX	WOMEN FIRST HLTHCARE	0.025MG/24HR	N20847 001 AUG 04, 1998	
BX		0.0375MG/24HR	N20847 002 AUG 04, 1998	
BX		0.05MG/24HR	N20847 003 AUG 04, 1998	
BX		0.075MG/24HR	N20847 004 AUG 04, 1998	
BX		0.1MG/24HR	N20847 005 AUG 04, 1998	
	ESTRADIOL			
BX	CYGNUS CA	0.05MG/24HR	N21048 001 SEP 20, 1999	
BX		0.075MG/24HR	N21048 002 SEP 20, 1999	
BX		0.1MG/24HR	N21048 003 SEP 20, 1999	
AB	MENOREST	**0.0375MG/24HR**	**N20538 001** JUL 31, 1996	
AB		**0.05MG/24HR**	**N20538 003** JUL 31, 1996	
AB		**0.075MG/24HR**	**N20538 002** JUL 31, 1996	
AB		**0.1MG/24HR**	**N20538 004** JUL 31, 1996	
BX	WYETH AYERST	0.05MG/24HR	N21048 001 SEP 20, 1999	
BX		0.075MG/24HR	N21048 002 SEP 20, 1999	
BX		0.1MG/24HR	N21048 003 SEP 20, 1999	
	VIVELLE-DOT			
AB	NOVARTIS	**0.0375MG/24HR**	**N20538 001** JUL 31, 1996	

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	VIVELLE-DOT			
AB	NOVARTIS	**0.05MG/24HR**	**N20538 003**	JUL 31, 1996
AB		**0.075MG/24HR**	**N20538 002**	JUL 31, 1996
AB		**0.1MG/24HR**	**N20538 004**	JUL 31, 1996

TABLET; ORAL

	ESTRADIOL			
AB	MYLAN	**0.5MG**	**N40326 001**	APR 21, 1999
AB		**1MG**	**N40326 002**	APR 21, 1999
AB		**2MG**	**N40326 003**	APR 21, 1999
	INNOFEM			
AB	NOVO NORDISK	**0.5MG**	**N40312 001**	NOV 19, 1999
AB		**1MG**	**N40312 002**	NOV 19, 1999
AB		**2MG**	**N40312 003**	NOV 19, 1999

TABLET; VAGINAL

	VAGIFEM			
+	NOVO NORDISK	25 UGM	N20908 001	MAR 26, 1999

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

	ORTHO-PREFEST			
+	JOHNSON RW	1MG,1MG;0.09MG,N/A	N21040 001	OCT 22, 1999

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

	CENESTIN			
	DURAMED	0.9MG	N20992 003	MAR 24, 1999
		0.625MG	N20992 002	MAR 24, 1999

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

	CENESTIN			
+	DURAMED	0.9MG	N20992 003	MAR 24, 1999

ESTRONE

INJECTABLE; INJECTION

	NATURAL ESTROGENIC SUBSTANCE ESTRONE			
+	STERIS	2MG/ML	N85237 001	NOV 23, 1982
@		2MG/ML	N85237 001	NOV 23, 1982

ESTROPIPATE

CREAM; VAGINAL

	OGEN			
+	ABBOTT	1.5MG/GM	N84710 001	
+	PHARMACIA AND UPJOHN	1.5MG/GM	N84710 001	

TABLET; ORAL

	ESTROPIPATE			
AB	DURAMED	**0.75MG**	**N40296 001**	NOV 01, 1999
AB		**1.5MG**	**N40296 002**	NOV 01, 1999
AB		**3MG**	**N40296 003**	NOV 01, 1999
AB	MYLAN	**0.75MG**	**N40359 001**	AUG 26, 1999
AB		**1.5MG**	**N40359 002**	AUG 26, 1999
AB		**3MG**	**N40359 003**	AUG 26, 1999
	OGEN .625			
AB	ABBOTT	**0.75MG**	**N83220 001**	
AB	PHARMACIA AND UPJOHN	**0.75MG**	**N83220 001**	
	OGEN 1.25			
AB	ABBOTT	**1.5MG**	**N83220 002**	
AB	PHARMACIA AND UPJOHN	**1.5MG**	**N83220 002**	
	OGEN 2.5			
AB	+ ABBOTT	**3MG**	**N83220 003**	
AB	+ PHARMACIA AND UPJOHN	**3MG**	**N83220 003**	
	OGEN 5			
AB	ABBOTT	**5MG**	**N83220 004**	

ESTROPIPATE

TABLET; ORAL

	OGEN 5			
AB	PHARMACIA AND UPJOHN	6MG		N83220 004

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

	ETHAMBUTOL HCL			
AB	WEST WARD	100MG		N75095 001
				NOV 30, 1999
AB		400MG		N75095 002
				NOV 30, 1999
	MYAMBUTOL			
AB	LEDERLE	100MG		N16320 001
AB	+	400MG		N16320 003
	+	100MG		N16320 001
	+	400MG		N16320 003

ETHCHLORVYNOL

CAPSULE; ORAL

	ETHCHLORVYNOL			
AA	BANNER PHARMACAPS	200MG		N84463 002
AA		500MG		N84463 003
AA		750MG		N84463 004
		100MG		N84463 001
	@	100MG		N84463 001
	@	200MG		N84463 002
	@	500MG		N84463 003
	@	750MG		N84463 004
	PLACIDYL			
AA	+ ABBOTT	200MG		N10021 007
AA	+	500MG		N10021 002
AA	+	750MG		N10021 010
	+	200MG		N10021 007
	+	500MG		N10021 002
	+	750MG		N10021 010

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	LEVLITE			
	+ BERLEX LABS	0.02MG;0.1MG		N20860 001
				JUL 13, 1998

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	BREVICON 21-DAY			
AB	SEARLE	0.035MG;0.5MG		N17566 001
AB	WATSON LABS	0.035MG;0.5MG		N17566 001
	NORINYL 1+35 21-DAY			
AB	SEARLE	0.035MG;1MG		N17565 001
AB	WATSON LABS	0.035MG;1MG		N17565 001
	TRI-NORINYL 21-DAY			
	+ SEARLE	0.035MG,0.035MG;0.5MG,1MG		N18977 001
				APR 13, 1984
	+ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG		N18977 001
				APR 13, 1984

TABLET; ORAL-28

	BREVICON 28-DAY			
AB	SEARLE	0.035MG;0.5MG		N17743 001
AB	WATSON LABS	0.035MG;0.5MG		N17743 001
	NORINYL 1+35 28-DAY			
AB	SEARLE	0.035MG;1MG		N17565 002
AB	WATSON LABS	0.035MG;1MG		N17565 002
	TRI-NORINYL 28-DAY			
	SEARLE	0.035MG,0.035MG;0.5MG,1MG		N18977 002
				APR 13, 1984
	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG		N18977 002
				APR 13, 1984

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

	FEMHRT			
	+ PARKE DAVIS	0.005MG;1MG		N21065 002
				OCT 15, 1999

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

	LO/OVRAL			
AB	+ WYETH AYERST	0.03MG;0.3MG		N17612 001

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

		LO/OVRAL			
	+	WYETH AYERST	0.03MG;0.3MG	N17612 001	
		LOW-OGESTREL-21			
AB		SCS	0.03MG;0.3MG	N75288 001 JUL 28, 1999	> ADD >
AB		WATSON LABS	0.03MG;0.3MG	N75288 001 JUL 28, 1999	> ADD >
> ADD >		OGESTREL 0.5/50-21			
> ADD > AB		SCS	0.05MG;0.5MG	N75406 001 DEC 15, 1999	
> ADD >					
		OVRAL			
> ADD > AB	+	WYETH AYERST	0.05MG;0.5MG	N16672 001	
> DLT >	+		0.05MG;0.5MG	N16672 001	

TABLET; ORAL-28

		LO/OVRAL-28			
AB		WYETH AYERST	0.03MG;0.3MG	N17802 001	
			0.03MG;0.3MG	N17802 001	
		LOW-OGESTREL-28			
AB		SCS	0.03MG;0.3MG	N75288 002 JUL 28, 1999	
AB		WATSON LABS	0.03MG;0.3MG	N75288 002 JUL 28, 1999	
> ADD >		OGESTREL 0.5/50-28			
> ADD > AB		SCS	0.05MG;0.5MG	N75406 002 DEC 15, 1999	
> ADD >					
		OVRAL-28			
> ADD > AB		WYETH AYERST	0.05MG;0.5MG	N16806 001	
> DLT >			0.05MG;0.5MG	N16806 001	

ETODOLAC

CAPSULE; ORAL

	ETODOLAC			
AB	NOVOPHARM NC	200MG	N75126 001 SEP 16, 1999	
AB		300MG	N75126 002 SEP 16, 1999	

TABLET; ORAL

	ETODOLAC			
AB	EON	500MG	N74903 002 APR 19, 1999	
AB	NOVOPHARM	400MG	N74847 001 APR 23, 1999	
AB	NOVOPHARM	500MG	N74847 002 APR 23, 1999	
AB	TEVA	500MG	N75009 002 DEC 28, 1999	> ADD >

ETOPOSIDE

INJECTABLE; INJECTION

	ETOPOSIDE			
AP	AM PHARM PARTNERS	20MG/ML	N74983 001 SEP 30, 1998	
AP	APPLIED ANAL	20MG/ML	N74983 001 SEP 30, 1998	
AP	STERIS	20MG/ML	N74228 001 OCT 15, 1996	
@		20MG/ML	N74228 001 OCT 15, 1996	
	VEPESID			
AP +	BRISTOL	20MG/ML	N18768 001 NOV 10, 1983	
AP +	BRISTOL MYERS SQUIBB	20MG/ML	N18768 001 NOV 10, 1983	

ETRETINATE

CAPSULE; ORAL

	TEGISON			
	ROCHE	10MG	N19369 001 SEP 30, 1986	
+		25MG	N19369 002 SEP 30, 1986	
@		10MG	N19369 001 SEP 30, 1986	
@		25MG	N19369 002 SEP 30, 1986	

EXEMESTANE

TABLET; ORAL

	AROMASIN			
+	PHARMACIA AND UPJOHN	25MG	N20753 001 OCT 21, 1999	

FENOFIBRATE

CAPSULE; ORAL
TRICOR (MICRONIZED)

+	ABBOTT	67MG	N19304 002 FEB 09, 1998
		67MG	N19304 002 FEB 09, 1998
		134MG	N19304 003 JUN 30, 1999
+		200MG	N19304 004 JUN 30, 1999

FERRIC SODIUM GLUCONATE

INJECTABLE; INJECTION
FERRLECIT

+	R AND D LABS	62.5MG/5ML	N20955 001 FEB 18, 1999

FLUOCINONIDE

OINTMENT; TOPICAL
FLUOCINONIDE

AB	TARO	**0.05%**	**N75008 001** JUN 30, 1999

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL

AP	BIGMAR	**50MG/ML**	**N40291 001** MAR 24, 1999
AP	SMITH AND NEPHEW	50MG/ML	N88767 001 DEC 28, 1984
AP		50MG/ML	N89434 001 MAR 26, 1987
@		50MG/ML	N88767 001 DEC 28, 1984
@		50MG/ML	N89434 001 MAR 26, 1987

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
PROZAC

+	LILLY	EQ 20MG BASE	N18936 001 DEC 29, 1987
		EQ 20MG BASE	N18936 001 DEC 29, 1987
+		EQ 40MG BASE	N18936 003 JUN 15, 1999
@		EQ 60MG BASE	N18936 004 JUN 15, 1999

TABLET; ORAL
PROZAC

	LILLY	EQ 10MG BASE	N20974 001 MAR 09, 1999
+		EQ 20MG BASE	N20974 002 MAR 09, 1999
+		EQ 10MG BASE	N20974 001 MAR 09, 1999
@		EQ 20MG BASE	N20974 002 MAR 09, 1999

FOLIC ACID

TABLET; ORAL
FOLIC ACID

AA	VINTAGE PHARMS	**1MG**	**N86296 001**
@		1MG	N86296 001

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

AP	ABBOTT	**10MG/ML**	**N75241 001** MAY 28, 1999
AP	SMITH AND NEPHEW	**10MG/ML**	**N70078 001** FEB 05, 1986
@		10MG/ML	N70078 001 FEB 05, 1986
AP	STERIS	**10MG/ML**	**N70019 001** SEP 22, 1986
AP		**10MG/ML**	**N70604 001** JAN 02, 1987
@		10MG/ML	N70019 001 SEP 22, 1986

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

@	STERIS	10MG/ML	N70604 001 JAN 02, 1987

> ADD > GADOVERSETAMIDE

> ADD > INJECTABLE; INJECTION
> ADD > OPTIMARK

> ADD > +	MALLINCKRODT	330.9MG/ML	N20937 001 DEC 08, 1999
> ADD > +		330.9MG/ML	N20975 001 DEC 08, 1999

> ADD > OPTIMARK IN PLASTIC CONTAINER

> ADD > +	MALLINCKRODT	330.9MG/ML	N20976 001 DEC 08, 1999

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION
FLAXEDIL

+	DAVIS AND GECK	20MG/ML	N07842 001
+		100MG/ML	N07842 002
@		20MG/ML	N07842 001
@		100MG/ML	N07842 002

GALLIUM NITRATE

INJECTABLE; INJECTION
GANITE

+	SOLOPAK	25MG/ML	N19961 002 JAN 17, 1991
@		25MG/ML	N19961 002 JAN 17, 1991

GANIRELIX ACETATE

INJECTABLE; INJECTION
ANTAGON

+	ORGANON INC	EQ 250 UGM BASE/0.5ML	N21057 001 JUL 29, 1999

> ADD > GATIFLOXACIN

> ADD > INJECTABLE; INJECTION
> ADD > TEQUIN

> ADD > +	BRISTOL MYERS SQUIBB	200MG/VIAL	N21062 001 DEC 17, 1999
> ADD > +		400MG/VIAL	N21062 002 DEC 17, 1999

> ADD > TABLET; ORAL
> ADD > TEQUIN

> ADD >	BRISTOL MYERS SQUIBB	200MG	N21061 001 DEC 17, 1999
> ADD > +		400MG	N21061 002 DEC 17, 1999

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

AB	PUREPAC PHARM	600MG	N74360 001 AUG 31, 1994
@		600MG	N74360 001 AUG 31, 1994

GENTAMICIN SULFATE

INJECTABLE; INJECTION
APOGEN

AP	KING PHARMS	EQ 10MG BASE/ML	N62289 001
AP		EQ 40MG BASE/ML	N62289 002
@		EQ 10MG BASE/ML	N62289 001
@		EQ 40MG BASE/ML	N62289 002

BRISTAGEN

AP	BRISTOL	EQ 40MG BASE/ML	N62288 001
@		EQ 40MG BASE/ML	N62288 001

GENTAMICIN SULFATE

AP	SOLOPAK	EQ 10MG BASE/ML	N62507 001 JUN 06, 1985
AP		EQ 40MG BASE/ML	N62507 002 JUN 06, 1985
@		EQ 10MG BASE/ML	N62507 001 JUN 06, 1985
@		EQ 40MG BASE/ML	N62507 002 JUN 06, 1985

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

AT	ALCON	EQ 0.3% BASE	N62196 001

GENTAMICIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE

AT	FALCON PHARMS	EQ 0.3% BASE	N62196 001	

GLIPIZIDE

TABLET; ORAL
GLUCOTROL

	PFIZER	2.5MG	N17783 003	MAY 11, 1993
	@	2.5MG	N17783 003	MAY 11, 1993

TABLET, EXTENDED RELEASE; ORAL
GLUCOTROL XL

+	PFIZER	2.5MG	N20329 003	AUG 10, 1999

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)

AB	MOVA	4.5MG	N74591 003	DEC 22, 1997
		4.5MG	N74591 003	DEC 22, 1997
AB	MYLAN	6MG	N74792 003	AUG 17, 1999
AB	NOVOPHARM	1.5MG	N74686 001	APR 20, 1999
AB		3MG	N74686 002	APR 20, 1999
AB		4.5MG	N74686 003	APR 20, 1999
AB		6MG	N74686 004	APR 20, 1999

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

AP	STERIS	0.2MG/ML	N86947 001	JUN 24, 1983

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

	@ STERIS	0.2MG/ML	N86947 001	JUN 24, 1983

TABLET; ORAL
ROBINUL

+	HORIZON PHARM	1MG	N12827 001	
+	ROBINS AH	1MG	N12827 001	

ROBINUL FORTE

+	HORIZON PHARM	2MG	N12827 002	
+	ROBINS AH	2MG	N12827 002	

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	STERIS	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62788 001	JUN 11, 1987
	@	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N62788 001	JUN 11, 1987

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

AB	SCS	0.5MG	N70720 001	JUN 10, 1986
AB		1MG	N70721 001	JUN 10, 1986
AB		2MG	N70722 001	JUN 10, 1986
AB		5MG	N70723 001	JUN 10, 1986
AB		10MG	N70724 001	JUN 10, 1986
AB		20MG	N70725 001	SEP 24, 1986
	@	0.5MG	N70720 001	JUN 10, 1986
	@	1MG	N70721 001	JUN 10, 1986

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

@ SCS	2MG	N70722 001 JUN 10, 1986
@	5MG	N70723 001 JUN 10, 1986
@	10MG	N70724 001 JUN 10, 1986
@	20MG	N70725 001 SEP 24, 1986

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75393 001 MAY 11, 1999
AO		EQ 100MG BASE/ML	N75393 002 MAY 11, 1999

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALOPERIDOL

AA	SCS	EQ 2MG BASE/ML	N70726 001 JUN 10, 1986
@		EQ 2MG BASE/ML	N70726 001 JUN 10, 1986

INJECTABLE; INJECTION
HALOPERIDOL

AP	SOLOPAK	EQ 5MG BASE/ML	N70801 001 DEC 14, 1987
AP		EQ 5MG BASE/ML	N70864 001 DEC 14, 1987
@		EQ 5MG BASE/ML	N70801 001 DEC 14, 1987
@		EQ 5MG BASE/ML	N70864 001 DEC 14, 1987
AP	STERIS	EQ 5MG BASE/ML	N70713 001 MAY 17, 1988
AP		EQ 5MG BASE/ML	N70744 001 MAY 17, 1988
@		EQ 5MG BASE/ML	N70713 001 MAY 17, 1988

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

@ STERIS		EQ 5MG BASE/ML	N70744 001 MAY 17, 1988

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

AP	SMITH AND NEPHEW	10 UNITS/ML	N88458 001 JUL 26, 1984
AP		10 UNITS/ML	N88580 001 OCT 25, 1984
AP		100 UNITS/ML	N88460 001 JUL 26, 1984
AP		100 UNITS/ML	N88581 001 OCT 25, 1984
@		10 UNITS/ML	N88458 001 JUL 26, 1984
@		10 UNITS/ML	N88580 001 OCT 25, 1984
@		100 UNITS/ML	N88460 001 JUL 26, 1984
@		100 UNITS/ML	N88581 001 OCT 25, 1984
AP	SOLOPAK	100 UNITS/ML	N88459 001 JUL 26, 1984
@		100 UNITS/ML	N88459 001 JUL 26, 1984

HEPARIN SODIUM

AP	SMITH AND NEPHEW	1,000 UNITS/ML	N88239 001 JUL 26, 1984
@		1,000 UNITS/ML	N88239 001 JUL 26, 1984

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	HALSEY	1.5MG/5ML;5MG/5ML	N40285 001 JUL 19, 1999

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HCL

AP	* LUITPOLD	20MG/ML	N40136 001 JUN 30, 1997	
	+	20MG/ML	N40136 001 JUN 30, 1997	
AP	SOLOPAK	20MG/ML	N88517 001 AUG 22, 1985	
	@	20MG/ML	N88517 001 AUG 22, 1985	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

AB	SOLVAY	25MG;25MG	N87608 001 FEB 08, 1982	> ADD >
AB		50MG;50MG	N87213 001 FEB 08, 1982	> ADD >
	@	25MG;25MG	N87608 001 FEB 08, 1982	> ADD >
	@	50MG;50MG	N87213 001 FEB 08, 1982	> ADD >

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE

BP	SOLVAY	25MG;15MG;0.1MG	N88376 001 OCT 28, 1983
	@	25MG;15MG;0.1MG	N88376 001 OCT 28, 1983

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

AB	MAST MM	25MG	N86192 001	
AB		50MG	N86192 002	
	@	25MG	N86192 001	> ADD >
	@	50MG	N86192 002	> ADD >

> ADD >

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
AVALIDE

	@ SANOFI SYNTHELABO	12.5MG;75MG	N20758 001 SEP 30, 1997
		12.5MG;150MG	N20758 002 SEP 30, 1997
	+	12.5MG;300MG	N20758 003 AUG 31, 1998

AVAPRO HCT

	@ SANOFI	12.5MG;75MG	N20758 001 SEP 30, 1997
	+	12.5MG;150MG	N20758 002 SEP 30, 1997

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
ACCURETIC

	PARKE DAVIS	12.5MG;EQ 10MG BASE	N20125 001 DEC 28, 1999
		12.5MG;EQ 20MG BASE	N20125 002 DEC 28, 1999
	+	25MG;EQ 20MG BASE	N20125 003 DEC 28, 1999

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	DURAMED	25MG;37.5MG	N75052 001 JUN 18, 1999

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

AT	G AND W LABS	1%	N84059 001
	@	1%	N84059 001

ENEMA; RECTAL
COLOCORT

AB	PADDOCK	100MG/60ML	N75172 001 DEC 03, 1999

CORTENEMA

AB	+ SOLVAY	100MG/60ML	N16199 001

HYDROCORTISONE

ENEMA; RECTAL

CORTENEMA

BR	*	SOLVAY	100MG/60ML	N16199 001

HYDROCORTISONE

AB		COPLEY PHARM	100MG/60ML	N74171 001 MAY 27, 1994
BR			100MG/60ML	N74171 001 MAY 27, 1994

LOTION; TOPICAL

DERMACORT

AT		SOLVAY	0.5%	N84573 002
AT			1%	N86462 001
	@		0.5%	N84573 002
	@		1%	N86462 001

HYDROCORTISONE

AT		THAMES	2.5%	N40247 001 JUL 23, 1999

SOLUTION; TOPICAL

TEXACORT

AT	+	BIOGLAN PHAR	1%	N80425 001
	+		2.5%	N81271 001 APR 17, 1992
	*	GENDERM	2.5%	N81271 001 APR 17, 1992
AT	*	MEDICIS	1%	N80425 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEO-OTOSOL-HC

AT		ALCON	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62423 001 AUG 25, 1983
AT		STERIS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62423 001 AUG 25, 1983

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HYDROCORTISONE ACETATE

	+	FERNDALE LABS	2.5%	N40259 001 JUL 29, 1999

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

AP		STERIS	EQ 100MG BASE/VIAL	N84737 002
AP			EQ 100MG BASE/VIAL	N84738 001
AP			EQ 250MG BASE/VIAL	N84737 001
AP			EQ 500MG BASE/VIAL	N84747 001
AP			EQ 1GM BASE/VIAL	N84748 001
	@		EQ 100MG BASE/VIAL	N84737 002
	@		EQ 100MG BASE/VIAL	N84738 001
	@		EQ 250MG BASE/VIAL	N84737 001
	@		EQ 500MG BASE/VIAL	N84747 001
	@		EQ 1GM BASE/VIAL	N84748 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRINE

	+	AKORN	1%	N00004 004
	*	PHARMICS	1%	N00004 004

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

AB		PAR PHARM	500MG	N75340 001 FEB 24, 1999

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

AP		SOLOPAK	25MG/ML	N87591 001
AP			50MG/ML	N87593 001
AP			50MG/ML	N87595 001
	@		25MG/ML	N87591 001
	@		50MG/ML	N87593 001
	@		50MG/ML	N87595 001

IBUPROFEN

SUSPENSION; ORAL

MOTRIN

AB	*	MCNEIL	100MG/5ML	N19842 001 SEP 19, 1989

IBUPROFEN

SUSPENSION; ORAL

	MOTRIN				
AB	+ MCNEIL CONS	100MG/5ML	N19842 001		
			SEP 19, 1989		

TABLET; ORAL

	IBUPROFEN				
AB	NORTON HN	400MG	N71145 001		
			SEP 23, 1986		
AB		600MG	N71146 001		
			SEP 23, 1986		
AB		800MG	N71769 001		
			MAY 08, 1987	> DLT >	
AB	ZENITH GOLDLINE	400MG	N71145 001	> DLT >	
			SEP 23, 1986	> DLT >	
AB		600MG	N71146 001	> ADD >	
			SEP 23, 1986		
AB		800MG	N71769 001		
			MAY 08, 1987		
	MOTRIN				
AB	MCNEIL	300MG	N17463 003		
AB		400MG	N17463 002		
AB		600MG	N17463 004		
AB	+	800MG	N17463 005		
			MAY 22, 1985		
		100MG	N20418 001		
			NOV 16, 1994		
AB	MCNEIL CONS	300MG	N17463 003		
AB		400MG	N17463 002		
AB		600MG	N17463 004		
AB	+	800MG	N17463 005		
			MAY 22, 1985		
		100MG	N20418 001		
			NOV 16, 1994		

TABLET, CHEWABLE; ORAL

	MOTRIN				
	MCNEIL	50MG	N20135 001		
			NOV 16, 1994		
	+	100MG	N20135 002		
			NOV 16, 1994	> ADD >	
	MCNEIL CONS	50MG	N20135 001		
			NOV 16, 1994	> ADD >	
	+	100MG	N20135 002	> ADD >	
			NOV 16, 1994	> ADD >	
				> ADD >	

IMIGLUCERASE

INJECTABLE; INJECTION

CEREZYME			
+ GENZYME	200 UNITS/VIAL	N20367 001	
		MAY 23, 1994	
	200 UNITS/VIAL	N20367 001	
		MAY 23, 1994	
+	400 UNITS/VIAL	N20367 002	
		SEP 22, 1999	

IMIPRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

TOFRANIL			
+ NOVARTIS	12.5MG/ML	N11838 002	
@	12.5MG/ML	N11838 002	

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

	INDOCIN SR			
AB	EON	75MG	N74464 001	
			MAY 28, 1998	
AB	+	75MG	N74464 001	
			MAY 28, 1998	
AB	+ MERCK	75MG	N18185 001	
			FEB 23, 1982	
	@	75MG	N18185 001	
			FEB 23, 1982	

INSULIN HUMAN

INJECTABLE; INJECTION

VELOSULIN BR			
+ NOVO NORDISK	100 UNITS/ML	N21028 001	
		JUL 19, 1999	

INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION

HUMALOG MIX 50/50			
+ LILLY	100 UNITS/ML	N21018 001	
		DEC 22, 1999	

> ADD > INSULIN LISPRO PROTAMINE

> ADD > INJECTABLE; INJECTION
> ADD > HUMALOG MIX 75/25
> ADD > + LILLY 100 UNITS/ML N21017 001
> ADD > DEC 22, 1999

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION
RENOVUE 65
+ BRACCO 65% N17902 001
@ 65% N17902 001

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE
AN ALPHARMA **0.02%** **N75111 001**
APR 22, 1999

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL
AN INTL MEDICATION **0.08%** **N86651 002**
AN **0.1%** **N86651 003**
AN + **0.1%** **N86651 003**
AN **0.167%** **N86651 005**
AN + **0.167%** **N86651 005**
AN **0.25%** **N86651 007**
AN + **0.25%** **N86651 007**
+ 0.08% N86651 002
ISOETHARINE HCL S/F
AN + DEY **0.08%** **N89817 001**
NOV 22, 1988
AN + **0.1%** **N89818 001**
NOV 22, 1988
AN + **0.17%** **N89819 001**
NOV 22, 1988
AN + **0.25%** **N89820 001**
NOV 22, 1988
@ 0.08% N89817 001
NOV 22, 1988
@ 0.1% N89818 001
NOV 22, 1988

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL S/F
@ DEY 0.17% N89819 001
NOV 22, 1988
@ 0.25% N89820 001
NOV 22, 1988

ISOFLURANE

LIQUID; INHALATION
FORANE
AN + BAXTER PHARM PROD **99.9%** **N17624 001**
AN + OHMEDA **99.9%** **N17624 001**
ISOFLURANE
AN HALOCARBON PRODS **99.9%** **N75225 001**
OCT 20, 1999

ISONIAZID; RIFAMPIN

CAPSULE; ORAL
RIFAMATE
+ DON PHARM 150MG;300MG N61884 001
+ HOECHST MARION RSSL 150MG;300MG N61884 001

ISOSORBIDE DINITRATE

TABLET; ORAL
SORBITRATE
AB ZENECA **30MG** **N88124 001**
AUG 21, 1990
@ 30MG N88124 001
AUG 21, 1990

ISOSORBIDE MONONITRATE

TABLET; ORAL
ISMO
> ADD > **AB** ROBINS AH **20MG** **N19091 001**
> ADD > DEC 30, 1991
> DLT > **AB** WYETH **20MG** **N19091 001**
> DLT > DEC 30, 1991

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

	ISOSORBIDE MONONITRATE			
AB	BRIGHTSTONE	**60MG**	**N75166 001**	
			OCT 07, 1999	

ISOTRETINOIN

CAPSULE; ORAL

	ACCUTANE			
	HLR	10MG	N18662 002	
			MAY 07, 1982	
		20MG	N18662 004	
			MAR 28, 1983	
+		40MG	N18662 003	> ADD >
			MAY 07, 1982	> ADD >
	ROCHE	10MG	N18662 002	
			MAY 07, 1982	
		20MG	N18662 004	
			MAR 28, 1983	
+		40MG	N18662 003	
			MAY 07, 1982	

ITRACONAZOLE

INJECTABLE; INJECTION

	SPORANOX			
+	JANSSEN	10MG/ML	N20966 001	
			MAR 30, 1999	

KANAMYCIN SULFATE

INJECTABLE; INJECTION

	KANAMYCIN SULFATE			
AP	SOLOPAK	EQ 75MG BASE/2ML	N62605 003	
			FEB 26, 1986	
AP		EQ 500MG BASE/2ML	N62605 001	
			FEB 26, 1986	
AP		EQ 1GM BASE/3ML	N62605 002	
			FEB 26, 1986	
@		EQ 75MG BASE/2ML	N62605 003	
			FEB 26, 1986	
@		EQ 500MG BASE/2ML	N62605 001	
			FEB 26, 1986	

KANAMYCIN SULFATE

INJECTABLE; INJECTION

	KANAMYCIN SULFATE			
@	SOLOPAK	EQ 1GM BASE/3ML	N62605 002	
			FEB 26, 1986	

KETOCONAZOLE

TABLET; ORAL

	KETOCONAZOLE			
AB	APPLIED ANAL	**200MG**	**N75341 001**	
			JUL 27, 1999	
AB	MUTUAL PHARMA	**200MG**	**N75314 001**	
			JUN 15, 1999	
AB	MYLAN	**200MG**	**N75597 001**	
			DEC 23, 1999	
AB	NOVOPHARM	**200MG**	**N74971 001**	
			JUN 15, 1999	
AB	SIDMAK LABS CA	**200MG**	**N75362 001**	
			JUN 15, 1999	
AB	TARO	**200MG**	**N75319 001**	
			JUN 15, 1999	
AB	TEVA	**200MG**	**N75273 001**	
			JUN 15, 1999	
	NIZORAL			
AB	+ JANSSEN	**200MG**	**N18533 001**	
	+	200MG	N18533 001	

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

	KETOPROFEN			
AB	ANDRX PHARMS	**100MG**	**N75270 002**	
			MAR 24, 1999	
AB		**150MG**	**N75270 003**	
			MAR 24, 1999	
AB		**200MG**	**N75270 001**	
			MAR 24, 1999	
	ORUVAIL			
AB	WYETH AYERST	**100MG**	**N19816 003**	
			FEB 08, 1995	
AB		**150MG**	**N19816 002**	
			FEB 08, 1995	
		100MG	N19816 003	
			FEB 08, 1995	

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

ORUVAIL

	WYETH AYERST	150MG	N19816 002	
			FEB 08, 1995	

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	ABBOTT	**15MG/ML**	**N74993 001**	
			JAN 27, 1999	
AP		**30MG/ML**	**N74993 002**	
			JAN 27, 1999	
AP	BAXTER PHARM PROD	**15MG/ML**	**N75299 001**	
			NOV 03, 1999	
AP		**30MG/ML**	**N75299 002**	
			NOV 03, 1999	
AP	BEDFORD	**15MG/ML**	**N75222 001**	
			APR 26, 1999	
AP		**15MG/ML**	**N75230 002**	
			OCT 25, 1999	
AP		**30MG/ML**	**N75222 002**	
			APR 26, 1999	
AP		**30MG/ML**	**N75228 001**	
			APR 26, 1999	
AP		**30MG/ML**	**N75230 001**	
			OCT 25, 1999	

SOLUTION/DROPS; OPHTHALMIC

ACULAR

+	ALLERGAN	0.5%	N19700 001	
			NOV 09, 1992	
+	SYNTEX	0.5%	N19700 001	
			NOV 09, 1992	

TABLET; ORAL

KETOROLAC TROMETHAMINE

AB	SIDMAK LABS CA	**10MG**	**N75284 001**	
			JUN 23, 1999	

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ZADITOR

+	CIBA	EQ 0.025% BASE	N21066 001	
			JUL 02, 1999	

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HCL

AP	ABBOTT	**5MG/ML**	**N75239 001**	
			NOV 29, 1999	
AP		**5MG/ML**	**N75240 001**	
			NOV 29, 1999	
AP	APOTHECON	**5MG/ML**	**N75355 001**	
			NOV 29, 1999	
AP	BEDFORD	**5MG/ML**	**N75303 001**	
			MAY 28, 1999	
AP	FAULDING	**5MG/ML**	**N75242 001**	
			SEP 30, 1999	
AP	TAYLOR	**5MG/ML**	**N75431 001**	
			NOV 29, 1999	
AP		**5MG/ML**	**N75524 001**	
			NOV 29, 1999	

TABLET; ORAL

LABETALOL HCL

AB	MUTUAL PHARM	**100MG**	**N75215 001**	
			JUL 29, 1999	
AB		**200MG**	**N75215 002**	
			JUL 29, 1999	
AB		**300MG**	**N75215 003**	
			JUL 29, 1999	

TRANDATE

AB	FARO PHARMS	**100MG**	**N18716 001**	
			MAY 24, 1985	
AB		**200MG**	**N18716 002**	
			AUG 01, 1984	
AB		**300MG**	**N18716 003**	
			AUG 01, 1984	
	@	400MG	N18716 004	
			AUG 01, 1984	
AB	GLAXO WELLCOME	**100MG**	**N18716 001**	
			MAY 24, 1985	
AB		**200MG**	**N18716 002**	
			AUG 01, 1984	
AB		**300MG**	**N18716 003**	
			AUG 01, 1984	
	@	400MG	N18716 004	
			AUG 01, 1984	

LACTULOSE

SOLUTION; ORAL
LACTULOSE

AA		PACO	10GM/15ML	N73160 001 AUG 25, 1992
	@		10GM/15ML	N73160 001 AUG 25, 1992

SOLUTION; ORAL, RECTAL
LACTULOSE

AA		PACO	10GM/15ML	N72029 001 AUG 25, 1992
	@		10GM/15ML	N72029 001 AUG 25, 1992

LAMIVUDINE

SOLUTION; ORAL
EPIVIR-HBV

	+	GLAXO WELLCOME	5MG/ML	N20596 002 DEC 08, 1998
			5MG/ML	N20596 002 DEC 08, 1998
	+		5MG/ML	N21004 001 DEC 08, 1998

TABLET; ORAL
EPIVIR-HBV

	+	GLAXO WELLCOME	100MG	N20564 002 DEC 08, 1998
			100MG	N20564 002 DEC 08, 1998
	+		100MG	N21003 001 DEC 08, 1998

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP	+	ABBOTT	EQ 10MG BASE/ML	N40147 001 JUN 25, 1997
AP	+	BEDFORD	EQ 200MG BASE/VIAL	N40056 001 MAY 23, 1995
> ADD > AP		PHARMACHEMIE	EQ 350MG BASE/VIAL	N40262 001 DEC 15, 1999 > ADD >

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE

	+	ABBOTT	EQ 10MG BASE/ML	N40147 001 JUN 25, 1997
AP	+	BEDFORD	EQ 200MG BASE/VIAL	N40056 001 MAY 23, 1995
AP		BIGMAR	EQ 10MG BASE/ML	N40286 001 FEB 26, 1999
AP			EQ 200MG BASE/VIAL	N40258 001 FEB 26, 1999
	+		EQ 500MG BASE/VIAL	N40286 001 FEB 26, 1999
AP		GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N40332 001 JUN 28, 1999

TABLET; ORAL
LEUCOVORIN CALCIUM

AB		INVAMED	EQ 15MG BASE	N75327 001 MAR 24, 1999

WELLCOVORIN

AB		GLAXO WELLCOME	EQ 5MG BASE	N18342 001 JUL 08, 1983
AB	+		EQ 25MG BASE	N18342 002 JUL 08, 1983
	@		EQ 5MG BASE	N18342 001 JUL 08, 1983
	@		EQ 25MG BASE	N18342 002 JUL 08, 1983

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
XOPENEX

	+	SEPRACOR	EQ 0.021% BASE	N20837 001 MAR 25, 1999
	+		EQ 0.042% BASE	N20837 002 MAR 25, 1999

LEVETIRACETAM

TABLET; ORAL
KEPPRA

		UCB	250MG	N21035 001 NOV 30, 1999

LEVETIRACETAM

TABLET; ORAL
KEPPRA
UCB 500MG N21035 002 NOV 30, 1999
+ 750MG N21035 003 NOV 30, 1999

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHIROCAINE
DARWIN DISCOVERY EQ 2.5MG BASE/ML N20997 001 AUG 05, 1999
EQ 5MG BASE/ML N20997 002 AUG 05, 1999
+ EQ 7.5MG BASE/ML N20997 003 AUG 05, 1999

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL
ORLAAM
+ BIODEVELOPMENT 10MG/ML N20315 001 JUL 09, 1993
+ ROXANE 10MG/ML N20315 001 JUL 09, 1993

LEVONORGESTREL

TABLET; ORAL
PLAN B
+ WOMENS CAPITAL 0.75MG N21045 001 JUL 28, 1999

LIDOCAINE

FILM, EXTENDED RELEASE; TOPICAL
LIDODERM
+ TEIKOKU PHARMA USA 700MG/12HR N20612 001 MAR 19, 1999

FILM, EXTENDED RELEASE; TRANSDERMAL
LIDODERM
+ HIND HLTHCARE 700MG/12HR N20612 001 MAR 19, 1999

LIDOCAINE; PRILOCAINE

AEROSOL; TOPICAL
EMLA
+ ASTRA PHARMS 2.5%;2.5% N20962 001 FEB 04, 1998

DISC; TOPICAL
EMLA
+ ASTRAZENECA 2.5%;2.5% N20962 001 FEB 04, 1998

LINDANE

CREAM; TOPICAL
KWELL
+ REED AND CARNRICK 1% N84218 001
@ 1% N84218 001

LOTION; TOPICAL
KWELL
AT + REED AND CARNRICK 1% N84218 002
@ 1% N84218 002
LINDANE
AT ALPHARMA 1% N87313 001
AT + 1% N87313 001

SHAMPOO; TOPICAL
KWELL
AT + REED AND CARNRICK 1% N84219 001
@ 1% N84219 001
LINDANE
AT ALPHARMA 1% N87266 001
AT + 1% N87266 001

LISINOPRIL

TABLET; ORAL
ZESTRIL
ZENECA 30MG N19777 006 JAN 20, 1999

LITHIUM CARBONATE

CAPSULE; ORAL
LITHONATE
AB SOLVAY 300MG N16782 001

LITHIUM CARBONATE

CAPSULE; ORAL
LITHONATE
@ SOLVAY 300MG N16782 001

TABLET; ORAL
LITHIUM CARBONATE
AB PFIZER 300MG N16834 001
AB + 300MG N16834 001
LITHOTABS
AB + SOLVAY 300MG N16980 001
@ 300MG N16980 001

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
IMODIUM
AB + JANSSEN 2MG N17694 001
@ 2MG N17690 001
AB + MCNEIL CONS 2MG N17694 001
@ 2MG N17690 001

LORACARBEF

CAPSULE; ORAL
LORABID
KING PHARMS 200MG N50668 001 DEC 31, 1991
+ 400MG N50668 002 APR 05, 1996
LILLY 200MG N50668 001 DEC 31, 1991
+ 400MG N50668 002 APR 05, 1996

POWDER FOR RECONSTITUTION; ORAL
LORABID
KING PHARMS 100MG/5ML N50667 001 DEC 31, 1991
+ 200MG/5ML N50667 002 DEC 31, 1991
LILLY 100MG/5ML N50667 001 DEC 31, 1991
+ 200MG/5ML N50667 002 DEC 31, 1991

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
LOTEMAX
+ PHARMOS 0.5% N20841 001 MAR 09, 1998
@ 0.5% N20841 001 MAR 09, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER
B BRAUN 30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML N19006 001 APR 04, 1984
@ 30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML N19006 001 APR 04, 1984

MALATHION

LOTION; TOPICAL
OVIDE
@ MEDICIS 0.5% N18613 001 AUG 02, 1982
+ 0.5% N18613 001 AUG 02, 1982

MANNITOL

INJECTABLE; INJECTION
MANNITOL 25%
AP STERIS 12.5GM/50ML N87460 001 JUN 27, 1983
@ 12.5GM/50ML N87460 001 JUN 27, 1983

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

AP	SMITH AND NEPHEW	50MG/ML	N70841 001	
			JAN 02, 1987	
	@	50MG/ML	N70841 001	
			JAN 02, 1987	

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
METADATE ER

> DLT >		MEDEVA	10MG	N40306 001	
> DLT >				OCT 20, 1999	
> ADD >	+		10MG	N40306 001	
> ADD >				OCT 20, 1999	

METHYLPHENIDATE HCL

> DLT >	AB	MEDEVA PHARMS CA	20MG	N89601 001	
> DLT >				JUN 01, 1988	
> ADD >	AB	+	20MG	N89601 001	
> ADD >				JUN 01, 1988	

RITALIN-SR

> DLT >	AB	+ NOVARTIS	20MG	N18029 001	
> DLT >				MAR 30, 1982	
> ADD >	AB		20MG	N18029 001	
> ADD >				MAR 30, 1982	

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

AP	STERIS	EQ 40MG BASE/VIAL	N86953 001		
			JUL 22, 1982		
AP		EQ 125MG BASE/VIAL	N87030 001		
			JUL 22, 1982		
AP		EQ 500MG BASE/VIAL	N88523 001		
			JUL 24, 1984		
AP		EQ 1GM BASE/VIAL	N88524 001		
			JUL 24, 1984		
	@	EQ 40MG BASE/VIAL	N86953 001	> DLT >	
			JUL 22, 1982	> DLT >	
	@	EQ 125MG BASE/VIAL	N87030 001	> DLT >	
			JUL 22, 1982	> DLT >	
	@	EQ 500MG BASE/VIAL	N88523 001	> ADD >	
			JUL 24, 1984	> ADD >	

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

@ STERIS	EQ 1GM BASE/VIAL	N88524 001	
		JUL 24, 1984	

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	SMITH AND NEPHEW	EQ 5MG BASE/ML	N70623 001
			MAR 02, 1987
	@	EQ 5MG BASE/ML	N70623 001
			MAR 02, 1987

METOLAZONE

TABLET; ORAL
ZAROXOLYN

	MEDEVA	2.5MG	N17386 001
	+	2.5MG	N17386 001

METOPROLOL TARTRATE

TABLET; ORAL
METOPROLOL TARTRATE

AB	PUREPAC PHARM	50MG	N74380 001
			JUL 29, 1994
AB		100MG	N74380 002
			JUL 29, 1994
	@	50MG	N74380 001
			JUL 29, 1994
	@	100MG	N74380 002
			JUL 29, 1994

METRIZAMIDE

INJECTABLE; INJECTION
AMIPAQUE

+	NYCOMED	3.75GM/VIAL	N17982 001
+		6.75GM/VIAL	N17982 002
	@	3.75GM/VIAL	N17982 001
	@	6.75GM/VIAL	N17982 002

METRONIDAZOLE

INJECTABLE; INJECTION
FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+ BAXTER HLTHCARE	500MG/100ML	N18657 001	
AP	+ SCS	500MG/100ML	N18657 001	
	METRONIDAZOLE			
AP	STERIS	500MG/100ML	N70170 001 APR 01, 1986	
	@	500MG/100ML	N70170 001 APR 01, 1986	

MICONAZOLE NITRATE

INSERT, CREAM; VAGINAL, TOPICAL
MONISTAT DUAL- PAK

	+ ADVANCED CARE PRODS	1.2GM,2%	N20968 001 JUN 30, 1999	

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

AB	ALPHARMA US PHARM	200MG	N73508 001 NOV 19, 1993	
AB	NMC	200MG	N73508 001 NOV 19, 1993	

TAMPON; VAGINAL
MONISTAT 5

	+ ADVANCED CARE PRODS	100MG	N18592 001 OCT 27, 1989	
	@	100MG	N18592 001 OCT 27, 1989	

MIGLITOL

TABLET; ORAL
GLYSET

	BAYER	25MG	N20682 001 DEC 18, 1996	> ADD >
		50MG	N20682 002 DEC 18, 1996	> ADD >
	+	100MG	N20682 003 DEC 18, 1996	> ADD >
	PHARMACIA AND UPJOHN	25MG	N20682 001 DEC 18, 1996	
		50MG	N20682 002 DEC 18, 1996	

MIGLITOL

TABLET; ORAL
GLYSET

+	PHARMACIA AND UPJOHN	100MG	N20682 003 DEC 18, 1996

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL

+	DANBURY PHARMA	EQ 75MG BASE	N63065 002 JUN 10, 1999
AB	GLOBAL PHARM	EQ 50MG BASE	N65005 001 MAR 23, 1999
AB		EQ 100MG BASE	N65005 002 MAR 23, 1999
AB	WARNER CHILCOTT	EQ 50MG BASE	N63066 001 AUG 14, 1990
AB		EQ 100MG BASE	N63067 001 JUL 31, 1990

VECTRIN

AB	MEDICIS	EQ 50MG BASE	N63066 001 AUG 14, 1990
AB		EQ 75MG BASE	N63067 002 SEP 15, 1999
AB		EQ 100MG BASE	N63067 001 JUL 31, 1990
AB	WARNER CHILCOTT	EQ 75MG BASE	N63067 002 SEP 15, 1999

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	ESI LEDERLE	5MG/VIAL	N64180 001 DEC 23, 1999
AP		20MG/VIAL	N64180 002 DEC 23, 1999

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION
MIVACRON

+	ABBOTT	EQ 2MG BASE/ML	N20098 001 JAN 22, 1992

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

	MIVACRON			
	+ GLAXO WELLCOME	EQ 2MG BASE/ML		N20098 001 JAN 22, 1992
	MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER			
	+ ABBOTT	EQ 0.5MG BASE/ML		N20098 002 JAN 22, 1992
	+	EQ 50MG BASE/100ML		N20098 003 JAN 22, 1992
	+ GLAXO WELLCOME	EQ 0.5MG BASE/ML		N20098 002 JAN 22, 1992
	+	EQ 50MG BASE/100ML		N20098 003 JAN 22, 1992

> ADD > MOXIFLOXACIN HYDROCHLORIDE

> ADD > TABLET; ORAL

> ADD >	AVELOX			
> ADD >	+ BAYER	EQ 400MG BASE		N21085 001 DEC 10, 1999

NADOLOL

TABLET; ORAL

	CORGARD			
AB	APOTHECON	**20MG**		**N18063 005** OCT 28, 1986
AB		**40MG**		**N18063 001**
AB		**80MG**		**N18063 002**
AB		**120MG**		**N18063 003**
AB	+	**160MG**		**N18063 004**
AB	BRISTOL MYERS SQUIBB	20MG		N18063 005 OCT 28, 1986
AB		40MG		N18063 001
AB		80MG		N18063 002
AB		120MG		N18063 003
AB	+	160MG		N18063 004

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NALOXONE HCL			
AP	SMITH AND NEPHEW	**0.02MG/ML**		N71671 001 NOV 17, 1987

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NALOXONE HCL			
AP	SMITH AND NEPHEW	**0.4MG/ML**		**N71681 001** NOV 17, 1987
	@	0.02MG/ML		N71671 001 NOV 17, 1987
	@	0.4MG/ML		N71681 001 NOV 17, 1987
AP	STERIS	**0.4MG/ML**		**N71339 001** NOV 18, 1987
	@	0.4MG/ML		N71339 001 NOV 18, 1987

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

	NALTREXONE HCL			
AB	AMIDE PHARM	**50MG**		**N75274 001** MAY 26, 1999

NANDROLONE DECANOATE

INJECTABLE; INJECTION

	NANDROLONE DECANOATE			
AQ	STERIS	**50MG/ML**		**N88554 001** FEB 10, 1986
	@	50MG/ML		N88554 001 FEB 10, 1986

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

	DURABOLIN			
AQ	+ ORGANON	**25MG/ML**		**N11891 001**
AQ	+	**50MG/ML**		**N11891 002**
	+	25MG/ML		N11891 001
	+	50MG/ML		N11891 002
	NANDROLONE PHENPROPIONATE			
AQ	STERIS	**25MG/ML**		**N86386 001** JUN 17, 1983
AQ		**50MG/ML**		**N87488 001** JUN 17, 1983
	@	25MG/ML		N86386 001 JUN 17, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION
NANDROLONE PHENPROPIONATE

@	STERIS	50MG/ML	N87488 001 JUN 17, 1983	> ADD > > ADD > > ADD > > ADD >

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
NAPHAZOLINE HCL

AT	AKORN	0.1%	N83590 001	
AT	TAYLOR	0.1%	N83590 001	

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN

AB	SIDMAK LABS CA	375MG	N75337 001 MAY 26, 1999	
AB		500MG	N75337 002 MAY 26, 1999	

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

AB	PUREPAC PHARM	EQ 250MG BASE	N74319 001 MAR 20, 1995	
AB		EQ 500MG BASE	N74319 002 MAR 20, 1995	> ADD >
@		EQ 250MG BASE	N74319 001 MAR 20, 1995	> ADD > > ADD >
@		EQ 500MG BASE	N74319 002 MAR 20, 1995	> ADD > > ADD > > ADD >

NEDOCROMIL SODIUM

SOLUTION, INHALATION
TILADE

+	RHONE POULENC RORER	0.5%	N20750 001 OCT 01, 1997	> ADD > > ADD > > ADD >
@		0.5%	N20750 001 OCT 01, 1997	> ADD > > ADD > > ADD >

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC
ALOCRIL

+	ALLERGAN	2%	N21009 001 DEC 08, 1999

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION, ORAL
TPN SUSPENSION

+	INTL MINERALS	15MG/5ML;3.75MG/5ML; 600MG/5ML	N08378 003
@		15MG/5ML;3.75MG/5ML; 600MG/5ML	N08378 003

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL
PROSTEP

+	ELAN PHARM	11MG/24HR	N19983 001 JAN 28, 1992
+		22MG/24HR	N19983 002 JAN 28, 1992
@		11MG/24HR	N19983 001 JAN 28, 1992
@		22MG/24HR	N19983 002 JAN 28, 1992

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL
NIFEDIPINE

@	MYLAN	30MG	N75108 001 DEC 17, 1999

NITRIC OXIDE

GAS; INHALATION
INOMAX

	INO	100PPM	N20845 002 DEC 23, 1999
+		800PPM	N20845 003 DEC 23, 1999

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	NITROGLYCERIN			
AB1	MYLAN TECHNOLOGIES	**0.1MG/HR**	**N75076 001**	NOV 12, 1999
AB1		**0.2MG/HR**	**N75073 001**	NOV 12, 1999
AB1		**0.4MG/HR**	**N75075 001**	NOV 12, 1999
AB1		**0.6MG/HR.**	**N74992 001**	NOV 12, 1999

INJECTABLE; INJECTION

	NITROGLYCERIN			
AP	SMITH AND NEPHEW	**5MG/ML**	**N70633 001**	JUN 19, 1986
	@	5MG/ML	N70633 001	JUN 19, 1986

OINTMENT; TRANSDERMAL

	NITROGLYCERIN			
	ALTANA	2%	N87355 001	JUL 08, 1988
	+	2%	N87355 001	JUL 08, 1988

SPRAY, METERED; SUBLINGUAL

	NITROLINGUAL PUMPSPRAY			
	+ POHL BOSKAMP	0.4MG/SPRAY	N18705 002	JAN 10, 1997

OLANZAPINE

TABLET; ORAL

	ZYPREXA			
	* LILLY	2.5MG	N20592 001	SEP 30, 1996
		2.5MG	N20592 001	SEP 30, 1996

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

	PRILOSEC			
	* ASTRA PHARMS	10MG	N19810 003	OCT 05, 1995

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

	PRILOSEC			
	ASTRAZENECA	10MG	N19810 003	OCT 05, 1995

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

	ZOFRAN ODT			
	GLAXO WELLCOME	EQ 4MG BASE	N20781 001	JAN 27, 1999
	+	EQ 8MG BASE	N20781 002	JAN 27, 1999

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL

	ZOFRAN			
	* GLAXO WELLCOME	EQ 8MG BASE	N20103 002	DEC 31, 1992
		EQ 8MG BASE	N20103 002	DEC 31, 1992
	+	EQ 24MG BASE	N20103 003	AUG 27, 1999

ORLISTAT

CAPSULE; ORAL

	XENICAL			
	+ ROCHE	120MG	N20766 001	APR 23, 1999

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

	ORPHENADRINE CITRATE			
AB	KIEL	**100MG**	**N40249 001**	JAN 29, 1999

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

		TAMIFLU		
	+	ROCHE	EQ 75MG BASE	N21087 001 OCT 27, 1999

OXAZEPAM

CAPSULE; ORAL

		SERAX		
> ADD >	AB	FAULDING	10MG	N15539 002
> ADD >	AB		15MG	N15539 004
> ADD >	AB	+	30MG	N15539 006
> DLT >	AB	WYETH AYERST	10MG	N15539 002
> DLT >	AB		15MG	N15539 004
> DLT >	AB	*	30MG	N15539 006

TABLET; ORAL

		SERAX		
> ADD >		+ FAULDING	15MG	N15539 008
> DLT >		* WYETH AYERST	15MG	N15539 008

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

		OXYBUTYNIN CHLORIDE		
AA		MIKART	5MG/5ML	N75039 001 JAN 29, 1999

TABLET, EXTENDED RELEASE; ORAL

		DITROPAN XL		
	+	ALZA	15MG	N20897 003 JUN 22, 1999

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL

		TERRAMYCIN		
	*	PFIZER	EQ 125MG BASE/5ML	N60595 001
	@		EQ 125MG BASE/5ML	N60595 001

OXYTETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

		TERRAMYCIN		
	*	PFIZER	EQ 250MG BASE/VIAL	N60586 001
	*		EQ 500MG BASE/VIAL	N60586 002
	@		EQ 250MG BASE/VIAL	N60586 001
	@		EQ 500MG BASE/VIAL	N60586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC

		TERRAMYCIN W/ POLYMYXIN		
	*	PFIZER	EQ 5MG BASE/GM; 10,000 UNITS/GM	N61841 001
	@		EQ 5MG BASE/GM; 10,000 UNITS/GM	N61841 001

TABLET, VAGINAL

		TERRAMYCIN-POLYMYXIN		
	*	PFIZER	EQ 100MG BASE; 100,000 UNITS	N61009 001
	@		EQ 100MG BASE; 100,000 UNITS	N61009 001

PAROMOMYCIN SULFATE

CAPSULE; ORAL

		HUMATIN		
AA	*	PARKEDALE	EQ 250MG BASE	N60521 001
AA			EQ 250MG BASE	N62310 001
AA	+		EQ 250MG BASE	N62310 001
	@		EQ 250MG BASE	N60521 001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

		PAXIL		
		SMITHKLINE BEECHAM	EQ 10MG BASE	N20885 001 OCT 09, 1998
			EQ 20MG BASE	N20885 002 OCT 09, 1998
			EQ 30MG BASE	N20885 003 OCT 09, 1998
	*		EQ 40MG BASE	N20885 004 OCT 09, 1998

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL
PAXIL
@ SMITHKLINE BEECHAM EQ 10MG BASE N20885 001 OCT 09, 1998
@ EQ 20MG BASE N20885 002 OCT 09, 1998
@ EQ 30MG BASE N20885 003 OCT 09, 1998
@ EQ 40MG BASE N20885 004 OCT 09, 1998

TABLET, EXTENDED RELEASE; ORAL
PAXIL CR
+ SMITHKLINE BEECHAM EQ 12.5MG BASE N20936 001 FEB 16, 1999
+ EQ 25MG BASE N20936 002 FEB 16, 1999

PEMIROLAST POTASSIUM

SOLUTION/DROPS; OPHTHALMIC
ALAMAST
+ SANTEN 0.1% N21079 001 SEP 24, 1999

PEMOLINE

TABLET; ORAL
CYLERT
> ADD > **AB** + ABBOTT **18.75MG** **N16832 001**
AB **37.5MG** **N16832 002**
AB + **75MG** **N16832 003**
> DLT > * 18.75MG N16832 001
37.5MG N16832 002
* 75MG N16832 003
PEMOLINE
AB COPLEY PHARM **37.5MG** **N75030 001** JAN 29, 1999
AB **75MG** **N75030 002** JAN 29, 1999
> ADD > **AB** INVAMED **18.75MG** **N75286 001** DEC 27, 1999
> ADD > **AB** **37.5MG** **N75286 002** JUN 30, 1999

PEMOLINE

TABLET; ORAL
PEMOLINE
AB INVAMED **75MG** **N75286 003** JUN 30, 1999

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
TALWIN 50
@ SANOFI SYNTHELABO EQ 50MG BASE N16732 001
@ STERLING WINTHROP EQ 50MG BASE N16732 001

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE
AB IMPAX PHARM **400MG** **N75093 001** AUG 10, 1999
AB SIDMAK LABS NJ **400MG** **N74874 001** MAY 25, 1999
AB TEVA **400MG** **N75199 001** SEP 03, 1999
AB TORPHARM **400MG** **N75191 001** JUN 09, 1999
PENTOXIL
AB UPSHER SMITH **400MG** **N74962 001** MAR 31, 1999

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON
@ HUBSCHEM 2MG N20184 001 DEC 30, 1993
@ 4MG N20184 002 DEC 30, 1993
@ 8MG N20184 003 DEC 30, 1993
@ SOLVAY 2MG N20184 001 DEC 30, 1993
@ 4MG N20184 002 DEC 30, 1993
@ 8MG N20184 003 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

	PHENAZINE			
AA	MAST MM	35MG	N86523 001	
AA		35MG	N86524 001	
AA		35MG	N86525 001	
	@	35MG	N86523 001	
	@	35MG	N86524 001	
	@	35MG	N86525 001	

TABLET; ORAL

	PHENAZINE			
AA	MAST MM	35MG	N87305 001	
	@	35MG	N87305 001	
	PHENDIMETRAZINE TARTRATE			
AA	MPG CHEMISTS	35MG	N85914 001	
	@	35MG	N85914 001	
AA	PVT FORM	35MG	N85697 001	
	@	35MG	N85697 001	

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

		DIBENZYLINE			
> DLT >	*	SMITHKLINE BEECHAM	10MG	N08708 001	
> ADD >	+	WELLSPRING PHARM	10MG	N08708 001	

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

		FASTIN			
AA	*	SMITHKLINE BEECHAM	30MG	N17352 001	
	@		30MG	N17352 001	
		PHENTERMINE HCL			
AA		ECR	30MG	N86945 001	
				JUL 20, 1983	
AA	**+**		**30MG**	**N86945 001**	
				JUL 20, 1983	

PHENYTOIN SODIUM

INJECTABLE; INJECTION

	PHENYTOIN SODIUM			
AP	STERIS	50MG/ML	N85434 001	
	@	50MG/ML	N85434 001	

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

	ACTOS			
	TAKEDA	EQ 15MG BASE	N21073 001	
			JUL 15, 1999	
		EQ 30MG BASE	N21073 002	
			JUL 15, 1999	
+		EQ 45MG BASE	N21073 003	
			JUL 15, 1999	

POLYETHYLENE GLYCOL 3350

POWDER FOR RECONSTITUTION; ORAL

	MIRALAX			
+	BRAINTREE	17GM/SCOOPFUL	N20698 001	
			FEB 18, 1999	

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE			
AT	ALCON	10,000 UNITS/ML; EQ 1MG BASE/ML	N64211 001	
			APR 13, 1998	
AT	FALCON PHARMS	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N64211 001**	
			APR 13, 1998	

PORACTANT ALPHA

SUSPENSION; INTRATRACHEAL

	CUROSURF			
+	DEY	80MG/ML	N20744 001	
			NOV 18, 1999	

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	MICRO-K			
AB	KV PHARM	8MEQ	N18238 001	
AB	ROBINS AH	8MEQ	N18238 001	
	MICRO-K 10			
AB	**+** KV PHARM	**10MEQ**	**N18238 002**	
			MAY 14, 1984	

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
MICRO-K 10

AB	*	ROBINS AH	10MEQ	N18238 002 MAY 14, 1984

GRANULE, FOR RECONSTITUTION ER; ORAL
MICRO-K LS

	@	KV PHARM	20MEQ/PACKET	N19561 003 AUG 26, 1988
	@	ROBINS AH	20MEQ/PACKET	N19561 003 AUG 26, 1988

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP		AM PHARM PARTNERS	3MEQ/ML	N80225 003
	+		3MEQ/ML	N80225 003
	*	MILES	4MEQ/ML	N80195 004
	@		4MEQ/ML	N80195 004
AP		STERIS	2MEQ/ML	N86208 001
AP			2MEQ/ML	N89163 001 MAR 10, 1988
AP			2MEQ/ML	N89421 001 JAN 02, 1987
AP	*		3MEQ/ML	N86210 001
	@		2MEQ/ML	N86208 001
	@		2MEQ/ML	N89163 001 MAR 10, 1988
	@		2MEQ/ML	N89421 001 JAN 02, 1987
	@		3MEQ/ML	N86210 001

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION
THAM-E

	*	ABBOTT	370MG/VIAL;1.75GM/VIAL; 36GM/VIAL	N13025 001
	@		370MG/VIAL;1.75GM/VIAL; 36GM/VIAL	N13025 001

POTASSIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL
POTASSIUM CITRATE

	@	MISSION PHARMA	10MEQ/PACKET	N19647 002 OCT 13, 1988

POTASSIUM CITRATE

POWDER FOR RECONSTITUTION; ORAL
POTASSIUM CITRATE

	@	MISSION PHARMA	20MEQ/PACKET	N19647 001 OCT 13, 1988
	@	UNIV IX	10MEQ/PACKET	N19647 002 OCT 13, 1988
	@		20MEQ/PACKET	N19647 001 OCT 13, 1988

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC
BETADINE

	+	ALCON	5%	N18634 001 DEC 17, 1986
	*	PURDUE FREDERICK	5%	N18634 001 DEC 17, 1986

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
PRAZOSIN HCL

AB		ZENITH GOLDLINE	EQ 2MG BASE	N71995 001 MAY 16, 1989
AB			EQ 2MG BASE	N71995 001 SEP 12, 1988
AB			EQ 5MG BASE	N71745 001 MAY 16, 1989
AB			EQ 5MG BASE	N71745 001 SEP 12, 1988

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE

AA		HALSEY	15MG/5ML	N40287 001 MAY 28, 1999
AA		UDL	15MG/5ML	N40323 001 MAY 13, 1999

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

	+	STERIS	40MG/ML	N83767 001
	@		40MG/ML	N83767 001

SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED PLUS

AB		ALCON	1%	N17469 001
AB		FALCON PHARMS	1%	N17469 001

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
HYDELTRASOL

	+	MERCK	EQ 20MG PHOSPHATE/ML	N11583 002
	@		EQ 20MG PHOSPHATE/ML	N11583 002

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION
HYDELTRA-TBA

BP	+	MERCK	20MG/ML	N10562 001
	+		20MG/ML	N10562 001

PREDNISOLONE TEBUTATE

BP		STERIS	20MG/ML	N83362 001 FEB 17, 1984
	@		20MG/ML	N83362 001 FEB 17, 1984

PREDNISONE

TABLET; ORAL
ORASONE

AB		SOLVAY	50MG	N85999 001
	@		50MG	N85999 001

PREDNISONE

BX		PHARMAVITE	5MG	N84662 002
	@		5MG	N84662 002

PROBENECID

TABLET; ORAL
BENEMID

AB	+	MERCK	500MG	N07898 004

PROBENECID

TABLET; ORAL
BENEMID

	@	MERCK	500MG	N07898 004

PROBENECID

AB		MYLAN	500MG	N84211 002
AB	+		500MG	N84211 002

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
PROCAINAMIDE HCL

AP		SMITH AND NEPHEW	100MG/ML	N88530 001 MAR 04, 1985
AP			500MG/ML	N88531 001 MAR 04, 1985
	@		100MG/ML	N88530 001 MAR 04, 1985
	@		500MG/ML	N88531 001 MAR 04, 1985
AP		STERIS	100MG/ML	N87079 001
AP			500MG/ML	N87080 001
	@		100MG/ML	N87079 001
	@		500MG/ML	N87080 001

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP		SMITH AND NEPHEW	EQ 5MG BASE/ML	N89251 001 DEC 04, 1986
	@		EQ 5MG BASE/ML	N89251 001 DEC 04, 1986
AP		STERIS	EQ 5MG BASE/ML	N89606 001 JUL 08, 1987
	@		EQ 5MG BASE/ML	N89606 001 JUL 08, 1987

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL
COMPAZINE

		SMITHKLINE BEECHAM	EQ 10MG BASE	N21019 001 OCT 06, 1999

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

	COMPAZINE			
	SMITHKLINE BEECHAM	EQ 15MG BASE	N21019 002 OCT 06, 1999	

PROGESTERONE

CAPSULE; ORAL

	PROMETRIUM			
	* SCHERING PLOUGH	100MG	N19781 001 MAY 14, 1998	
		100MG	N19781 001 MAY 14, 1998	
		200MG	N19781 002 OCT 15, 1999	
	+	300MG	N19781 003 OCT 15, 1999	

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	PROMAZINE HCL			
AP	STERIS	50MG/ML	N84517 001	
		25MG/ML	N84510 001	
	@	25MG/ML	N84510 001	
	@	50MG/ML	N84517 001	
	SPARINE			
AP	* WYETH AYERST	50MG/ML	N10349 006	
	+	50MG/ML	N10349 006	

PROPOFOL

INJECTABLE; INJECTION

	DIPRIVAN			
AB	+ ZENECA	10MG/ML	N19627 002 JUN 11, 1996	
	*	10MG/ML	N19627 002 JUN 11, 1996	
	PROPOFOL			
AB	GENSIA SICOR PHARMS	10MG/ML	N75102 001 JAN 04, 1999	

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	INDERAL LA			
AB	* WYETH AYERST	60MG	N18553 004 MAR 18, 1987	
AB	*	80MG	N18553 002 APR 19, 1983	
AB	*	120MG	N18553 003 APR 19, 1983	
AB	*	160MG	N18553 001 APR 19, 1983	
	+	60MG	N18553 004 MAR 18, 1987	
	+	80MG	N18553 002 APR 19, 1983	
	+	120MG	N18553 003 APR 19, 1983	
	+	160MG	N18553 001 APR 19, 1983	
	PROPRANOLOL HCL			
AB	INWOOD LABS	60MG	N72499 001 APR 11, 1989	
AB		80MG	N72500 001 APR 11, 1989	
AB		120MG	N72501 001 APR 11, 1989	
AB		160MG	N72502 001 APR 11, 1989	
	@	60MG	N72499 001 APR 11, 1989	
	@	80MG	N72500 001 APR 11, 1989	
	@	120MG	N72501 001 APR 11, 1989	
	@	160MG	N72502 001 APR 11, 1989	

INJECTABLE; INJECTION

	INDERAL			
AP	* WYETH AYERST	1MG/ML	N16419 001	
	+	1MG/ML	N16419 001	
	PROPRANOLOL HCL			
AP	SMITH AND NEPHEW	1MG/ML	N70137 001 APR 15, 1986	
	@	1MG/ML	N70137 001 APR 15, 1986	

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
ACIPHEX
+ EISAI 20MG N20973 002 AUG 19, 1999

RANITIDINE BISMUTH CITRATE

TABLET; ORAL
TRITEC
+ GLAXO WELLCOME 400MG N20559 001 AUG 08, 1996
@ 400MG N20559 001 AUG 08, 1996

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL
AB GRANUTEC PHARMS **EQ 150MG BASE** **N74488 001** JUL 31, 1997
AB **EQ 300MG BASE** **N74488 002** JUL 31, 1997
AB NOVOPHARM NC **EQ 150MG BASE** **N74488 001** JUL 31, 1997
AB **EQ 300MG BASE** **N74488 002** JUL 31, 1997
AB PAR PHARM **EQ 150MG BASE** **N75180 001** JAN 28, 1999
AB **EQ 300MG BASE** **N75180 002** JAN 28, 1999

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION
RAPLON
ORGANON 100MG/VIAL N20984 001 AUG 18, 1999
+ 200MG/VIAL N20984 002 AUG 18, 1999

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
ULTIVA
ABBOTT EQ 1MG BASE/VIAL N20630 001 JUL 12, 1996
EQ 2MG BASE/VIAL N20630 002 JUL 12, 1996
+ EQ 5MG BASE/VIAL N20630 003 JUL 12, 1996
GLAXO WELLCOME EQ 1MG BASE/VIAL N20630 001 JUL 12, 1996
EQ 2MG BASE/VIAL N20630 002 JUL 12, 1996
+ EQ 5MG BASE/VIAL N20630 003 JUL 12, 1996

RIFAMPIN

INJECTABLE; INJECTION
RIFADIN
AP + HOECHST MARION RSSL **600MG/VIAL** **N50627 001** MAY 25, 1989
+ 600MG/VIAL N50627 001 MAY 25, 1989
RIFAMPIN
AP BEDFORD **600MG/VIAL** **N64217 001** OCT 29, 1999

RISPERIDONE

TABLET; ORAL
RISPERDAL
JANSSEN 0.25MG N20272 008 MAY 10, 1999
+ 0.5MG N20272 007 JAN 27, 1999

RITONAVIR

CAPSULE; ORAL
NORVIR
ABBOTT 100MG N20945 001 JUN 29, 1999

RITONAVIR

SOLUTION; ORAL
NORVIR
ABBOTT 80MG/ML N20659 001 MAR 01, 1996
\+ 80MG/ML N20659 001 MAR 01, 1996

ROFECOXIB

SUSPENSION; ORAL
VIOXX
MERCK 12.5MG/5ML N21052 001 MAY 20, 1999
\+ 25MG/5ML N21052 002 MAY 20, 1999

TABLET; ORAL
VIOXX
MERCK 12.5MG N21042 001 MAY 20, 1999
\+ 25MG N21042 002 MAY 20, 1999

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
REQUIP
SMITHKLINE BEECHAM EQ 3MG BASE N20658 006 JAN 27, 1999
EQ 4MG BASE N20658 007 JAN 27, 1999 >ADD> >ADD> >ADD> >ADD>

ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDIA
SMITHKLINE BEECHAM EQ 2MG BASE N21071 002 MAY 25, 1999
EQ 4MG BASE N21071 003 MAY 25, 1999
EQ 8MG BASE N21071 004 MAY 25, 1999

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE
\+ HLR 200MG N20828 001 NOV 07, 1997
\+ ROCHE 200MG N20828 001 NOV 07, 1997

SAQUINAVIR MESYLATE

CAPSULE; ORAL
INVIRASE
\+ HLR EQ 200MG BASE N20628 001 DEC 06, 1995
\+ ROCHE EQ 200MG BASE N20628 001 DEC 06, 1995

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
ELDEPRYL
@ SOMERSET 5MG N19334 001 JUN 05, 1989

SELEGILINE HCL
AB + SOMERSET 5MG N19334 001 JUN 05, 1989

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL
ZOLOFT
\+ PFIZER EQ 20MG BASE/ML N20990 001 DEC 07, 1999

SILVER SULFADIAZINE

CREAM; TOPICAL
THERMAZENE
AB KENDALL LP **1%** **N18810 001** DEC 23, 1985
AB SHERWOOD MEDCL **1%** **N18810 001** DEC 23, 1985

SIROLIMUS

SOLUTION; ORAL
RAPAMUNE
+ WYETH AYERST 1MG/ML N21083 001 SEP 15, 1999

SODIUM PHENYLBUTYRATE

POWDER; ORAL
BUPHENYL
+ MEDICIS 3GM/TEASPOONFUL N20573 001 APR 30, 1996
* UCYCLYD 3GM/TEASPOONFUL N20573 001 APR 30, 1996

TABLET; ORAL
BUPHENYL
+ MEDICIS 500MG N20572 001 MAY 13, 1996
* UCYCLYD 500MG N20572 001 MAY 13, 1996

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
GENOTROPIN PRESERVATIVE FREE
* PHARMACIA AND UPJOHN 1.5MG/VIAL N20280 004 AUG 24, 1995
0.2MG/VIAL N20280 001 JAN 27, 1998
0.4MG/VIAL N20280 002 JAN 27, 1998
0.6MG/VIAL N20280 003 JAN 27, 1998
0.8MG/VIAL N20280 005 JAN 27, 1998
1MG/VIAL N20280 008 JAN 27, 1998
1.2MG/VIAL N20280 009 JAN 27, 1998
1.4MG/VIAL N20280 010 JAN 27, 1998
1.5MG/VIAL N20280 004 AUG 24, 1995
1.6MG/VIAL N20280 011 JAN 27, 1998

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
GENOTROPIN PRESERVATIVE FREE
PHARMACIA AND UPJOHN 1.8MG/VIAL N20280 012 JAN 27, 1998
+ 2MG/VIAL N20280 013 JAN 27, 1998

HUMATROPE
BX LILLY 6MG/VIAL N19640 005 FEB 04, 1999
+ 12MG/VIAL N19640 006 FEB 04, 1999
+ 24MG/VIAL N19640 007 FEB 04, 1999

NUTROPIN DEPOT
+ GENENTECH 13.5MG/VIAL N21075 001 DEC 22, 1999
+ 18MG/VIAL N21075 002 DEC 22, 1999
+ 22.5MG/VIAL N21075 003 DEC 22, 1999

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 10%
AP + FRESENIUS KABI 10% **N17643 001**
AP * PHARMACIA AND UPJOHN 10% N17643 001
INTRALIPID 20%
AP + FRESENIUS KABI 20% **N18449 001**
AP + 20% **N20248 001** AUG 07, 1996
AP * PHARMACIA AND UPJOHN 20% N18449 001
AP * 20% N20248 001 AUG 07, 1996
INTRALIPID 30%
AP + FRESENIUS KABI 30% **N19942 001** DEC 30, 1993
AP * PHARMACIA AND UPJOHN 30% N19942 001 DEC 30, 1993

SPIRONOLACTONE

TABLET; ORAL
ALDACTONE
AB SEARLE 50MG **N12151 008** DEC 30, 1982

SPIRONOLACTONE

TABLET; ORAL

	ALDACTONE			
AB	+ SEARLE	100MG	N12151 010	DEC 30, 1983
		50MG	N12151 008	DEC 30, 1982
	*	100MG	N12151 010	DEC 30, 1983
	SPIRONOLACTONE			
AB	MUTUAL PHARM	50MG	N89424 002	AUG 11, 1999
AB		100MG	N89424 003	AUG 11, 1999
AB	PUREPAC PHARM	25MG	N87998 001	OCT 14, 1983
AB		50MG	N40353 001	JUL 29, 1999
AB		100MG	N40353 002	JUL 29, 1999
	@	25MG	N87998 001	OCT 14, 1983

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

	SODIUM SULFACETAMIDE			
AT	AKORN	10%	N83021 001	
AT		15%	N83021 002	
AT		30%	N83021 003	
	@	10%	N83021 001	
	@	15%	N83021 002	
	@	30%	N83021 003	
	SULFACETAMIDE SODIUM			
AT	AKORN	10%	N40215 001	MAY 25, 1999
AT		30%	N40216 001	MAY 25, 1999

SULFADIAZINE

TABLET; ORAL

	SULFADIAZINE			
AB	+ EON	500MG	N40091 001	JUL 29, 1994

SULFADIAZINE

TABLET; ORAL

	SULFADIAZINE			
	+ EON	500MG	N40091 001	JUL 29, 1994
AB	GLOBAL PHARM	500MG	N80081 001	
	@	500MG	N80081 001	
AB	LANNETT	500MG	N80084 001	
	@	500MG	N80084 001	

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AP	STERIS	80MG/ML;16MG/ML	N71556 001	DEC 29, 1987
	@	80MG/ML;16MG/ML	N71556 001	DEC 29, 1987

TACROLIMUS

CAPSULE; ORAL

	PROGRAF			
	* FUJISAWA HLTHCARE	EQ 1MG BASE	N50708 001	APR 08, 1994
		EQ 0.5MG BASE	N50708 003	AUG 24, 1998
		EQ 1MG BASE	N50708 001	APR 08, 1994

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

	A-N STANNOUS AGGREGATED ALBUMIN		
	@ NORTH AM CHEMS	N/A	N17916 001
	@ SYNCOR PHARMS	N/A	N17916 001
	PULMOLITE		
BS	CIS	N/A	N17776 001
BS	DUPONT PHARMS	N/A	N17776 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION
MICROLITE

	CIS	N/A	N18263 001 MAR 25, 1983
	DUPONT PHARMS	N/A	N18263 001 MAR 25, 1983

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION
NEO TECT KIT

+	DIATIDE	N/A	N21012 001 AUG 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE

	CIS	N/A	N18467 001 MAR 16, 1982
	DUPONT PHARMS	N/A	N18467 001 MAR 16, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION
TECHNESCAN HIDA

	DRAXIMAGE	N/A	N18489 001 OCT 31, 1986
	@	N/A	N18489 001 OCT 31, 1986

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
OSTEOLITE

AP	CIS	**N/A**	**N17972 001**
AP	DUPONT PHARMS	**N/A**	**N17972 001**

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION
PYROLITE

	CIS	N/A	N17684 001
	DUPONT PHARMS	N/A	N17684 001

TEMOZOLOMIDE

CAPSULE; ORAL
TEMODAR

	SCHERING	5MG	N21029 001 AUG 11, 1999
		20MG	N21029 002 AUG 11, 1999
		100MG	N21029 003 AUG 11, 1999
+		250MG	N21029 004 AUG 11, 1999

TERBUTALINE SULFATE

INJECTABLE; INJECTION
BRETHINE

AP	* NOVARTIS	1MG/ML	N18571 001
	+	1MG/ML	N18571 001
	BRICANYL		
AP	* HOECHST MARION RSSL	1MG/ML	N17466 001
	@	1MG/ML	N17466 001

TABLET; ORAL
BRETHINE

BP	NOVARTIS	2.5MG	N17849 001
BP	*	5MG	N17849 002
		2.5MG	N17849 001
	+	5MG	N17849 002
	BRICANYL		
BP	HOECHST MARION RSSL	2.5MG	N17618 001
BP		5MG	N17618 002
	@	2.5MG	N17618 001
	@	5MG	N17618 002

TERIPARATIDE ACETATE

INJECTABLE; INJECTION
PARATHAR
* RHONE POULENC RORER 200 UNITS/VIAL N19498 001 DEC 23, 1987
@ 200 UNITS/VIAL N19498 001 DEC 23, 1987

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
TESTOSTERONE ENANTHATE
STERIS 100MG/ML N85599 001
@ 100MG/ML N85599 001

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
AB PUREPAC PHARM 250MG N60290 001
AB 500MG N60290 002
@ 250MG N60290 001
@ 500MG N60290 002
TETRACYN
AB PFIPHARMECS 250MG N60082 003
AB 500MG N60082 004
@ 250MG N60082 003
@ 500MG N60082 004

THEOPHYLLINE

CAPSULE; ORAL
BRONKODYL
@ SANOFI SYNTHELABO 100MG N85264 001
@ 200MG N85264 002
@ STERLING WINTHROP 100MG N85264 001
@ 200MG N85264 002

CAPSULE, EXTENDED RELEASE; ORAL
THEOCLEAR L.A.-130
BC * CENT PHARMS 130MG N86569 001 MAY 27, 1982
@ SCHWARZ PHARMA 130MG N86569 001 MAY 27, 1982

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEOCLEAR L.A.-260
BC * CENT PHARMS 260MG N86569 002 MAY 27, 1982
@ SCHWARZ PHARMA 260MG N86569 002 MAY 27, 1982

INJECTABLE; INJECTION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER
@ B BRAUN 40MG/100ML N19083 001 NOV 07, 1984
@ MCGAW 40MG/100ML N19083 001 NOV 07, 1984
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER
@ B BRAUN 80MG/100ML N19083 002 NOV 07, 1984
@ MCGAW 80MG/100ML N19083 002 NOV 07, 1984
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER
@ B BRAUN 160MG/100ML N19083 003 NOV 07, 1984
@ MCGAW 160MG/100ML N19083 003 NOV 07, 1984

SYRUP; ORAL
AQUAPHYLLIN
AA FERNDALE LABS 80MG/15ML N87917 001 JAN 18, 1983
@ 80MG/15ML N87917 001 JAN 18, 1983

TABLET, EXTENDED RELEASE; ORAL
SUSTAIRE
BC ROERIG 100MG N85665 001
BC 300MG N85665 002
@ 100MG N85665 001
@ 300MG N85665 002

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL
THIOTHIXENE HCL
AA ALPHARMA EQ 5MG BASE/ML N70969 001 OCT 16, 1987
@ EQ 5MG BASE/ML N70969 001 OCT 16, 1987

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

	GABITRIL			
	+ ABBOTT	2MG		N20646 005 APR 16, 1999

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

	TICLID			
	@ ROCHE	125MG		N19979 001 MAR 24, 1993
AB	+ SYNTEX	**250MG**		**N19979 002** OCT 31, 1991
	@	125MG		N19979 001 MAR 24, 1993
	+ SYNTEX USA	250MG		N19979 002 OCT 31, 1991
	TICLOPIDINE HCL			
AB	EON	**250MG**		**N75326 001** AUG 20, 1999
AB	GENPHARM	**250MG**		**N75161 001** SEP 13, 1999
AB	INVAMED	**250MG**		**N75318 001** AUG 20, 1999
AB	MYLAN	**250MG**		**N75316 001** NOV 02, 1999
AB	PUREPAC PHARM	**250MG**		**N75253 001** AUG 20, 1999
AB	TEVA	**250MG**		**N75149 001** AUG 20, 1999
AB	TORPHARM	**250MG**		**N75089 001** JUL 01, 1999

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AB	ALCON	EQ 0.25% BASE		N20963 001 OCT 21, 1998
AB		EQ 0.5% BASE		N20963 002 OCT 21, 1998
AB	FALCON PHARMS	**EQ 0.25% BASE**		**N20963 001** OCT 21, 1998
AB		**EQ 0.5% BASE**		**N20963 002** OCT 21, 1998

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AT	ADV REMEDIES	EQ 0.5% BASE		N74466 001 MAR 25, 1997
AT	AKORN	**EQ 0.5% BASE**		**N74466 001** MAR 25, 1997
AT	ALCON	EQ 0.25% BASE		N74261 001 APR 28, 1995
AT		EQ 0.5% BASE		N74262 001 APR 28, 1995
	@ FALCON PHARMS	EQ 0.25% BASE		N74261 001 APR 28, 1995
	@	EQ 0.5% BASE		N74262 001 APR 28, 1995

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

	TOBREX			
AT	+ ALCON	0.3%		N50541 001
AT	+ FALCON PHARMS	**0.3%**		**N50541 001**

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

	TOBRAMYCIN SULFATE			
AP	APOTHECON	EQ 40MG BASE/ML		N64026 001 MAY 31, 1994
	@	EQ 40MG BASE/ML		N64026 001 MAY 31, 1994

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

	HYCAMTIN			
	+ SMITHKLINE	EQ 4MG BASE/VIAL		N20671 001 MAY 28, 1996
	+ SMITHKLINE BEECHAM	EQ 4MG BASE/VIAL		N20671 001 MAY 28, 1996

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
DESYREL

> DLT >	AB	+	APOTHECON	100MG	N18207 002
> ADD >	AB			100MG	N18207 002
> ADD >	AB	+		300MG	N18207 004
> ADD >					NOV 07, 1988
> DLT >				300MG	N18207 004
> DLT >					NOV 07, 1988

TRAZODONE HCL

> ADD >	AB		BARR	150MG	N71196 002
> ADD >					APR 26, 1999
> ADD >	AB			300MG	N71196 003
> ADD >					APR 26, 1999

TRETINOIN

GEL; TOPICAL
RETIN-A MICRO

		+	ADV POLYMER	0.1%	N20475 001
					FEB 07, 1997
		+	JOHNSON AND JOHNSON	0.1%	N20475 001
					FEB 07, 1997

SOLUTION; TOPICAL
TRETINOIN

	AT		MORTON GROVE	0.05%	N75260 001
					JAN 25, 1999

TRIAMCINOLONE

TABLET; ORAL
ARISTOCORT

	BP		FUJISAWA HLTHCARE	4MG	N11161 007
	BP	+		8MG	N11161 011
				1MG	N11161 009
				2MG	N11161 004
	BP		LEDERLE	2MG	N11161 004
	BP			4MG	N11161 007
	BP	+		8MG	N11161 011
				1MG	N11161 009

TRIAMCINOLONE

	BP		ROXANE	2MG	N84708 001
	BP			4MG	N84709 001
	BP			8MG	N84707 001
		@		2MG	N84708 001

TRIAMCINOLONE

TABLET; ORAL
TRIAMCINOLONE

		@	ROXANE	4MG	N84709 001
		@		8MG	N84707 001
	BP		TEVA	4MG	N84775 001
		@		4MG	N84775 001

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
ARISTOCORT

	AT		FUJISAWA HLTHCARE	0.025%	N83017 003
	AT			0.1%	N83016 004
	AT			0.5%	N83015 002
	AT		LEDERLE	0.025%	N83017 003
	AT			0.1%	N83016 004
	AT			0.5%	N83015 002

ARISTOCORT A

	AT		FUJISAWA HLTHCARE	0.025%	N83017 004
	AT			0.025%	N88818 001
					OCT 16, 1984
	AT			0.1%	N83016 005
	AT			0.1%	N88819 001
					OCT 16, 1984
	AT			0.5%	N83015 003
	AT			0.5%	N88820 001
					OCT 16, 1984
	AT		LEDERLE	0.025%	N83017 004
	AT			0.025%	N88818 001
					OCT 16, 1984
	AT			0.1%	N83016 005
	AT			0.1%	N88819 001
					OCT 16, 1984
	AT			0.5%	N83015 003
	AT			0.5%	N88820 001
					OCT 16, 1984

GEL; TOPICAL
ARISTOGEL

		@	FUJISAWA HLTHCARE	0.1%	N83380 001
		@	LEDERLE	0.1%	N83380 001

LOTION; TOPICAL
KENALOG

		@	APOTHECON	0.025%	N11602 003
		@		0.1%	N11602 001

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL

	KENALOG			
	@ BRISTOL MYERS SQUIBB	0.025%		N11602 003
	@	0.1%		N11602 001

OINTMENT; TOPICAL

	ARISTOCORT			
AT	FUJISAWA HLTHCARE	0.1%		N80750 004
AT		0.5%		N80745 002
AT	LEDERLE	0.1%		N80750 004
AT		0.5%		N80745 002
	ARISTOCORT A			
AT	FUJISAWA HLTHCARE	0.1%		N80750 003
AT		0.1%		N88780 001
				OCT 01, 1984
AT	+	0.5%		N80745 003
	@	0.5%		N88781 001
				OCT 05, 1984
AT	LEDERLE	0.1%		N80750 003
AT		0.1%		N88780 001
				OCT 01, 1984
AT	+	0.5%		N80745 003
	@	0.5%		N88781 001
				OCT 05, 1984
	TRIAMCINOLONE ACETONIDE			
AT	ALPHARMA	0.5%		N89913 001
				DEC 23, 1988
	@	0.5%		N89913 001
				DEC 23, 1988

TRIAMCINOLONE DIACETATE

SYRUP; ORAL

	ARISTOCORT			
	FUJISAWA HLTHCARE	2MG/5ML		N11960 004
	LEDERLE	2MG/5ML		N11960 004

TRIAMTERENE

CAPSULE; ORAL

	DYRENIUM			
	SMITHKLINE BEECHAM	50MG		N13174 001
+		100MG		N13174 002
	WELLSPRING PHARM	50MG		N13174 001
+		100MG		N13174 002

TRICHLORMETHIAZIDE

TABLET; ORAL

	TRICHLORMAS			
BP	MAST MM	4MG		N86259 001
	@	4MG		N86259 001

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

	TRIFLURIDINE			
AT	ALCON	1%		N74311 001
				OCT 06, 1995
AT	STERIS	1%		N74311 001
				OCT 06, 1995

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

	TRIHEXYPHENIDYL HCL			
AA	MIKART	2MG/5ML		N40251 001
				SEP 27, 1999

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

	TIGAN			
AP	+ KING PHARMS	100MG/ML		N17530 001
AP	+ ROBERTS LABS	100MG/ML		N17530 001
	TRIMETHOBENZAMIDE HCL			
AP	SMITH AND NEPHEN	100MG/ML		N88960 001
				APR 04, 1986
	@	100MG/ML		N88960 001
				APR 04, 1986

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET; ORAL

	SULFA TRIPLE #2			
AB	+ GLOBAL PHARM	167MG;167MG;167MG		N80079 001
	@	167MG;167MG;167MG		N80079 001
	TRIPLE SULFOID			
AB	PAL PAK	167MG;167MG;167MG		N80094 001
	+	167MG;167MG;167MG		N80094 001

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

	TROPICAMIDE			
AT	STERIS	0.5%	N89171 001 DEC 28, 1990	
	@	0.5%	N89171 001 DEC 28, 1990	

TYROPANOATE SODIUM

> DLT >	CAPSULE; ORAL			
> DLT >	BILOPAQUE			
> DLT >	+ NYCOMED	750MG	N13731 001	
> ADD >	@	750MG	N13731 001	

UREA, C-13

POWDER FOR RECONSTITUTION; ORAL

> ADD >	HELICOSOL			
> ADD > BX	+ METABOLIC SOLUTIONS	125MG/VIAL	N21092 001 DEC 17, 1999	
> ADD >	PYLORI-CHEK BREATH TEST			
	+ ALIMENTERICS	100MG/VIAL	N20900 001 FEB 04, 1999	

VALRUBICIN

SOLUTION;

	VALSTAR PRESERVATIVE FREE			
	+ ANTHRA	40MG/ML	N20892 001 SEP 25, 1998	

SOLUTION; INTRAVESICAL

	VALSTAR PRESERVATIVE FREE			
	+ ANTHRA	40MG/ML	N20892 001 SEP 25, 1998	

VECURONIUM BROMIDE

INJECTABLE; INJECTION

	VECURONIUM BROMIDE			
AP	ABBOTT	**10MG/VIAL**	**N75164 001** OCT 21, 1999	

VECURONIUM BROMIDE

INJECTABLE; INJECTION

	VECURONIUM BROMIDE			
AP	ABBOTT	**20MG/VIAL**	**N75164 002** OCT 21, 1999	
AP	ESI LEDERLE	**10MG/VIAL**	**N75218 001** AUG 23, 1999	
AP		**20MG/VIAL**	**N75218 002** AUG 23, 1999	
AP	GENSIA	**10MG/VIAL**	**N74688 001** AUG 25, 1999	
AP		**20MG/VIAL**	**N74688 002** AUG 25, 1999	

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	VERAPAMIL HCL			
AB	MYLAN	**120MG**	**N75138 001** APR 20, 1999	
AB		**180MG**	**N75138 002** APR 20, 1999	
AB		**240MG**	**N75138 003** APR 20, 1999	
	VERELAN			
	+ ELAN	120MG	N19614 001 MAY 29, 1990	
	+	180MG	N19614 003 JAN 09, 1992	
	+	240MG	N19614 002 MAY 29, 1990	
AB	+ ELAN PHARM	**120MG**	**N19614 001** MAY 29, 1990	
AB	+	**180MG**	**N19614 003** JAN 09, 1992	
AB	+	**240MG**	**N19614 002** MAY 29, 1990	

INJECTABLE; INJECTION

	VERAPAMIL HCL			
AP	SMITH AND NEPHEW	2.5MG/ML	N70696 001 JUL 31, 1987	
	@	2.5MG/ML	N70696 001 JUL 31, 1987	

TABLET, EXTENDED RELEASE; ORAL

	VERAPAMIL HCL			
AB	DURAMED	**120MG**	**N75072 001** MAY 25, 1999	

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	VERAPAMIL HCL			
AB	DURAMED	**240MG**	**N75072 003**	MAY 25, 1999

VINCRISTINE SULFATE

INJECTABLE; INJECTION

	VINCRISTINE SULFATE PFS			
AP	GENSIA SICOR PHARMS	**1MG/ML**	**N75493 001**	SEP 01, 1999

VITAMIN A PALMITATE

CAPSULE; ORAL

	DEL-VI-A			
AA	DEL RAY LABS	**EQ 50,000 UNITS BASE**	**N80830 001**	
	@	EQ 50,000 UNITS BASE	N80830 001	

WARFARIN SODIUM

TABLET; ORAL

	COUMADIN			
AB	+ DUPONT MERCK	**2MG**	**N09218 013**	
AB		**2MG**	**N09218 013**	
AB		**2.5MG**	**N09218 018**	
AB	+	**2.5MG**	**N09218 018**	
AB		**5MG**	**N09218 007**	
AB	+	**5MG**	**N09218 007**	
	WARFARIN SODIUM			
AB	TARO	**1MG**	**N40301 002**	JUL 15, 1999
AB		**2MG**	**N40301 003**	JUL 15, 1999
AB		**2.5MG**	**N40301 004**	JUL 15, 1999
AB		**3MG**	**N40301 005**	JUL 15, 1999
AB		**4MG**	**N40301 006**	JUL 15, 1999
AB		**5MG**	**N40301 007**	JUL 15, 1999
AB		**6MG**	**N40301 008**	JUL 15, 1999

WARFARIN SODIUM

TABLET; ORAL

	WARFARIN SODIUM			
AB	TARO	**7.5MG**	**N40301 009**	JUL 15, 1999
AB		**10MG**	**N40301 001**	JUL 15, 1999

XYLOSE

POWDER; ORAL

	XYLO-PFAN			
AA	+ SAVAGE LABS	**25GM/BOT**	**N17605 001**	
	@	25GM/BOT	N17605 001	
	XYLOSE			
AA	LYNE	**25GM/BOT**	**N18856 001**	MAR 26, 1987
	+	25GM/BOT	N18856 001	MAR 26, 1987

ZALEPLON

CAPSULE; ORAL

	SONATA		
	WYETH AYERST	5MG	N20859 001 AUG 13, 1999
	+	10MG	N20859 002 AUG 13, 1999

ZANAMIVIR

CAPSULE; INHALATION

	RELENZA		
	+ GLAXO WELLCOME	5MG	N21036 001 JUL 26, 1999

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN			
+ C AND W LABS	120MG		N18060 001
+	325MG		N18060 003
			DEC 18, 1986
+	650MG		N18060 002
	120MG		N18060 001
	325MG		N18060 003
			DEC 18, 1986
	650MG		N18060 002
ACETAMINOPHEN			
ASCENT PEDS	120MG		N18337 003
			SEP 12, 1983
	325MG		N18337 002
+	650MG		N18337 001
UPSHER SMITH	120MG		N18337 003
			SEP 12, 1983
	325MG		N18337 002
	650MG		N18337 001
INFANTS' FEVERALL			
ASCENT PEDS	80MG		N18337 004
			AUG 26, 1992
UPSHER SMITH	80MG		N18337 004
			AUG 26, 1992

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONTAC			
+ SMITHKLINE	8MG;75MG		N18099 001
@	8MG;75MG		N18099 001
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE			
CENT PHARMS	8MG;75MG		N18809 001
			MAY 07, 1984
+	8MG;75MG		N18809 001
			MAY 07, 1984

TABLET, EXTENDED RELEASE; ORAL

CONTAC			
NOVARTIS	12MG;75MG		N19613 001
			JUN 13, 1986
+	12MG;75MG		N19613 001
			JUN 13, 1986
TRIAMINIC-12			
+ NOVARTIS	12MG;75MG		N18115 001
@	12MG;75MG		N18115 001

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200			
+ SMITHKLINE BEECHAM	200MG/20ML		N20951 001
			JUL 09, 1999

TABLET; ORAL

CIMETIDINE			
DANBURY PHARMA	200MG		N75425 001
			JUL 29, 1999
ZENITH GOLDLINE	200MG		N75345 001
			JUN 16, 1999

CLOTRIMAZOLE

CREAM; TOPICAL

LOTRIMIN AF			
SCHERING PLOUGH	1%		N17619 002
			OCT 27, 1989

LOTION; TOPICAL

LOTRIMIN AF			
SCHERING	1%		N18813 002
			OCT 27, 1989

SOLUTION; TOPICAL

LOTRIMIN AF			
SCHERING PLOUGH	1%		N17613 002
			OCT 27, 1989

EPINEPHRINE BITARTRATE

AEROSOL, METERED, INHALATION

MEDIHALER-EPI			
+ 3M	0.3MG/INH		N10374 003
@	0.3MG/INH		N10374 003

FAMOTIDINE

TABLET; ORAL

PEPCID AC			
MERCK	10MG		N20902 001
			AUG 05, 1999

IBUPROFEN

SUSPENSION; ORAL			
IBUPROFEN			
ALPHARMA		100MG/5ML	N74916 001 APR 30, 1999
TABLET; ORAL			
IBUPROFEN			
LNK		200MG	N75010 001 MAR 01, 1999
		200MG	N75139 001 MAR 01, 1999
NORTON HN		200MG	N71144 001 JAN 20, 1987
		200MG	N72901 001 DEC 19, 1991
		200MG	N72903 001 DEC 19, 1991
ZENITH GOLDLINE		200MG	N71144 001 JAN 20, 1987
		200MG	N72901 001 DEC 19, 1991
		200MG	N72903 001 DEC 19, 1991
JUNIOR STRENGTH IBUPROFEN			
PERRIGO		100MG	N75367 001 APR 22, 1999

IBUPROFEN POTASSIUM

CAPSULE; ORAL			
PROVEL			
#	NOVARTIS	200MG	N20402 001 APR 20, 1995
+	WHITEHALL ROBINS	200MG	N20402 001 APR 20, 1995

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION			
LENTE ILETIN II			
#	LILLY	100 UNITS/ML	N18477 001
@		100 UNITS/ML	N18477 001

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL			
M-ZOLE 3 COMBINATION PACK			
ALPHARMA US PHARM		2%,200MG	N74926 001 APR 16, 1999
MICONAZOLE NITRATE COMBINATION PACK			
PERRIGO		2%,200MG	N75329 001 APR 20, 1999
SUPPOSITORY; VAGINAL			
MICONAZOLE NITRATE			
ALPHARMA US PHARM		100MG	N73507 001 NOV 19, 1993
NMC		100MG	N73507 001 NOV 19, 1993

MINOXIDIL

SOLUTION; TOPICAL			
MINOXIDIL (FOR MEN)			
PERRIGO		2%	N75357 001 JUL 30, 1999
MINOXIDIL (FOR WOMEN)			
PERRIGO		2%	N75357 002 JUL 30, 1999

NAPROXEN SODIUM

TABLET; ORAL			
NAPROXEN SODIUM			
GRANUTEC		EQ 200MG BASE	N74635 001 JAN 13, 1997
NOVOPHARM NC		EQ 200MG BASE	N74635 001 JAN 13, 1997

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL			
ALEVE COLD AND SINUS			
+	BAYER	EQ 200MG BASE;120MG	N21076 001 NOV 29, 1999

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

> ADD >	HABITROL			
> ADD >	+ NOVARTIS	7MG/24HR	N20076 004	NOV 12, 1999
> ADD >	+	14MG/24HR	N20076 005	NOV 12, 1999
> ADD >	+	21MG/24HR	N20076 006	NOV 12, 1999
> ADD >	PROSTEP			
	+ ELAN PHARM	11MG/24HR	N19983 003	DEC 23, 1998
	+	22MG/24HR	N19983 004	DEC 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX			
WATSON LAB	EQ 2MG BASE	N74507 001	MAR 15, 1999
	EQ 4MG BASE	N74707 001	MAR 19, 1999

NONOXYNOL-9

SPONGE; VAGINAL

TODAY			
@ ALLENDALE PHARMS	1GM	N18683 001	APR 01, 1983
@ WHITEHALL ROBINS	1GM	N18683 001	APR 01, 1983

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HCL			
PERRIGO	120MG	N75153 001	FEB 26, 1999

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HCL			
NOVOPHARM	EQ 75MG BASE	N75094 001	JUN 21, 1999
RANBAXY	EQ 75MG BASE	N75132 001	
ZANTAC 75			
+ GLAXO WELLCOME	EQ 75MG BASE	N20520 001	DEC 19, 1995
+ WARNER LAMBERT	EQ 75MG BASE	N20520 001	DEC 19, 1995

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL			
+ NOVARTIS	1%	N20980 001	MAR 09, 1999

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 12 DEC '99

NO DECEMBER 1999 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
111Indium pentetreotide TN= SomatoTher	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation 1600 Canal St. 10th Floor New Orleans, LA 70112 DD=06/10/1999
166Ho-DOTMP TN=	Treatment of multiple myeloma.	NeoRx Corporation 410 W. Harrison Seattle, WA 98119 DD=02/10/1999
506U78 TN=	Treatment of chronic lymphocytic leukemia.	Glaxo Wellcome, Inc. Five Moore Dr. P.O. Box 13398 Durham, NC 27709 DD=09/02/1999
6-hydroxymethylacylfulvene TN=	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=04/06/1999
6-hydroxymethylacylfulvene TN=	Treatment of ovarian cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=07/06/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
6-hydroxymethylacylfulvene TN=	Treatment of renal cell carcinoma.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington, MN 55438 DD=07/27/1999
AP1903 TN=	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Ariad Gene Therapeutics, Inc. 26 Landsdowne St. Cambridge, MA 02139 DD=11/24/1999
Adenovirus-based vector Factor VIII complementary DNA to somatic cells TN= MiniAdFVIII	Treatment of hemophilia A.	GenStar Therapeutics Corporation 10835 Altman Row Suite 150 San Diego, CA 92121 DD=12/15/1999
Alitretinoin TN= Panretin	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive San Diego, CA 92121 DD=03/24/1998 MA=02/02/1999
Alpha1-proteinase inhibitor (human) TN=	For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.	Centeon LLC 1020 First Ave. King of Prussia, PA 19406 DD=11/24/1999
Amifostine TN= Ethyol	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	U.S. Bioscience, Inc. One Tower Bridge 100 Front Street, Suite 400 Conshohocken, PA 19428 DD=05/12/1998 MA=06/24/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Amifostine TN= Ethyol	Treatment of myelodysplastic syndromes.	US Bioscience, Inc. One Tower Bridge 100 Front St., Suite 400 West Conshohocken, PA 19428 DD=10/04/1999
Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized TN= Humate-P	Treatment and prevention of bleeding in hemophilia A (classical hemophilia) in adult patients; and treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate in adult and pediatric patients.	Centeon Pharma GmbH Emil-von-Behring-Strasse 76 35041 Marburg Germany, DE DD=10/16/1992 MA=04/01/1999
Artesunate TN=	Treatment of malaria.	World Health Organisation Special Programme for Research and Training in Tropical Diseases Via Appia , Geneva 27 Switzerland, CH DD=07/19/1999
Atovaquone TN= Mepron	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development 5 Moore Drive PO Box 13398 Research Triangle Park, NC 27709 DD=08/14/1991 MA=01/05/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Autologous DNP-conjugated tumor vaccine TN= M-Vax	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc. 4520 Main St. Suite 930 Kansas City, MO 64111 DD=02/23/1999
Azathioprine TN= Imuran	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc. 787 Seventh Ave., 48th Floor New York, NY 10019 DD=09/14/1999
Beraprost TN=	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	United Therapeutics Corporation 68 T.W. Alexander Drive, PO Box 14186 Research Triangle Park, NC 27709 DD=04/29/1999
Bexarotene TN= Targretin	Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.	Ligand Pharmaceuticals, Inc. 10275 Science Center Dr. San Diego, CA 92121 DD=06/18/1999 MA=12/29/1999
Bleomycin TN= Blenoxane	Treatment of pancreatic cancer.	Genetronics, Inc. 11199 Sorrento Valley Rd. San Diego, CA 92121 DD=02/09/1999
Botulinum toxin type A TN= Dysport	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited 1 Bath Rd., Maidenhead Berkshire SL6 4UH England, GB DD=10/20/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Busulfan TN= Busulfex	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 250 Minnetonka, MN 55305 DD=07/28/1994 MA=02/04/1999
CT-2584 mesylate TN=	Treatment of adult soft tissue sarcoma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Suite 400 Seattle, WA 98119 DD=04/16/1999
CT-2584 mesylate TN=	Treatment of malignant mesothelioma.	Cell Therapeutics, Inc. 201 Elliott Ave. West Seattle, WA 98119 DD=04/16/1999
Caffeine TN= Cafcit	Treatment of apnea of prematurity.	O.P.R. Development, L.P. 1501 Wakarusa Drive Lawrence, KS 66047 DD=09/20/1988 MA=09/21/1999
Coagulation factor VIIa (recombinant) TN= NovoSeven	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk Pharmaceuticals, Inc. 100 Overlook Center Suite 200 Princeton, NJ 08540 DD=06/06/1988 MA=03/25/1999
Cytarabine liposomal TN= DepoCyt	Treatment of neoplastic meningitis.	DepoTech Corporation 10450 Science Center Drive San Diego, CA 92121 DD=06/02/1993 MA=04/01/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Decitabine TN=	Treatment of myelodysplastic syndromes.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem The Netherlands, NL DD=03/08/1999
Decitabine TN=	Treatment of chronic myelogenous leukemia.	Pharmachemie B.V. Swensweg 5 2031 GA Haarlem The Netherlands, NL DD=03/08/1999
Denileukin diftitox TN= Ontak	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	Seragen, Inc. 97 South Street Hopkinton, MA 01748 DD=08/21/1996 MA=02/05/1999
Doxorubicin liposome TN= Doxil	Treatment of ovarian cancer.	Alza Corporation 1550 Plymouth St. PO Box 7210 Mountain View, CA 94039 DD=11/04/1998 MA=06/28/1999
Epirubicin TN= Ellence	Treatment of breast cancer.	Pharmacia & Upjohn Company 0634-298-113 7000 Portage Rd. Kalamazoo, MI 49001 DD=09/14/1999 MA=09/15/1999
Epoprostenol TN= Flolan	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	Glaxo Wellcome Inc. Five Moore Dr. PO Box 13398 Research Triangle Park, NC 27709 DD=03/22/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Etanercept TN= Enbrel	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=10/27/1998 MA=05/27/1999
Etanercept TN= Enbrel	Treatment of Wegener's granulomatosis.	Immunex Corporation 51 University Street Seattle, WA 98101 DD=04/06/1999
Exemestane TN= Aromasin	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn 7000 Portage Road Mail Stop: 0636-298-113 Kalamazoo, MI 49001 DD=09/19/1991 MA=10/21/1999
Fluoxetine TN= Prozac	Treatment of autism.	Hollander, MD, Eric Mt. Sinai School of Medicine, Dept. of Psychiatry Box 1230, One Gustave L. Levy Place New York, NY 10029 DD=04/30/1999
Gemtuzumab zogamicin TN=	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories PO Box 8299 Philadelphia, PA 19101 DD=11/24/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Guanfacine TN= Tenex	Treatment of fragile X syndrome.	Watson Laboratories, Inc. 311 Bonnie Circle PO Box 1900 Corona, CA 91718 DD=08/05/1999
HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex TN= Allovectin-7	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated 9373 Towne Centre Dr., Suite 100 San Diego, CA 92121 DD=09/30/1999
Histamine TN= Maxamine	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	Maxim Pharmaceuticals, Inc. 8899 University Center Lane Suite 400 San Diego, CA 92122 DD=12/15/1999
Humanized MAb (IDEC-131) to CD40L TN=	Treatment of systemic lupus erythematosus.	Idec Pharmaceuticals Corporation 3030 Callan Rd. San Diego, CA 92121 DD=02/09/1999
Interferon beta-1a (recombinant human) TN= Avonex	Treatment of pulmonary fibrosis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=01/07/1999
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B) TN= 131IchTNT-1	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Techniclone Corporation 14282 Franklin Ave Tustin, CA 92780 DD=02/12/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Japanese encephalitis vaccine (live, attenuated) TN=	Prevention of Japanese encephalitis.	Boran Pharmaceuticals 3F, Koryo Academytel, 437-3 Ahyun-Dong, Mapo-Gu, Seoul 121-010 South Korea, KR DD=05/19/1999
L-5-hydroxytryptophan TN=	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories Inc. 311 Bonnie Circle P.O. Box 1900 Corona, CA 91718 DD=01/20/1999
L-glutamyl-L-tryptophan TN=	Treatment of AIDS-related Kaposi's sarcoma.	Cytran Incorporated 10230 N.E. Points Dr. Suite 530 Kirkland, WA 98033 DD=10/20/1999
Lactic acid TN= Aphthaid	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc. SUNY Farmingdale Conklin Hall Farmingdale, NY 11735 DD=06/29/1999
Levocarnitine TN= Carnitor	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue, Suite 300 Gaithersburg, MD 20877 DD=09/06/1988 MA=12/15/1999
Lidocaine patch 5% TN= Lidoderm Patch	For relief of allodynia (painful hypersensitivity), and chronic pain in post-herpetic neuralgia.	Hind Health Care, Inc. 3707 Williams Rd., Suite 101 San Jose, CA 95117 DD=10/24/1995 MA=03/19/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II) TN=	Treatment of malignant mesothelioma.	Aronex Pharmaceuticals, Inc. 8707 Technolgoy Forest Place The Woodlands, TX 77381 DD=09/01/1999
Lisofylline TN=	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc. 201 Elliot Ave. W., Suite 400 Seattle, WA 98119 DD=06/10/1999
Marijuana TN=	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc. 3 Francis St. Belmont, MA 02478 DD=05/25/1999
Mitoxantrone TN= Novantrone	Treatment of secondary-progressive multiple sclerosis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=08/13/1999
Mitoxantrone TN= Novantrone	Treatment of progressive-relapsing multiple sclerosis.	Immunex Corporation 51 University St. Seattle, WA 98101 DD=08/13/1999
Murine MAb to polymorphic epithelial mucin, human milk fat globule 1 TN= Theragyn	Adjuvant treatment of ovarian cancer.	Antisoma West Africa House Hanger Lane London W5 3QR, GB DD=03/22/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
N-acetylgalactosamine-4-sulfatase, recombinant human TN=	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc. 11 Pimental Court Novato, CA 94949 DD=02/17/1999
Nitric oxide TN= INOmax	Treatment of persistent pulmonary hypertension in the newborn.	INO Therapeutics, Inc. 54 Old Highway 22 Clinton, NJ 08809 DD=06/22/1993 MA=12/23/1999
Parovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine TN= MEDI-491	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg, MD 20878 DD=05/07/1999
Peginterferon alfa-2a TN= PEGASYS	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley, NJ 07110 DD=09/30/1999
Pegylated arginine deiminase TN= Hepacid	Treatment of hepatocellular carcinoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=03/26/1999
Pegylated arginine deiminase TN= Melanocid	Treatment of invasive malignant melanoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=04/12/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Pentostatin TN= Nipent	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc. Two Annabel Lane, Suite 220 San Ramon, CA 94583 DD=11/24/1999
Polyethylene glycol-modified uricase TN= Zurase	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton, PA 19341 DD=09/14/1999
Recombinant human C1-esterase inhibitor TN=	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel Belgium, BE DD=02/23/1999
Recombinant human C1-esterase inhibitor TN=	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel Belgium, BE DD=02/23/1999
Recombinant human insulin-like growth factor-I/insulin -like growth factor binding protein-3 TN=	Treatment of major burns that require hospitalization.	Celtrix Pharmaceuticals, Inc. 3055 Patrick Henry Dr. Santa Clara, CA 95054 DD=06/15/1999
Recombinant human keratinocyte growth factor TN=	Reducing the incidence and severity of radiation-induced xerostomia.	Amgen Inc. One Amgen Center Dr. Thousand Oaks, CA 91320 DD=12/20/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Recombinant human nerve growth factor TN=	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=04/16/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of solid organ transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Recombinant humanized MAb 5c8 TN=	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=03/22/1999
Rifalazil TN=	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=04/13/1999
SCH 58500 TN=	Treatment of primary ovarian cancer.	Schering Corporation 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=04/12/1999
Silver sulfadiazine and cerium nitrate TN= Flammacerium	Prevention of mortality in severely burned patients.	Synthes (USA) 1690 Russell Road PO Box 1766 Paoli, PA 19301 DD=11/17/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Sodium 1,3-propanedisulfonate TN=	Treatment of secondary amyloidosis.	Neurochem, Inc. 7220 Frederick Banting, Suite 100 Saint-Laurent, Quebec Canada H4S 2A1, CA DD=04/06/1999
Sodium dichloroacetate TN= Ceresine	Treatment of severe head injury.	Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, CA 92008 DD=06/14/1999
Somatropin (rDNA origin) TN= Nutropin Depot	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=10/28/1999 MA=12/22/1999
Somatropin [rDNA] TN= Genotropin	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn 7000 Portage Rd. 0633-298-113 Kalamazoo, MI 49001 DD=07/06/1999
Synthetic human secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 1550 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic human secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Synthetic human secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/16/1999
Synthetic porcine secretin TN=	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Synthetic porcine secretin TN=	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring, MD 20905 DD=06/18/1999
Temoporfin TN= Foscan	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Scotia Pharmaceuticals Ltd. Scotia House, Castle Business Park Stirling Scotland FK9 4TZ, GB DD=10/28/1999
Temozolomide TN= Temodar	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute 2000 Galloping Hill Rd. Kenilworth, NJ 07033 DD=10/05/1998 MA=08/11/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Teriparatide TN= Parathar	Treatment of idiopathic osteoporosis.	Henri Beaufour Institute USA, Inc. 27 Maple St. Milford, MA 01757 DD=10/28/1999
Thalidomide TN= Thalomid	Treatment of Crohn's disease.	Celgene Corporation 7 Powder Horn Dr. Warren, NJ 07059 DD=04/06/1999
Tobramycin TN= Tobi	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle, WA 98119 DD=06/18/1999
Transgenic human alpha 1 antitrypsin TN=	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh EH25 9PP Scotland, GB DD=05/19/1999
Trastuzumab TN= Herceptin	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Genentech, Inc. 1 DNA Way South San Francisco, CA 94080 DD=12/14/1999
Ubiquinone TN= Ubiqgel	Treatment of mitochondrial cytopathies.	Gel-Tec, Division of Tishcon Corp. 30 New York Ave. PO Box 331 Westbury, NY 11590 DD=12/14/1999

Orphan Product Designations and Approvals List
December 1999

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembryonic antigen IgG antibody TN= Cea-Cide	Treatment of ovarian carcinoma.	Immunomedics, Inc. 300 American Rd. Morris Plains, NJ 07950 DD=08/03/1999
pVGI.1(VEGF2) TN=	Treatment of thromboangiitis obliterans.	Vascular Genetics, Inc. 200 Westpark Corporate Center 4364 South Alston Ave. Durham, NC 27713 DD=11/09/1999

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO DECEMBER 1999 ADDITIONS

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 19TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

NP* NEW PRODUCT (MINT FLAVORED)

REFERENCES

NEW DOSING SCHEDULE

D-50	**INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS**
D-51	**TO BE DEFINED IN SUPPLEMENT**
D-52	**ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY**
D-53	**USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE**

NEW INDICATION

I-250	**PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPTOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C**
I-251	**TREATMENT OF GENERALIZED ANXIETY DISORDER**
I-252	**NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN**
I-253	**COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN**
I-254	**PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)**
I-255	**PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)**
I-256	**USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY**
I-257	**TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION**
I-258	**FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES FOUR AND ABOVE**
I-259	**PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY**
I-260	**EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)**
I-261	**TREATMENT OF SOCIAL ANXIETY DISORDER**
I-262	**TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12**
I-263	**TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY**
I-264	**PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION**
I-265	**TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER**
I-266	**USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES**

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-267	USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER-FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
I-268	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-277	TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
I-278	TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
I-279	TREATMENT OF POST-TRAUMATIC STRESS DISORDER
I-280	USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
I-281	INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON-FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIa and IIb)
I-282	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
I-283	TO BE DEFINED IN SUPPLEMENT
I-284	TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AND ADJUNCT TO USUAL CARE
I-285	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER

REFERENCES

MISCELLANEOUS EXCLUSIVITY CODES

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION

PATENT USE CODE

U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECITON IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION OF DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN.
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN.
U-265	USE AS A LAXATIVE
U-266	OSTEOARTHRITIS
U-267	METHOD FOR PREVENTING HEARTBURN
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD FOR IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY, TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA
U-289	TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
U-290	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294	TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296	TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA, NAUSEA AND FUNCTIONAL DISABILITY
U-297	PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298	METHOD OF COMBATING BACTERIA IN A PATIENT
U-299	TREATMENT OF ADENOMATOUS POLYPS
U-300	INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

U-302	TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303	METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPORISIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS
U-304	A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
U-305	METHODS FOR USING THE DRUG PRODUCT
U-306	TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307	CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308	CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020482 004	ACARBOSE;PRECOSE				I-252	SEP 29, 2001
						I-253	SEP 29, 2001
>ADD>	020802 001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)	5972916	JUL 14, 2017	U-296		
>ADD>			4943565	JUL 24, 2007			
	020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010	U-134		
			RE34440	MAR 31, 2010	U-275		
	020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010	U-134		
			RE34440	MAY 31, 2010	U-275		
	020059 001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		
	020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA				I-262	JUN 02, 2002
	019621 001	ALBUTEROL SULFATE;VENTOLIN	4594359	JUN 10, 2003			
>ADD>	020560 001	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	I-272	JUN 16, 2002
>ADD>	020560 002	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	I-272	JUN 16, 2002
>ADD>	020560 003	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	I-272	JUN 16, 2002
	020886 001	ALITRETINOIN;PANRETIN				ODE	FEB 02, 2006
						NCE	FEB 02, 2004
>ADD>	020379 001	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
>ADD>	020379 002	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
>ADD>	020379 003	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
>ADD>	020379 004	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
>ADD>	020221 001	AMIFOSTINE;ETHYOL	5994409	DEC 08, 2017	U-305	ODE	JUN 24, 2006
>ADD>	020221 002	AMIFOSTINE;ETHYOL	5242471	JUL 31, 2012		NCE	DEC 08, 2000
>ADD>			5591731	JUL 31, 2012		ODE	JUN 24, 2006
>ADD>			5994409	DEC 08, 2017	U-305	ODE	DEC 08, 2002
	020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE;LEVULAN	5079262	JUL 28, 2009	U-289	NCE	DEC 03, 2004
			5211938	MAY 18, 2010	U-289		
			5422093	JUL 28, 2009	U-289		
	020364 002	AMLODIPINE BESYLATE;LOTREL	4572909	JUL 31, 2006			
	020364 003	AMLODIPINE BESYLATE;LOTREL	4572909	JUL 31, 2006			
	020364 004	AMLODIPINE BESYLATE;LOTREL	4572909	JUL 31, 2006			
	020508 001	AMMONIUM LACTATE;LAC-HYDRIN				PED	FEB 29, 2000
	021007 001	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021007 002	AMPRENAVIR;AGENERASE				NCE	APR 15, 2004
	021039 001	AMPRENAVIR;AGENERASE	5585397	DEC 17, 2013		NCE	APR 15, 2004
>ADD>	020884 001	ASPIRIN;AGGRENOX	6015577	JAN 18, 2017	U-302	NC	NOV 22, 2002
>ADD>	020702 001	ATORVASTATIN CALCIUM;LIPITOR	5969156	JUL 08, 2016		I-281	DEC 02, 2002
>ADD>	020702 002	ATORVASTATIN CALCIUM;LIPITOR	5969156	JUL 08, 2016		I-281	DEC 02, 2002
>ADD>	020702 003	ATORVASTATIN CALCIUM;LIPITOR	5969156	JUL 08, 2016		I-281	DEC 02, 2002
	020500 001	ATOVAQUONE;MEPRON				ODE	JAN 05, 2006
						I-255	JAN 05, 2002
>ADD>	021055 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		NCE	DEC 29, 2004
>ADD>			5466861	NOV 14, 2012			
	020746 001	BUDESONIDE;RHINOCORT				NDF	OCT 01, 2002
	020746 002	BUDESONIDE;RHINOCORT				NDF	OCT 01, 2002
	020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5763493	AUG 12, 2013			
	020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
			5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
>ADD>	020664 001	CABERGOLINE;DOSTINEX	4526892	DEC 29, 2005			
	020793 001	CAFFEINE CITRATE;CAFCIT				NE	SEP 21, 2002
	020313 002	CALCITONIN, SALMON;MIACALCIN	5759565	JUN 02, 2015			
	020896 001	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271		
			4966891	NOV 08, 2008	U-272		
	020896 002	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U-271		
			4966891	NOV 08, 2008	U-272		
	020712 001	CARBAMAZEPINE;CARBATROL	5912013	JUN 15, 2016	U-277		
	020712 002	CARBAMAZEPINE;CARBATROL	5912013	JUN 15, 2016	U-277		
>ADD>	020998 001	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19	I-284	DEC 23, 2002
>ADD>			5972986	OCT 14, 2017	U-299		
>ADD>			5760068	JUN 02, 2015	U-299		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			
>ADD>	020998 002	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U-19	I-284	DEC 23, 2002
>ADD>			5760068	JUN 02, 2015	U-299		
>ADD>			5972986	OCT 14, 2017	U-299		
			5466823	NOV 30, 2013			
			5563165	NOV 30, 2013			
	020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		NS	MAY 24, 2002
			5177080	NOV 26, 2011			
>ADD>	021022 001	CICLOPIROX;PENLAC				NDF	DEC 17, 2002
	020638 001	CIDOFOVIR;VISTIDE	5142051	JUN 26, 2010			
	020863 001	CILOSTAZOL;PLETAL	4277479	AUG 29, 2000		NCE	JAN 15, 2004
	020863 002	CILOSTAZOL;PLETAL	4277479	AUG 29, 2000		NCE	JAN 15, 2004
	019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U-36		
			5286754	FEB 15, 2011			
	020767 001	CISAPRIDE MONOHYDRATE;PROPULSID QUICKSOLV	5648093	JUL 15, 2014			
>ADD>	074735 001	CISPLATIN;CISPLATIN				PC	MAY 15, 2000
	020463 001	CROMOLYN SODIUM;NASALCROM				PED	JUL 03, 2000
	021041 001	CYTARABINE;DEPOCYT				ODE	APR 01, 2006
						NP	APR 01, 2002
	020287 001	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 003	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	020287 004	DALTEPARIN SODIUM;FRAGMIN				I-263	MAY 25, 2002
						I-259	MAR 30, 2002
	017922 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	018938 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 001	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	019955 002	DESMOPRESSIN ACETATE;DDAVP	5763407	JUN 29, 2013			
	017922 003	DESMOPRESSIN ACETATE;DDAVP (NEEDS NO REFRIGERATION)	5763407	JUN 29, 2013			
>ADD>	020713 001	DESOGESTREL;MIRCETTE	4921843	OCT 20, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021038 001	DEXMEDETOMIDINE;PRECEDEX				NCE	DEC 17, 2004
	074752 001	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 20, 1999
	074752 003	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 20, 1999
	074752 004	DILTIAZEM HYDROCHLORIDE;CARTIA XT				PC	DEC 20, 1999
>ADD>	020449 001	DOCETAXEL;TAXOTERE	4814470	MAY 14, 2010		I-282	DEC 23, 2002
			5438072	NOV 22, 2013			
			5698582	JUL 03, 2012			
			5714512	JUL 03, 2012			
	020931 001	DOFETILIDE;TIKOSYN				NCE	OCT 01, 2004
	020931 002	DOFETILIDE;TIKOSYN				NCE	OCT 01, 2004
	020931 003	DOFETILIDE;TIKOSYN				NCE	OCT 01, 2004
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008			
			4619939	OCT 28, 2003			
	020862 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-278	NCE	JUN 09, 2004
			5707980	FEB 11, 2117	U-278		
	050718 001	DOXORUBICIN HYDROCHLORIDE;DOXIL				ODE	JUN 28, 2006
	020972 001	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256		
			5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
	020972 002	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U-256		
			5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
	020972 003	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013			
			5663169	SEP 02, 2014	U-257		
			5811423	AUG 07, 2012	U-256		
	020796 001	ENTACAPONE;COMTAN				NCE	OCT 19, 2004
	050778 001	EPIRUBICIN HYDROCHLORIDE;ELLENCE				ODE	SEP 15, 2006
	020375 001	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 002	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 003	ESTRADIOL;CLIMARA				I-254	MAR 05, 2002
	020375 004	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010		I-254	MAR 05, 2002
>ADD>	020472 001	ESTRADIOL;ESTRING	4871543	JUN 12, 2007	U-306		
>ADD>			5188835	JUN 12, 2007	U-306		
	020908 001	ESTRADIOL;VAGIFEM				NP	MAR 26, 2002
	020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NP	MAR 24, 2002
	020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN				NP	MAR 24, 2002
	010971 005	ESTROGENS, CONJUGATED;PMB 200	5210081	FEB 26, 2012			
	010971 003	ESTROGENS, CONJUGATED;PMB 400	5210081	FEB 26, 2012			
	004782 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	004782 002	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	004782 003	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	004782 004	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	004782 005	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	010402 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	020216 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
	020303 002	ESTROGENS, CONJUGATED;PREMPHASE (PREMARIN;CYCRIN 14/14)	5210081	FEB 26, 2012			
	020527 002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	5210081	FEB 26, 2012			
	020303 001	ESTROGENS, CONJUGATED;PREMPRO (PREMARIN;CYCRIN 14/14)	5210081	FEB 26, 2012			
			RE36247	MAY 02, 2006	U-284		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020527 001	ESTROGENS, CONJUGATED;PREMPRO 14/14	RE36247	MAY 02, 2006			
			5210081	FEB 26, 2012			
	020527 003	ESTROGENS, CONJUGATED;PREMPRO 14/14	4826831	MAY 02, 2006			
			5547948	JAN 17, 2015			
			RE36247	MAY 02, 2006			
			5210081	FEB 26, 2012			
	021065 001	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
	021065 002	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
	021065 003	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U-283	NP	OCT 15, 2002
	020584 001	ETODOLAC;LODINE XL	4966768	OCT 30, 2007		PED	APR 25, 2000
			4966768*PED	APR 30, 2007		NDF	OCT 25, 1999
	020584 002	ETODOLAC;LODINE XL	4966768	OCT 30, 2007		PED	APR 25, 2000
			4966768*PED	APR 30, 2007	PED	NDF	OCT 25, 1999
	020584 003	ETODOLAC;LODINE XL	4966768	OCT 30, 2007		NDF	OCT 25, 1999
			4966768*PED	APR 30, 2007	PED	PED	APR 25, 2000
	020753 001	EXEMESTANE;AROMASIN	4808616	JUL 07, 2006		NCE	OCT 21, 2004
			4904650	JUL 07, 2006		ODE	OCT 21, 2006
	020363 001	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
	020363 003	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U-96		
	020325 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-267		
	020801 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015			
			5854267	DEC 29, 2015	U-267		
			5075114	DEC 24, 2008			
	019304 002	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
	019304 003	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
	019304 004	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
	020747 001	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 002	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 003	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 004	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 005	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020747 006	FENTANYL CITRATE;ACTIQ				NP	NOV 04, 2001
	020955 001	FERRIC SODIUM GLUCONATE;FERRLECIT				NCE	FEB 18, 2004
>ADD>	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5932247	FEB 28, 2015			
			5855912	FEB 28, 2015			
			5738872	FEB 28, 2015			
	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	5855912	FEB 28, 2015			
	020788 001	FINASTERIDE;PROPECIA	5571817	NOV 05, 2013	U-259		
			5886184	NOV 19, 2012			
	020180 001	FINASTERIDE;PROSCAR	4760071	JUN 19, 2006	U-262		
			5886184	NOV 19, 2012			
			4377584	MAR 22, 2000	U-261		
			5942519	OCT 23, 2018	U-280		
	019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-265	AUG 18, 2002
	018936 003	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
			4626549	DEC 02, 2003	U-154		
			4626549	DEC 02, 2003	U-84		
	018936 004	FLUOXETINE HYDROCHLORIDE;PROZAC	4314081	FEB 02, 2001			
			4626549	DEC 02, 2003	U-154		
			4626549	DEC 02, 2003	U-84		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
					U-154		
	020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
			4626549	DEC 02, 2003	U-154		
			4314081	FEB 02, 2001			
	020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
			4626549	DEC 02, 2003	U-154		
			4314081	FEB 02, 2001			
	019958 001	FLUTICASONE PROPIONATE;CUTIVATE				I-267	JUN 17, 2002
	020121 001	FLUTICASONE PROPIONATE;FLONASE				I-258	DEC 11, 2001
>ADD>	020243 001	FLUVOXAMINE MALEATE;LUVOX				PED	JUN 05, 2000
>ADD>						NCE	DEC 05, 1999
>ADD>	020243 002	FLUVOXAMINE MALEATE;LUVOX				PED	JUN 05, 2000
>ADD>						NCE	DEC 05, 1999
>ADD>	020243 003	FLUVOXAMINE MALEATE;LUVOX				PED	JUN 05, 2000
>ADD>						NCE	DEC 05, 1999
>ADD>	020243 004	FLUVOXAMINE MALEATE;LUVOX				PED	JUN 05, 2000
>ADD>						NCE	DEC 05, 1999
	020582 001	FOLLITROPIN ALFA/BETA;FOLLISTIM	5767251	JUN 16, 2015			
	020582 002	FOLLITROPIN ALFA/BETA;FOLLISTIM	5767251	JUN 16, 2015			
	020882 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		
	020882 002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			5084479	JAN 02, 2010	U-258		
>ADD>	020937 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
>ADD>			5137711	JUL 14, 2009			
>ADD>	020975 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
>ADD>			5137711	JUL 14, 2009			
>ADD>	020976 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
>ADD>			5137711	JUL 14, 2009			
>ADD>	020460 001	GANCICLOVIR;CYTOVENE	4507305	MAY 21, 2001	U-64		
>ADD>	020460 002	GANCICLOVIR;CYTOVENE	4507305	MAY 21, 2001	U-64		
	021057 001	GANIRELIX ACETATE;ANTAGON	4801577	FEB 05, 2007		NCE	JUL 29, 2004
			5767082	JUN 16, 2015			
	021061 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
	021061 002	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
	021062 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
	021062 002	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
	020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010			
	020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010			
	020496 001	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
	020496 002	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
	020496 003	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U-118		
	020305 001	GRANISETRON HYDROCHLORIDE;KYTRIL				I-264	JUL 27, 2002
	020305 002	GRANISETRON HYDROCHLORIDE;KYTRIL				I-264	JUL 27, 2002
>ADD>	020125 001	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3		
>ADD>			4743450	FEB 24, 2007			
>ADD>	020125 002	HYDROCHLOROTHIAZIDE;ACCURETIC	4743450	FEB 24, 2007			
>ADD>			4344949	OCT 03, 2002	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020125 003	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3		
>ADD>			4743450	FEB 24, 2007			
	020758 001	HYDROCHLOROTHIAZIDE;AVALIDE	5994348	JUN 07, 2015			
	020758 002	HYDROCHLOROTHIAZIDE;AVALIDE	5994348	JUN 07, 2015			
	020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	MAR 20, 2011		NCE	SEP 30, 2002
			5994348	JUN 07, 2015			
	020491 001	IBUTILIDE FUMARATE;CORVERT				D-50	MAY 13, 2002
	020723 001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2009	U-172		
>ADD>	020685 001	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
>ADD>	020685 003	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
>ADD>	020685 005	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
	021028 001	INSULIN HUMAN;VELOSULIN BR				NP	JUL 19, 2002
>ADD>	021017 001	INSULIN LISPRO PROTAMINE;HUMALOG MIX 75/25				NC	DEC 22, 2002
>ADD>	021018 001	INSULIN LISPRO PROTAMINE;HUMALOG MIX 50/50	5461031	JUN 26, 2014			
>ADD>			5474978	JUN 16, 2014			
>ADD>			5514646	MAY 07, 2013			
>ADD>			5747642	JUN 16, 2014			
	020083 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020657 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
	020966 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005			
			4267179	JUN 23, 2000			
	021066 001	KETOTIFEN FUMARATE;ZADITOR				NCE	JUL 02, 2004
	020564 001	LAMIVUDINE;EPIVIR	5905082	MAY 18, 2016			
>ADD>	020596 001	LAMIVUDINE;EPIVIR	6004968	MAR 20, 2018			
	021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
			5532246	JUL 02, 2013	U-250		
			5905082	MAY 18, 2016			
>ADD>	021004 001	LAMIVUDINE;EPIVIR-HBV	6004968	MAR 20, 2018		NCE	NOV 17, 2000
			5047407	FEB 08, 2009		I-257	DEC 08, 2001
			5532246	JUL 02, 2013	U-250		
	020764 001	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 002	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020764 003	LAMOTRIGINE;LAMICTAL CD				I-247	DEC 14, 2001
	020406 001	LANSOPRAZOLE;PREVACID				M-1	JUL 06, 2002
	020406 002	LANSOPRAZOLE;PREVACID				M-1	JUL 06, 2002
	020597 001	LATANOPROST;XALATAN	5296504	MAR 22, 2011	U-260		
			5422368	MAR 22, 2011	U-260		
			4599353	JUL 28, 2006	U-260		
	020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	4652441	NOV 01, 2004			
	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX				NP	MAR 25, 2002
	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX				NP	MAR 25, 2002
	020035 001	LEVAMISOLE HYDROCHLORIDE;ERGAMISOL	4584305	JUN 18, 2004	U-42		
	021035 001	LEVETIRACETAM;KEPPRA	4943639	JUL 06, 2006		NCE	NOV 30, 2004
			4837223	JUN 06, 2006			
	021035 002	LEVETIRACETAM;KEPPRA	4943639	JUL 06, 2006		NCE	NOV 30, 2004
			4837223	JUN 06, 2006			
	021035 003	LEVETIRACETAM;KEPPRA	4943639	JUL 06, 2006		NCE	NOV 30, 2004
			4837223	JUN 06, 2006			
>ADD>	020997 001	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276	NP	AUG 05, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020997 002	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276	NP	AUG 05, 2002
>ADD>	020997 003	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U-276	NP	AUG 05, 2002
>ADD>	020182 001	LEVOCARNITINE;CARNITOR				I-280	DEC 15, 2002
>ADD>						ODE	DEC 15, 2006
	021045 001	LEVONORGESTREL;PLAN B				NP	JUL 28, 2002
	019941 001	LIDOCAINE;EMLA				I-260	MAR 11, 2002
	020612 001	LIDOCAINE;LIDODERM				ODE	MAR 19, 2006
>ADD>	019558 001	LISINOPRIL;PRINIVIL	4374829	DEC 30, 2001			
	019777 006	LISINOPRIL;ZESTRIL	4374829	DEC 30, 2001			
	019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
	021047 001	LUTEINIZING HORMONE;REPRONEX				NP	AUG 27, 2002
	021047 002	LUTEINIZING HORMONE;REPRONEX				NP	AUG 27, 2002
>ADD>	020922 001	MEQUINOL;SOLAGE	5194247	MAR 16, 2010	U-294	NC	DEC 10, 2004
			5470567	MAR 19, 2010	U-294		
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020969 001	METHOXSALEN;UVADEX	4845075	APR 11, 2009		NP	FEB 25, 2002
			5036102	JUL 30, 2008	U-273		
			4999375	MAR 12, 2008			
	020968 001	MICONAZOLE NITRATE;MONISTAT DUAL- PAK	5514698	MAR 21, 2014		NP	JUN 30, 2002
	020682 001	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020682 002	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	020682 003	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U-111		
	019436 001	MILRINONE LACTATE;PRIMACOR	4313951	NOV 26, 2001			
	020343 001	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
	020343 002	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
	020343 003	MILRINONE LACTATE;PRIMACOR IN DEXTROSE 5%	4313951	NOV 26, 2001			
	020717 001	MODAFINIL;PROVIGIL	4177290	MAR 09, 1999			
			5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		
	020717 002	MODAFINIL;PROVIGIL	4177290	MAR 09, 1999			
			5618845	OCT 06, 2014	U-255		
			4927855	MAY 22, 2007	U-255		
>ADD>	020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX				I-285	DEC 02, 2002
>ADD>	021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX	4990517	JUN 30, 2009	U-298	NCE	DEC 10, 2004
>ADD>			5607942	MAR 04, 2014	U-298		
>ADD>			5849752	DEC 05, 2016	U-298		
>ADD>	021076 001	NAPROXEN SODIUM;ALEVE COLD AND SINUS				NC	NOV 29, 2002
>ADD>	021009 001	NEDOCROMIL SODIUM;ALOCRIL	4474787	OCT 02, 2006	U-304	NP	DEC 08, 2002
			4760072	JUL 26, 2005			
>ADD>	020778 001	NELFINAVIR MESYLATE;VIRACEPT	5952343	OCT 07, 2013	U-257	D-52	NOV 24, 2002
>ADD>	020779 001	NELFINAVIR MESYLATE;VIRACEPT	5952343	OCT 07, 2013	U-257	D-52	NOV 24, 2002
	020933 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011			
	018612 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020066 003	NICOTINE POLACRILEX;NICORETTE (MINT)				NP*	DEC 23, 2001
	020385 001	NICOTINE;NICOTROL	5656255	AUG 12, 2014			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020714 001	NICOTINE;NICOTROL	5400808	JUN 08, 2010			
			4917120	APR 17, 2007			
			4800903	JAN 31, 2006			
			4793366	DEC 27, 2005			
			5167242	JUN 08, 2010			
			5501236	JUN 08, 2010			
>ADD>	020845 002	NITRIC OXIDE;INOMAX	5485827	JAN 23, 2013	U-297	ODE	DEC 23, 2006
>ADD>						NCE	DEC 23, 2004
>ADD>	020845 003	NITRIC OXIDE;INOMAX	5485827	JAN 23, 2013	U-297	ODE	DEC 23, 2006
>ADD>						NCE	DEC 23, 2004
	018705 002	NITROGLYCERIN;NITROLINGUAL PUMPSPRAY	5186925	FEB 16, 2010			
>ADD>	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	NP	NOV 25, 2001
			4395403	NOV 21, 2002	U-269	ODE	NOV 25, 2005
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			
>ADD>	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	NP	NOV 25, 2001
			4395403	NOV 21, 2002	U-269	ODE	NOV 25, 2005
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			
>ADD>	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U-268	NP	NOV 25, 2001
			4395403	NOV 21, 2002	U-269	ODE	NOV 25, 2005
			5538739	JUL 23, 2013			
			5639480	JUN 17, 2014			
			5922338	JUL 13, 2016			
			5922682	JUL 13, 2016			
>ADD>	020592 001	OLANZAPINE;ZYPREXA	5736541	MAR 24, 2015	U-307		
>ADD>			5919485	MAR 24, 2015	U-308		
>ADD>	020592 002	OLANZAPINE;ZYPREXA	5736541	MAR 24, 2015	U-307		
>ADD>			5919485	MAR 24, 2015	U-308		
>ADD>	020592 003	OLANZAPINE;ZYPREXA	5736541	MAR 24, 2015	U-307		
>ADD>			5919485	MAR 24, 2015	U-308		
>ADD>	020592 004	OLANZAPINE;ZYPREXA	5736541	MAR 24, 2015	U-307		
>ADD>			5919485	MAR 24, 2015	U-308		
>ADD>	020592 005	OLANZAPINE;ZYPREXA	5736541	MAR 24, 2015	U-307		
>ADD>			5919485	MAR 24, 2015	U-308		
>ADD>	020592 006	OLANZAPINE;ZYPREXA	5736541	MAR 24, 2015	U-307		
>ADD>			5919485	MAR 24, 2015	U-308		
	020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN				I-269	AUG 27, 2002
	020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN				I-269	AUG 27, 2002
>ADD>	020766 001	ORLISTAT;XENICAL	6004996	JAN 18, 2018		NCE	APR 23, 2004
			4598089	JUN 18, 2004			
	021087 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016		NCE	OCT 27, 2004
			5866601	FEB 02, 2016			
			5952375	FEB 02, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018841 004	OXAPROZIN;DAYPRO				PED	APR 29, 2000
					NCE	OCT 29, 1999
020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	4783337	SEP 16, 2003		NP	DEC 16, 2001
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		5840754	MAY 22, 2015			
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
		5912268	MAY 22, 2015			
020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	5840754	MAY 22, 2015		NP	DEC 16, 2001
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
		5912268	MAY 22, 2015			
020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	5912268	MAY 22, 2015		NP	DEC 16, 2001
		4612008	SEP 16, 2003			
		4519801	JUL 12, 2002			
		5840754	MAY 22, 2015			
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013			
		5656295	FEB 05, 2008			
020262 001	PACLITAXEL;TAXOL				I-270	OCT 25, 2002
020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		
020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-285		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
			4721723	DEC 29, 2006	U-12		
>ADD>	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
			4721723	DEC 29, 2006	U-12		
>ADD>	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
			4721723	DEC 29, 2006	U-12		
>ADD>	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-285		
			4721723	DEC 29, 2006	U-12		
	020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-286		
	020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		NDF	FEB 16, 2002
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			4721723	DEC 29, 2006			
			5900423	MAY 19, 2015			
			5789449	JAN 06, 2009	U-286		
	021079 001	PEMIROLAST POTASSIUM;ALAMAST	5034230	DEC 23, 2008	U-184	PED	MAR 24, 2005
			5034230*PED	JUN 23, 2009	U-184	NCE	SEP 24, 2004
	021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
			4687777	JAN 17, 2006			
	021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
			4687777	JAN 17, 2006			
	021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4444779	JUL 27, 1999		NCE	JUL 15, 2004
			4687777	JAN 17, 2006			
	020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	5710183	JUL 14, 2015	U-265	NP	FEB 18, 2002
	020744 001	PORACTANT ALPHA;CUROSURF				NCE	NOV 18, 2004
	020667 001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
	020667 002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
	020667 003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
	020667 004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
	020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4866812	MAR 25, 2011			
	020667 006	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
	019627 002	PROPOFOL;DIPRIVAN	5714520	MAR 22, 2015			
			5714520*PED	SEP 22, 2015			
			5731355	MAR 22, 2015	U-217		
			5731355*PED	SEP 22, 2015	U-217		
			5731356	MAR 22, 2015	U-218		
			5731356*PED	SEP 22, 2015	U-218		
			5908869	MAR 22, 2015	U-270		
			5908869*PED	SEP 22, 2015	U-270		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	075102 001	PROPOFOL;PROPOFOL				PC	OCT 17, 1999
	020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	MAR 20, 2007		NCE	SEP 26, 2002
	020973 002	RABEPRAZOLE SODIUM;ACIPHEX				NCE	AUG 19, 2004
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	5466810	JUN 10, 2014		I-271	SEP 30, 2002
			5514826	JUN 07, 2015			
			5569772	JUN 07, 2015			
			5629425	SEP 19, 2014			
			5659087	JUN 07, 2015			
			5710285	MAR 31, 2015			
			5731327	MAR 24, 2015			
			5731342	JAN 27, 2017			
			5747510	MAR 02, 2014			
			5808061	MAR 31, 2014			
			5811120	MAR 02, 2014			
			5843984	APR 14, 2017			
			5972383	MAR 02, 2014	U-287		
	075094 001	RANITIDINE HYDROCHLORIDE;RANITIDINE HCL				PC	JAN 14, 2000
>ADD>	019090 001	RANITIDINE HYDROCHLORIDE;ZANTAC				D-53	OCT 29, 2002
>ADD>	019593 001	RANITIDINE HYDROCHLORIDE;ZANTAC				D-53	OCT 29, 2002
>ADD>	019593 002	RANITIDINE HYDROCHLORIDE;ZANTAC				D-53	OCT 29, 2002
>ADD>	019675 001	RANITIDINE HYDROCHLORIDE;ZANTAC				D-53	OCT 29, 2002
>ADD>	018703 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				D-53	OCT 29, 2002
>ADD>	020095 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				D-53	OCT 29, 2002
>ADD>	020251 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				D-53	OCT 29, 2002
>ADD>	020251 002	RANITIDINE HYDROCHLORIDE;ZANTAC 150				D-53	OCT 29, 2002
>ADD>	018703 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300				D-53	OCT 29, 2002
>ADD>	020095 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300				D-53	OCT 29, 2002
	020984 001	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
	020984 002	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
	020903 001	RIBAVIRIN;REBETOL	5914128	DEC 22, 2017			
	020272 007	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90	D-37	OCT 17, 2000
			4804663	DEC 29, 2007	U-90		
	020272 008	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U-90	D-37	OCT 17, 2000
			5158952	OCT 27, 2009	U-90		
	020680 001	RITONAVIR;NORVIR	5948436	SEP 13, 2013			
	020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5457895	OCT 01, 2013			
	020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5457895	OCT 01, 2013			
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266	NCE	MAY 20, 2004
			5691374	NOV 25, 2017			
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA				NCE	MAY 25, 2004
>ADD>	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152	I-279	DEC 07, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152	I-279	DEC 07, 2002
>ADD>	019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152	I-279	DEC 07, 2002
>ADD>	019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152	I-279	DEC 07, 2002
>ADD>	019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-152	I-279	DEC 07, 2002
>ADD>	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				I-193	JUL 08, 2000
>ADD>						I-208	OCT 10, 2000
	020478 001	SEVOFLURANE;ULTANE	5990176	JAN 27, 2017			
>ADD>	019766 001	SIMVASTATIN;ZOCOR	RE36481	JUL 10, 2007	U-300	I-277	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-278	NOV 22, 2002
						I-273	AUG 05, 2002
>ADD>	019766 002	SIMVASTATIN;ZOCOR	RE36481	JUL 10, 2007	U-300	I-277	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-278	NOV 22, 2002
						I-273	AUG 05, 2002
>ADD>	019766 003	SIMVASTATIN;ZOCOR	RE36481	JUL 10, 2007	U-300	I-277	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-278	NOV 22, 2002
						I-273	AUG 05, 2002
>ADD>	019766 004	SIMVASTATIN;ZOCOR	RE36481	JUL 10, 2007	U-300	I-277	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-278	NOV 22, 2002
						I-273	AUG 05, 2002
>ADD>	019766 005	SIMVASTATIN;ZOCOR	RE36481	JUL 10, 2007	U-300	I-277	NOV 22, 2002
>ADD>			RE36520	MAY 26, 2009	U-300	I-278	NOV 22, 2002
						I-273	AUG 05, 2002
	021083 001	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U-290	NCE	SEP 15, 2004
			5212155	MAY 18, 2010	U-291		
			5308847	MAY 03, 2011	U-292		
			5403833	APR 04, 2012	U-293		
			5536729	SEP 30, 2013			
	019640 005	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
						ODE	DEC 30, 2003
	019640 006	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
						ODE	DEC 30, 2003
	019640 007	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				I-182	DEC 30, 1999
						ODE	DEC 30, 2003
>ADD>	021075 001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN DEPOT	5656297	JUL 25, 2014		NP	DEC 22, 2002
>ADD>			5654010	AUG 05, 2014			
>ADD>	021075 002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN DEPOT	5656297	JUL 25, 2014		NP	DEC 22, 2002
>ADD>			5654010	AUG 05, 2014			
>ADD>	021075 003	SOMATROPIN, BIOSYNTHETIC;NUTROPIN DEPOT	5656297	JUL 25, 2014		NP	DEC 22, 2002
>ADD>			5654010	AUG 05, 2014			
>ADD>	019865 001	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 30, 2000
>ADD>						ODE	OCT 30, 1999
>ADD>	019865 002	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 30, 2000
>ADD>						ODE	OCT 30, 1999
>ADD>	019865 003	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 30, 2000
>ADD>						ODE	OCT 30, 1999
>ADD>	019865 004	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 30, 2000
>ADD>						ODE	OCT 30, 1999
>ADD>	019865 005	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 30, 2000
>ADD>						ODE	OCT 30, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020412 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
	020412 002	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
	020412 003	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
	020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
	020412 005	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
	020413 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008			
	020579 001	TAMSULOSIN HYDROCHLORIDE;FLOMAX	4703063	OCT 27, 2009			
	021012 001	TECHNETIUM TC-99M DEPREOTIDE;NEO TECT KIT				NCE	AUG 03, 2004
	021029 001	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 002	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 003	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	021029 004	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
						ODE	AUG 11, 2006
	074823 001	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
	074823 002	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
	074823 003	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
	074823 004	TERAZOSIN HYDROCHLORIDE;TERAZOSIN HCL				PC	FEB 09, 2000
	020539 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-281		
	020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL				NCE	DEC 30, 1999
	020980 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U-73	NCE	DEC 30, 1999
			4755534	DEC 30, 2006	U-73		
	020846 001	TERBINAFINE;LAMISIL				NP	APR 29, 2001
						NCE	DEC 30, 1999
	019762 001	TESTOSTERONE;TESTODERM	5840327	AUG 15, 2016			
	019762 002	TESTOSTERONE;TESTODERM	5840327	AUG 15, 2016			
	020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	OCT 07, 2008		NCE	SEP 30, 2002
			5354760	MAR 24, 2012			
	020707 001	TILUDRONATE DISODIUM;SKELID	4876248	JAN 30, 2010			
>ADD>	020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5978698	OCT 08, 2017			
			5292756	MAY 14, 2012	U-230		
			5880136	SEP 27, 2010	U-254		
			5965581	OCT 23, 2016			
			5972967	OCT 23, 2016			
>ADD>	020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5978698	OCT 08, 2017			
			5292756	MAY 14, 2012	U-230		
			5880136	SEP 27, 2010	U-254		
			5965581	OCT 23, 2016			
			5972967	OCT 23, 2016			
	020505 001	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
						I-274	OCT 01, 2002
	020505 002	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
						I-274	OCT 01, 2002
	020505 003	TOPIRAMATE;TOPAMAX				I-266	JUL 23, 2002
						I-274	OCT 01, 2002
	020505 004	TOPIRAMATE;TOPAMAX				I-274	OCT 01, 2002
						I-266	JUL 23, 2002

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020505 005	TOPIRAMATE;TOPAMAX				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020505 006	TOPIRAMATE;TOPAMAX				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				I-274	OCT 01, 2002
						I-266	JUL 23, 2002
	020671 001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN				I-256	NOV 30, 2001
>ADD>	020497 001	TOREMIFENE CITRATE;FARESTON	4696949	SEP 29, 2009	U-196		
	020137 002	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
	020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	5976573	JUL 03, 2016	U-295		
>ADD>	020719 001	TROGLITAZONE;PRELAY	6011049	NOV 13, 2017	U-301	I-275	JUN 16, 2002
>ADD>	020719 002	TROGLITAZONE;PRELAY	6011049	NOV 13, 2017	U-301	I-275	JUN 16, 2002
>ADD>	020719 003	TROGLITAZONE;PRELAY	6011049	NOV 13, 2017	U-301	I-275	JUN 16, 2002
>ADD>	020720 001	TROGLITAZONE;REZULIN	6011049	NOV 13, 2017	U-301	I-276	JUN 16, 2002
>ADD>	020720 002	TROGLITAZONE;REZULIN	6011049	NOV 13, 2017	U-301	I-276	JUN 16, 2002
>ADD>	020720 003	TROGLITAZONE;REZULIN	6011049	NOV 13, 2017	U-301	I-276	JUN 16, 2002
	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		
	020759 002	TROVAFLOXACIN MESYLATE;TROVAN	5164402	NOV 17, 2009	U-282		
			5763454	JUN 15, 2015	U-282		
>ADD>	021092 001	UREA, C-13;HELICOSOL				NP	DEC 17, 2002
	020900 001	UREA, C-13;PYLORI-CHEK BREATH TEST				NCE	SEP 17, 2001
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-251	MAR 11, 2002
	019614 004	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007			
	020943 001	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020943 002	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020943 003	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
	020547 001	ZAFIRLUKAST;ACCOLATE	4859692	SEP 26, 2010		I-268	SEP 17, 2002
	020859 001	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
	020859 002	ZALEPLON;SONATA	4626538	JUN 23, 2003		NCE	AUG 13, 2004
	021036 001	ZANAMIVIR;RELENZA	D379506	MAY 27, 2011		NCE	JUL 26, 2004
			4778054	OCT 18, 2005			
			4811731	JUL 29, 2006			
			5035237	JUL 30, 2008			
			5360817	NOV 01, 2011			
			5648379	JUL 15, 2014	U-274		
			4627432	DEC 09, 2003			

New 20th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8312

Charge your order. It's easy!

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $90.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐–☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Authorizing Signature) (10/98)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.